

JC893 U.S. PTO
11/28/00

JC893 U.S. PTO
09/724254
11/28/00

S I R:

Riccardo Dalla-Favera for
Inventor(s) ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS--TYPE MELANOMA
INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MYELOMA

Title of Invention

Also enclosed are:

X 34 sheet(s) of informal X formal drawings.

X Oath or declaration of Applicant(s). (unsigned)

X A power of attorney

An assignment of the invention to

 X A Preliminary Amendment

x Applicant(s) hereby establish small entity status under 37 C.F.R. §1.9 and §1.27.

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT


	NUMBER FILED		NUMBER EXTRA*		RATE		FEE		
					SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
Total Claims	33-20	=	13	X	\$ 9.00	\$18.00	=	\$ 117.00	\$
Independent Claims	7-3	=	4	X	\$40.00	\$80.00	=	\$ 160.00	\$
Multiple Dependent Claims Presented: <u> </u> Yes <u> X </u> No					\$135.00	\$270.00	=	\$	\$
*If the different in Col. 1 is less than zero, enter "0" in Col. 2					BASIC FEE			\$355.00	\$ 710.00
					TOTAL FEE			\$632.00	\$

Riccardo Dalla-Favera
U.S. Serial No.: Not Yet Known
Filed: Herewith
Letter of Transmittal
Page 2

November 28, 2000

- ☒ A check in the amount of \$ 632.00 to cover the filing fee.
- ☐ Please charge Deposit Account No. _____ in the amount of \$ _____.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-3125:
- ☒ Filing fees under 37 C.F.R. §1.16.
- ☒ Patent application processing fees under 37 C.F.R. §1.17.
- ☐ The issue fee set in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).
- ☒ Three copies of this sheet are enclosed.
- ☐ A certified copy of previously filed foreign application No. _____ filed in _____ on _____.
Applicant(s) hereby claim priority based upon this aforementioned foreign application under 35 U.S.C. §119.
- ☒ Other (identify) Express Mail Certificate of Mailing bearing Label No. EK 166 982 810 US dated November 28, 2000, and a loose set of Formal Drawings (34 sheets).

Respectfully submitted,


John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Riccardo Dalla-Favera
Serial No. : Not Yet Known
Filed : Herewith
For : ISOLATION OF FIVE NOVEL GENES CODING FOR NEW
Fc RECEPTORS-TYPE MOLECULES INVOLVED IN THE
PATHOGENESIS OF LYMPHOMA/MYELOMA

1185 Avenue of the Americas
New York, New York 10036
November 28, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

Box: Patent Application

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

In the claims:

Please cancel claims 26-32 and 48-68 without disclaimer or prejudice to applicant's right to pursue the subject matter of these claims in a future continuation or divisional application.

REMARKS

Applicant has hereinabove canceled claims 26-32 and 48-68 without prejudice to applicant's right to pursue the subject matter of these claims in a continuation or divisional application at a later date. Accordingly, upon entry of the amendment claims 1-25 and 33-47 will be pending and under examination. Accordingly,

Riccardo Dalla-Favera
U.S. Serial No.: Not Yet Known
Filed: Herewith
Page 2

applicant respectfully requests entry of the Amendment.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any fee is required authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

**Application
for
United States Letters Patent**

To all whom it may concern:

Be it known that I, Riccardo Dalla-Favera

have invented certain new and useful improvements in

**ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA
INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MYELOMA**

of which the following is a full, clear and exact description.

58044-A/JPW/EMW

**ISOLATION OF FIVE NOVEL GENES
CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA
INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA**

5 This application claims benefit of copending U.S. Provisional Application Serial No. 60/168,151, filed November 29, 1999, the contents of which are hereby incorporated by reference into the present application.

10 The invention disclosed was herein made in the course of work under NCI Grant No. CA 44029 from the National Cancer Institute. Accordingly, the U.S. Government has certain rights in this invention.

15 Throughout this application, various references are referred to in parentheses. Disclosures of these publication in their entirety are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full
20 bibliographic citation for these references may be found at the end of this application, preceding the claims.

BACKGROUND OF THE INVENTION

25 Abnormalities of chromosome 1q21 are common in B cell malignancies, including B cell lymphoma and myeloma, but the genes targeted by these aberrations are largely unknown. By cloning the breakpoints of a t(1;14)(q21;q32) chromosomal translocation in a myeloma cell line, we have
30 identified two novel genes, *IRTA1* and *IRTA2*, encoding cell surface receptors with homologies to the Fc and Inhibitory

Receptor families. Both genes are normally expressed in mature B cells, but with different distributions in peripheral lymphoid organs: *IRTA1* is expressed in marginal zone B cells, while *IRTA2* is also expressed in germinal center centrocytes and in immunoblasts. As the result of the t(1;14) translocation, the *IRTA1* signal peptide is fused to the Immunoglobulin C α domain to produce a chimaeric *IRTA1/C α* fusion protein. In Multiple Myeloma and Burkitt lymphoma cell lines with 1q21 abnormalities, *IRTA2* expression is deregulated. Thus, *IRTA1* and *IRTA2* are novel immunoreceptors with a potentially important role in B cell development and lymphomagenesis.

B-cell Non-Hodgkin's Lymphoma (B-NHL) and Multiple Myeloma (MM) represent a heterogeneous group of malignancies derived from mature B cells with phenotypes corresponding to pre-Germinal Center (GC) (mantle cell), GC (follicular, diffuse large cell, Burkitt's), or post-GC B cells (MM) (for review, Gaidano and Dalla-Favera, 1997; Kuppers et al., 1999). Insights into the pathogenesis of these malignancies have been gained by the identification of recurrent clonal chromosomal abnormalities characteristic for specific disease subtypes. The common consequence of these translocations is the transcriptional deregulation of protooncogenes by their juxtaposition to heterologous transcriptional regulatory elements located in the partner chromosome (Gaidano and Dalla-Favera, 1997). These heterologous transcriptional regulatory elements can be derived from the Immunoglobulin (IG) locus or from other partner chromosomal loci. Examples include *MYC* in t(8;14)(q24;q32) in Burkitt's lymphoma (BL) (Dalla-Favera et al., 1982; Taub et al., 1982), the *CCND1* gene

deregulated by the t(11;14)(q13;q32) in mantle cell lymphoma (MCL) (Rosenberg et al., 1991) and multiple myeloma (MM) (Ronchetti et al., 1999), *BCL2* involved in the t(14;18)(q32;q21) in follicular lymphoma (FL) (Bakhshi et al., 1985), *BCL6* in t(3;14)(q27;q32) in diffuse large B cell lymphoma (DLCL) (Ye et al., 1993), as well as *FGFR3* in t(4;14)(p16;q32) (Chesi et al., 1997), *MAF* in t(14;16)(q32;q23) (Chesi et al., 1998) and *MUM1/IRF4* in t(6;14)(p25;q32) (Iida et al., 1997) in multiple myeloma (MM). The identification of these oncogenes has offered valuable insights into the pathogenesis and diagnosis of their corresponding malignancies.

Chromosomal abnormalities involving band 1q21-q23 are among the most frequent genetic lesions in both B-NHL and MM. Among NHL subtypes, translocation breakpoints at 1q21-q23, including translocations and duplications, have been reported, often as the single chromosomal abnormality, in 17-20% of follicular and diffuse large B-cell lymphoma (DLCL), in 39% of marginal-zone B cell lymphoma (Offit et al., 1991; Whang-Peng et al., 1995; Cigudosa et al., 1999) and in 27-38% of Burkitt lymphoma, where they represent the second most common cytogenetic abnormality after translocations involving the *MYC* proto-oncogene (Berger and Bernheim, 1985; Kornblau et al., 1991). Comparative genome hybridization (CGH) has also identified 1q21-q23 as a recurring site for high-level amplification in 10% of DLCL cases (Rao et al., 1998). In MM, trisomy of the 1q21-q32 region has been reported in 20-31% of cases (Sawyer et al., 1995), amplification of the 1q12-qter region in 80% of cell lines and 40% of primary tumors (Avet-Loiseau et al., 1997), and nonrandom

unbalanced whole-arm translocations of 1q, associated with the multiduplication of the adjacent 1q21-22 region, were found in 23% of patients with abnormal karyotypes (Sawyer et al., 1998).

5

10

15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000

20

25

The high frequency of involvement of 1q21 structural rearrangements in B-cell malignancies suggests that this locus may harbor genes critical to the pathogenesis of these diseases. Cloning of a t(1;14)(q21;q32) in a pre-B cell acute lymphoblastic leukemia cell line previously identified a novel gene, *BCL9* deregulated in this single case (Willis et al., 1998), but not involved in other cases. A recent report characterized the t(1;22)(q22;q11) in a follicular lymphoma (FL) cell line and found that the *FCGR2B* locus, encoding the low affinity IgG Fc receptor FCGR1B, was targeted in this cell line and in two additional FL cases (Callanan et al., 2000). Finally, the *MUC1* locus has been identified in proximity of the breakpoint of a t(1;14)(q21;q32) in NHL (Dyomin et al., 2000; Gilles et al., 2000), and *MUC1* locus rearrangements have been found in 6% of NHL with 1q21 abnormalities (Dyomin et al., 2000). These results highlight the heterogeneity of the 1q21 breakpoints and the need to identify additional candidate oncogenes situated in this locus, since the large majority of these alterations remain unexplained.

30

The aim of this study was to further explore the architecture of 1q21 chromosomal rearrangements in B cell malignancy. To that end, we have employed a molecular cloning approach of the t(1;14)(q21;q32) present in the myeloma cell line FR4. We have identified two novel genes

5

SUMMARY OF THE INVENTION

This invention provides an isolated nucleic acid molecule which encodes immunoglobulin receptor, Immunoglobulin superfamily Receptor Translocation Associated, IRTA, protein.

This invention provides a method of producing an IRTA polypeptide (protein) which comprises: (a) introducing a vector comprising an isolated nucleic acid which encodes an immunoglobulin receptor, Immunoglobulin superfamily Receptor Translocation Associated, IRTA, protein into a suitable host cell; and (b) culturing the resulting cell so as to produce the polypeptide.

This invention provides an isolated nucleic acid molecule comprising at least 15 contiguous nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of the isolated nucleic acid molecule encoding IRTA protein. In an embodiment, the IRTA protein may be IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 protein, or fragment(s) thereof, having the amino acid sequence set forth in any of Figures 18A, 18B-1-18B-3, 18C-1-18C-2, 18D-1-18D-2 or 18E-1-18E-2, respectively.

This invention provides a method for detecting a B cell malignancy or a type of B cell malignancy in a sample from a subject wherein the B cell malignancy comprises a 1q21 chromosomal rearrangement which comprises: a) obtaining RNA from the sample from the subject; b) contacting the RNA of step (a) with a nucleic acid molecule of at least 15 contiguous nucleotides capable of specifically

hybridizing with a unique sequence included within the sequence of an isolated RNA encoding human IRTA protein selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5, under conditions permitting hybridization of the RNA of step (a) with the nucleic acid molecule capable of specifically hybridizing with a unique sequence included within the sequence of an isolated RNA encoding human IRTA protein, wherein the nucleic acid molecule is labeled with a detectable marker; and c) detecting any hybridization in step (b), wherein detection of hybridization indicates presence of B cell malignancy or a type of B cell malignancy in the sample.

This invention provides an antisense oligonucleotide having a sequence capable of specifically hybridizing to an mRNA molecule encoding a human IRTA protein so as to prevent overexpression of the mRNA molecule.

This invention provides a purified IRTA1 protein comprising the amino acid sequence set forth in Figure 18A (SEQ ID NO:1).

This invention provides a purified IRTA2 protein comprising the amino acid sequence set forth in Figures 18B-1-18B-3 (SEQ ID NO:3).

This invention provides a purified IRTA3 protein comprising the amino acid sequence set forth in Figures 18C-1-18C-2 (SEQ ID NO:5).

This invention provides a purified IRTA4 protein comprising the amino acid sequence set forth in Figures 18D-1-18D-2 (SEQ ID NO: 7).

5 This invention provides a purified IRTA5 protein comprising the amino acid sequence set forth in Figures 18E-1-18E-2 (SEQ ID NO: 9).

10 This invention provides an antibody/antibodies directed to an epitope of a purified IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 protein, or fragment(s) thereof, having the amino acid sequence set forth in any of Figures 18A, 18B-1-18B-3, 18C-1-18C-2, 18D-1-18D-2 or 18E-1-18E-2.

15 This invention provides an antibody directed to a purified IRTA protein selected from the group consisting of IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5.

20 This invention provides a pharmaceutical composition comprising an amount of the antibody directed to an IRTA protein effective to bind to cancer cells expressing an IRTA protein selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5 so as to prevent growth of the cancer cells and a pharmaceutically acceptable carrier.

25 This invention provides a pharmaceutical composition comprising an amount of any of the oligonucleotides of nucleic acid molecules encoding IRTA proteins described herein effective to prevent overexpression of a human IRTA protein and a pharmaceutically acceptable carrier capable.

10
15
20
25
30

This invention provides a method of diagnosing B cell malignancy which comprises a 1q21 chromosomal rearrangement in a sample from a subject which comprises: a) obtaining the sample from the subject; b) contacting the sample of step (a) with an antibody directed to a purified IRTA protein capable of specifically binding with a human IRTA protein selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5 IRTA protein on a cell surface of a cancer cell under conditions permitting binding of the antibody with human IRTA protein on the cell surface of the cancer cell, wherein the antibody is labeled with a detectable marker; and c) detecting any binding in step (b), wherein detection of binding indicates a diagnosis of B cell malignancy in the sample.

This invention provides a method of detecting human IRTA protein in a sample which comprises: a) contacting the sample with any of any of the above-described anti-IRTA antibodies under conditions permitting the formation of a complex between the antibody and the IRTA in the sample; and b) detecting the complex formed in step (a), thereby detecting the presence of human IRTA in the sample.

This invention provides a method of treating a subject having a B cell cancer which comprises administering to the subject an amount of anti-IRTA antibody effective to bind to cancer cells expressing an IRTA protein so as to prevent growth of the cancer cells and a pharmaceutically acceptable carrier, thereby treating the subject.

This invention provides a method of treating a subject having a B cell cancer which comprises administering to the subject an amount of an antisense oligonucleotide having a sequence capable of specifically hybridizing to an mRNA molecule encoding a human IRTA protein so as to prevent overexpression of the human IRTA protein, so as to arrest cell growth or induce cell death of cancer cells expressing IRTA protein(s) and a pharmaceutically acceptable carrier, thereby treating the subject.

The invention also provides a pharmaceutical composition comprising either an effective amount of any of the oligonucleotides described herein and a pharmaceutically acceptable carrier.

The invention also provides a pharmaceutical composition comprising either an effective amount of an antibody directed against an epitope of any IRTA protein described herein and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE FIGURES

Figures 1A-1B. Molecular cloning of the translocation t(1;14)(q21;q32) in the FR4 multiple myeloma cell line. Fig. 1A) Schematic representation of the λ FR4B-5 and λ FR4S-a clones, representing der(14) and der(1) breakpoints, and of the germline IgH and 1q21 loci. Fig. 1B) Nucleotide sequence of the breakpoint junction and its alignment to the corresponding germline regions of chromosome 14. S α , IgA switch region; LCR: 3' IgH locus control region; B, *Bam*HI; H, *Hind*III; X, *Xho*I.

Figures 2A-2B. Genomic map of the 1q21 locus in the vicinity of the FR4 breakpoint. Fig. 2A) Restriction endonuclease map and schematic representation of genomic clones, i.e. bacteriophages (1), P1 artificial chromosomes (PACs) (2), and yeast artificial chromosome (YAC) (3), spanning the germline 1q21 locus at the FR4 breakpoint region (arrowhead). The name of each clone is placed directly on top of its representation. End fragments derived from the PAC and YAC inserts are depicted as circles, with either an SP6/T7 vector orientation (PAC), or left/right arm vector orientation (YAC). The top panel in Fig. 1A depicts the genomic organization of two genes surrounding the FR4 breakpoint. The

two genes were identified by exon trapping of PAC 49A16. They are closely spaced in the genome, within ≤ 30 Kb of each other and are named MUM2 and MUM3 (multiple myeloma-2 and 3). In the scheme of their genomic loci, black boxes indicate coding exons, whereas white and light or medium grey boxes indicate non-coding exons. Connecting introns are lines. MUM3 (left) gives rise to three alternatively spliced mRNAs, all sharing a common 5' untranslated region (UTR) but diverse 3' UTRs (marked by different shades). Numbers underneath the boxes identify the order of exons in the cDNA. Exons less than 100 bp are depicted as thin vertical lines. The position and size of each exon was determined by sequencing of genomic PAC and phage clones and by hybridization of cDNA probes to endonuclease-digested clone DNA. PAC and YAC mapping was performed by partial digestion with rare cutting enzymes followed by Pulse-Field-Gel-Electrophoresis and hybridization to internal and end-derived probes. Dashed lines align regions of overlap. S, SacI; H, HindIII; S, SwaI; Pc, PacI; P, PmeI; Fig. 2B) Genethon genetic linkage map of 1q21 in the region of the MUM2/MUM3 locus. Sequence-tagged sites (STS) are ordered in approximate distance previously determined by Dib, C., et al. (1996) Nature, 380:162-

164. STS WI-5435 (in bold) is contained within YAC 23GC4 and PAC 49A16. Parallel vertical lines represent interrupted segments, whose approximate size is depicted above in megabases (MB). Sizing was estimated by the size of nonchimeric YAC contigs between two markers. The BCL9 gene at the centromere was cloned from a different t(1;14)(q21;q32) breakpoint by Willis T.G. et al., (1998) Blood 91, 6:1873-1881. The FcGRIIA gene is at the 1q21-q22 chromosomal band border.

Figures 3A-3C. MUM2 mRNA structure and expression pattern. Fig. 3A) Schematic representation of MUM2 mRNA. Pattern-filled, wide boxes represent coding domains and narrow empty boxes represent untranslated regions. SP, signal peptide; EC, extracellular domain; TM, transmembrane domain; CYT, cytoplasmic domain; A(n), polyA tail. The extracellular region is composed of four immunoglobulin-like domains as depicted. Alternative polyadenylation signals (arrows) generate three MUM2 mRNA species (a, b, c) whose length (in Kb) ranges from 2.6-3.5. Fig. 3B) Northern blot analysis of MUM2 mRNA expression in human tissues of the immune system. The cDNA probe used for the analysis is shown as a solid bar underneath the mRNA scheme in Fig. 3A). Each lane contains 2µg mRNA of the

corresponding tissue. On the right side of the blot, the position of RNA molecular weight markers is depicted. The position of MUM2 and GAPDH mRNA transcripts is shown by arrows. (A GAPDH probe was included in the hybridization as an internal control - 0.15 ng labelled +50 ng unlabelled probe-). The results of this analysis show weak expression of MUM2 in lymph node and spleen. MUM2 expression was not detected in a variety of other human tissues (data not shown). Fig. 3C) Northern blot analysis of MUM2 expression in total RNA from EREB, a conditional EBV-transformed B lymphoblastoid cell line. EREB carries the EBV genome with an EBNA2-estrogen receptor fusion protein, active only in the presence of estrogen. For this experiment, cells were grown in the presence of estrogen (1µg/ml), followed by estrogen withdrawal for the indicated times. Upon estrogen withdrawal, EREB cells undergo G0/G1 arrest, determined by the loss of c-myc expression. In Fig. 3C, a Northern blot of EREB total RNA (10µg per lane) was hybridized with the MUM2 cDNA probe shown in Fig. 3A and the GAPDH internal control probe, as in Fig. 3B. Arrows indicate the position of the corresponding mRNAs on the EREB blot. a, band c correspond to the MUM2 species in panel Fig 3A. The same blot was then stripped and reprobed with a

c-myc cDNA probe (exon 2) to verify cellular G0/G1 arrest. Quantitation of MUM2 mRNA by the use of a phosphorimager densitometric analysis demonstrates a 10-fold increase in their levels within 48 hrs of estrogen withdrawal, suggesting that MUM2 expression is elevated as the cells enter a resting phase.

Figures 4A-4B. MUM3 mRNA structure and expression pattern. Fig. 4A) Schematic representation of MUM3 mRNA. Pattern-filled, wide boxes represent coding domains and narrow empty or gray boxes represent untranslated regions. SP, signal peptide; EC, extracellular domain; TM, transmembrane domain; CYT, cytoplasmic domain; A(n), polyA tail. The extracellular region is composed of immunoglobulin-like domains, as depicted. Alternative splicing generates four mRNA species with diverse subcellular localization. MUM3-a and -d proteins are secreted, whereas MUM3-b contains a hydrophobic stretch of amino acids at its C-terminus which may serve as a signal for addition of a glycosylphosphatidylinositol anchor (GPI-anchor), as shown. MUM3-c spans the plasma membrane. Sequence identity among species is indicated by identical filling. Fig. 4B) Northern blot analysis of MUM3 mRNA expression in multiple human tissues (left) and in

various lymphoid and non-lymphoid cell lines (right). The cDNA probe used is shown as a solid bar below the cDNA scheme in Fig. 4A. Each lane contains 2 μ g mRNA of the corresponding tissue or cell line. The position of MUM3 and GAPDH mRNA transcripts is shown by arrows. (A GAPDH probe was included in the hybridization as an internal control as described in Fig. 3) a, b, c and d correspond to the MUM3 mRNA species shown in Fig. 4A. RD, NC42 and CB33, Epstein-Barr virus transformed B lymphoblastoid cell lines; EREB, conditional EBV-transformed B lymphoblastoid cell line; FR4, plasma cell line; MOLT4 and HUT78, T cell lines; HL60 and U937, myelomonocytic cell lines; K562, erythroid cell line. The results suggest that MUM3 is expressed solely in the immune system tissues of bone marrow, lymph and spleen and in particular in B cells with a lymphoblastoid phenotype.

Figure 5.

Nucleotide and amino acid sequence of human MUM2. The deduced amino acid sequence is shown above the nucleotide sequence in one-letter code and is numbered on the right, with position 1 set to the first codon of the signal peptide. The predicted signal peptidase site was derived by a computer algorithm described in Nielsen et al., Protein Engineering 10, 1-6 (1997) and is

marked by an arrowhead. The polyadenylation signal AATAAA is underlined. Potential sites for N-glycosylation are also underlined in the amino acid sequence. A hydrophobic stretch of 16 amino acids predicted to span the plasma membrane is doubly underlined. Consensus SH2-binding sites are highlighted by a wavy underline.

Figure 6A.

Nucleotide and amino acid sequence of human MUM3-a. The deduced amino acid sequence is shown above the nucleotide sequence in one-letter code and is numbered on the right, with position 1 set to the first codon of the signal peptide. The predicted site for signal peptidase cleavage was derived as previously stated above and is marked by an arrowhead. The polyadenylation signal ATTAAA is underlined. Potential sites for N-glycosylation are also underlined in the amino acid sequence. The protein lacks a transmembrane domain and is predicted to be secreted.

Figure 6B.

Nucleotide and amino acid sequence of human MUM3-b. The deduced amino acid sequence is shown above the nucleotide sequence in one-letter code and is numbered on the right, with position 1 set to the first codon of the signal peptide. The predicted site for signal peptidase cleavage was derived as

previously stated above and is marked by an arrowhead. The polyadenylation signal AATAAA is underlined. Potential sites for N-glycosylation are underlined in the amino acid sequence.

Figure 6C-1-6C-2. Nucleotide and amino acid sequence of human MUM3-c. The deduced amino acid sequence is shown above the nucleotide sequence in one-letter code and is numbered on the right, with position 1 set to the first codon of the signal peptide. The predicted site for signal peptidase cleavage was derived as previously stated above and is marked by an arrowhead. The polyadenylation signal AATAAA is underlined. Potential sites for N-glycosylation are underlined in the amino acid sequence. A hydrophobic stretch of 23 amino acids predicted to span the plasma membrane is doubly underlined. Consensus SH2-binding sites are highlighted by a wavy underline.

Figures 7A-7C. t(1;14)(q21;32) in FR4 generates a MUM2/Ca fusion transcript. Fig. 7A) Schematic representation of the der(14) genomic clone λ FR4B-5 and of the germline IgHA1 locus. The FR4 breakpoint is marked by an arrow. Filled and open boxes represent the

MUM2 and Calpha coding and non-coding exons respectively. The position of the MUM2 exon 1 probe used for Northern blot analysis is shown by a bar. Fig. 7B) Northern blot analysis with a MUM2 exon 1 probe on FR4 and additional cell lines detects an abnormal message of 0.8 Kb, selectively in FR4. Arrowheads point to the location of normal MUM2 message in EREB mRNA. JJN3 and U266, myeloma cell lines; EREB, conditional EBV-transformed B lymphoblastoid cell line. Two μ g of polyA+ RNA were loaded per lane. Fig. 7C) Nucleotide and amino acid sequence of the MUM2-Ca fusion cDNA in FR4. The cDNA was amplified by RT-PCR from FR4 total RNA using the primers shown in Fig. 7A, and was subsequently subcloned and sequenced. The deduced amino acid sequence is shown above the nucleotide sequence in one-letter code and is numbered on the right with position 1 set to the first codon of the signal peptide. The predicted site for signal peptidase cleavage was derived as previously stated above and is marked by an arrowhead. The polyadenylation signal AATAAA is underlined. The Calpha transmembrane domain is underlined. The MUM2 portion of the cDNA is shown on italics. H, HindIII; B, BamHI; X, XhoI; S α , IgA switch region; EC, extracellular

region; TM, transmembrane; CYT, cytoplasmic domain.

Figures 8A-8C. Molecular cloning of the translocation t(1;14)(q21;q32) in the FR4 multiple myeloma cell line. Fig. 8A) Schematic representation of the phage clones representing der(14) and der(1) breakpoints and the germline IGH and 1q21 loci. Chromosome 14 sequences are indicated by a solid black line with black boxes representing Ca1 exons. Chromosome 1 sequences are shown as a grey line. The probes used for chromosomal mapping are indicated below the map. Restriction enzyme codes are: B, BamHI; H, HindIII; X, XhoI; S, SacI; E, EcoRI. For enzymes marked by (*) only sites delineating the probes are shown. Sa: IgA switch region; LCR: 3'IgH locus control region. Fig. 8B) Nucleotide sequence of the breakpoint junctions and their alignment to the corresponding germline regions of chromosomes 14 and 1. Fig. 8C) Left, fluorescence in situ hybridization (FISH) analysis on human normal metaphase spreads with the PAC clone 49A16 (Fig. 13) spanning the germline1q21 region at the FR4 breakpoint. Right, DAPI stained image from the same metaphase spread.

Figures 9A-9B. Structure of *IRTA1* and *IRTA2* cDNAs. Figs. 9A,9B) Schematic representation of the full-length *IRTA1* (Fig. 9A) and *IRTA2* (Fig. 9B) cDNAs. Pattern-filled, wide boxes represent coding domains and narrow boxes represent untranslated regions (UTR). The predicted site for signal peptidase cleavage is marked by an arrowhead and was derived according to the SignalIP World Wide Web server at <http://www.cbs.dtu.dk/services/SignalIP>. The transmembrane domain prediction algorithm is described in Tusnady et al, 1998. SP, signal peptide; EC, extracellular domain; Ig, immuno-globulin-type; TM, transmembrane domain; CYT, cytoplasmic domain; A(n), polyA tail; GPI, glycoposphatidyl inositol. In (Fig. 9A), arrows in the 3' UTR indicate different polyadenylation addition sites utilized in the *IRTA1* cDNA. In (Fig. 9B), different 3'UTR regions in *IRTA2* isoforms are differentially shaded. Bars underneath the UTR regions in (Fig. 9A) and (Fig. 9B) identify probes used for Northern blot analysis in Figure 12.

Figures 10A-10B. Comparison of the amino acid sequences of *IRTA1* and *IRTA2* with members of the Fc Receptor family Fig. 10A) Multiple sequence alignment of the first two (top) and the third (bottom) extracellular Ig-domains of *IRTA1* and

IRTA2 to Fc receptor family members. The sequences were compared using the ClustalW program (Thompson et al., 1994). Black-shaded boxes indicate conserved aminoacids among all sequences; dark-grey shaded boxes indicate conserved aminoacids among at least half of the sequences; light-shaded boxes indicate conservative substitutions. Fig. 10B) Alignment of the SH2-binding domains of IRTA1 and IRTA2 with the ITAM and ITIM consensus motifs. Conserved aminoacid positions are in bold. Symbol X represents any aminoacid.

Figures 11A-11B-4. *IRTA1* expression pattern. Fig. 11A) Left panel. Northern blot analysis of *IRTA1* mRNA expression in tissues of the human immune system. Each lane contains 2mg mRNA. The position of RNA molecular weight markers is depicted on the right side of the blot. The positions of the *IRTA1* and *GAPDH* mRNA transcripts are shown by arrows. (A *GAPDH* probe was included in the hybridization as an internal control-0.15 ng labelled + 50 ng unlabelled probe-). Right Panel. Northern blot analysis of *IRTA1* expression in total RNA from the ER/EB

cell line (10 mg per lane). For this experiment, cells were grown in the presence of estrogen (1mg/ml), followed by estrogen withdrawal for the indicated times. Arrows indicate the positions of the corresponding mRNAs. a, b and c correspond to the *IRTA1* differentially polyadenylated species. The same blot was stripped and reprobbed with a *MYC* cDNA probe (exon 2) to verify cellular G₀/G₁ arrest. Densitometric analysis of *IRTA1* mRNA levels is plotted in the adjacent column graph. The cDNA probe used is shown as a solid bar underneath the *IRTA1* mRNA scheme in Figure 9A. Fig. 11B-1-11B-4) *In situ* hybridization analysis of *IRTA1* expression in serial sections of human tonsil. 1. Sense *IRTA1* probe 2. Antisense *IRTA1* probe 3. H&E staining 4. Antisense *IRTA1* signal superimposed over an H&E stained section. GC, germinal center, MargZ, marginal zone

Figure 12A-12B-4. *IRTA2* expression pattern. Fig. 12A) Northern blot analysis of *IRTA2* mRNA expression in multiple human tissues (left panel) and in various lymphoid and non-lymphoid cell lines (right panel). Each lane contains 2mg mRNA.

The positions of the *IRTA2* and *GAPDH* transcripts are shown by arrows. a, b, c and d correspond to the alternatively spliced *IRTA2* mRNA isoforms. RD, NC42 and CB33, Epstein-Barr virus transformed B lymphoblastoid cell lines; EREB, conditional EBV-transformed B lymphoblastoid cell line; FR4, plasma cell line; MOLT4 and HUT78, T cell lines; HL60 and U937, myelomonocytic cell lines; K562, erythroid cell line. The cDNA probe used is shown as a solid bar underneath the *IRTA2* mRNA scheme in Figure 9B. Figs. 12B-1-12B-4) *In situ* hybridization analysis of *IRTA2* mRNA expression in human tonsil. Fig. 12B-1. Sense *IRTA2* cDNA probe, Fig. 12B-2. Antisense *IRTA2* cDNA probe, Fig. 12B-3. H&E staining, Fig. 12B-4. Antisense *IRTA2* cDNA probe signal superimposed over H&E stained section. GC, germinal center, MargZ, marginal zone

Figure 13. Map of the germline 1q21 region spanning the FR4 breakpoint and genomic organization of *IRTA1* and *IRTA2*. Primers used to amplify *IRTA1* exons from spleen cDNA are marked by arrowheads on top panel. Black and light boxes indicate coding and non-coding exons respectively. Arrows indicate

position of *BCL9*, *MUC1*, *IRTA* family and *FCGR1IB* loci. S, SacI; H, HindIII; S, SmaI; P, PacI; P, PmeI; Mb, Megabases

Figures 14A-14D. t(1;14)(q21;q32) in FR4 generates an *IRTA1/C α* fusion transcript. Fig. 14A) Schematic representation of the der(14) genomic clone 1FR4B-5 and of the germline *IgC α_1* locus. The FR4 breakpoint is marked by an arrow. Filled and open boxes represent the *IRTA1* and *C α_1* coding and non-coding exons respectively. Fig. 14B) Northern blot analysis with an *IRTA1* exon 1 probe (shown by a bar in Fig. 14A) on FR4 and additional cell lines detects an abnormal message in FR4. Arrowheads point to the location of normal *IRTA1* message in ER/EB mRNA. JJN3 and U266, myeloma cell lines. Two mg of polyA+ RNA loaded per lane. Fig. 14C) Schematic representation of the *IRTA1/C α* fusion cDNA in FR4. The cDNA was amplified by RT-PCR from FR4 total RNA using the primers shown in (Fig. 14A), and sequenced after subcloning. Fig. 14D) SDS/PAGE analysis of immunoprecipitates obtained from vector control transfected and *IRTA1/C α* transient expression construct transfected 293-T

cells (lanes 1 & 2), or the following cell lines: mIgA positive lymphoblastoid cell line-Dakiki (lane 3), FR4 (lane 4), mIgM positive NHL cell line-Ramos (lane 5). H, HindIII; B, BamHI; X, XhoI; Sa, IgA switch region; EC, extracellular region; TM, transmembrane; CYT, cytoplasmic

Figures 15A-15B.

IRTA2 expression is deregulated in cell lines carrying 1q21 abnormalities. Figs. 15A, 15B) Northern blot analysis of *IRTA2* mRNA expression in Burkitt lymphoma (Fig. 15A) and Multiple Myeloma (Fig. 15B) cell lines. The cDNA probe used is the same as in Fig. 12. Each lane contains 2mg mRNA. The positions of the *IRTA2* and *GAPDH* mRNA transcripts are shown by dashes and arrows, respectively. The relative levels of *IRTA2* mRNA expression in the left panel (Fig. 15A) were plotted on the right panel (Fig. 15A) after densitometric analysis and normalization versus the *GAPDH* levels. The right panel of (Fig. 15B) is a summary of the Northern blot analysis results.

Figures 16-1-16-4

IRTA1 expression in normal lymphoid tissue. Paraffin-embedded sections

from normal human tonsil were stained with the following antibodies: Fig. 16-1) Negative control; Fig. 16-2) anti-CD3 mouse monoclonal to detect T cells; Fig. 16-3) anti-IRTA1 (mIRTA) mouse monoclonal; Fig. 16-4) anti-IRTA1 (J92884K) rabbit polyclonal. IRTA1 positive cells are located in the perifollicular and intraepithelial region of the tonsil, the equivalent of the marginal zone in the spleen.

Figure 17

IRTA1 expression in a stomach Mucosa-Associated-Lymphoid Tissue (MALT) B cell lymphoma. A paraffin-embedded section from a stomach MALT B cell lymphoma was stained with the anti-IRTA1 (mIRTA) mouse monoclonal antibody and counterstained with H&E. The majority of MALT lymphomas analyzed were IRTA1 positive. This antibody therefore can be an effective tool in the differential diagnosis of MALT lymphoma. The mIRTA1 antibody may also be proven useful in the therapy of this B cell tumor, similarly to the use of the anti-CD20 antibody (Rituximab) in the therapy of relapsed CD20-positive lymphomas (Foon K., Cancer J. 6: p273).

Figure 18A.

IRTA1 cDNA and the amino acid sequence of the encoded IRTA1 protein.

Figures 18B-1-18B-3. IRTA2 cDNA and the amino acid sequence of the encoded IRTA2 protein.

5 **Figures 18C-1-18C-2.** IRTA3 cDNA and the amino acid sequence of the encoded IRTA3 protein.

10 **Figures 18D-1-18D-2.** IRTA4 cDNA and the amino acid sequence of the encoded IRTA4 protein.

15 **Figures 18E-1-18E-2.** IRTA5 cDNA and the amino acid sequence of the encoded IRTA5 protein.

20

25

DETAILED DESCRIPTION OF THE INVENTION

The following standard abbreviations are used throughout the specification to indicate specific nucleotides: C=cytosine; A=adenosine; T=thymidine and G=guanosine.

5

This invention provides an isolated nucleic acid molecule which encodes immunoglobulin receptor, Immunoglobulin superfamily Receptor Translocation Associated, IRTA, protein.

10

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2

IRTA1 protein comprising the amino acid sequence set forth in Figure 18A (SEQ ID NO:1).

5 In another embodiment of the above-described isolated nucleic acid molecule, the encoded IRTA protein is IRTA2 protein comprising the amino acid sequence set forth in Figures 18B-1-18B-3 (SEQ ID NO:3).

10 In a further embodiment of the above-described isolated nucleic acid molecule, the encoded IRTA protein is IRTA3 protein comprising the amino acid sequence set forth in Figures 18C-1-18C-2 (SEQ ID NO:5).

15 In yet another embodiment of the above-described isolated nucleic acid molecule, the encoded IRTA protein is IRTA4 protein comprising the amino acid sequence set forth in Figures 18D-1-18D-2 (SEQ ID NO: 7).

20 In a still further embodiment of the above-described isolated nucleic acid molecule, the encoded IRTA protein is IRTA5 protein comprising the amino acid sequence set forth in Figures 18E-1-18E-2 (SEQ ID NO: 9).

25 In another embodiment of any of the above-described isolated nucleic acid molecules, the nucleic acid molecule is DNA. In further embodiments, the DNA is cDNA. In additional embodiments, the DNA is genomic DNA. In another embodiment, the nucleic acid molecule is an RNA molecule. In yet another embodiment, the DNA molecule is
30 cDNA having the nucleotide sequence set forth in Figure 18A (SEQ ID NO:2). In another embodiment, the DNA molecule is cDNA having the nucleotide sequence set forth in Figure

18A (SEQ ID NO:4). In a further embodiment, the DNA molecule is cDNA having the nucleotide sequence set forth in Figure 18A (SEQ ID NO:6). In another embodiment, the DNA molecule is cDNA having the nucleotide sequence set forth in Figure 18A (SEQ ID NO:8). In an embodiment, the DNA molecule is cDNA having the nucleotide sequence set forth in Figure 18A (SEQ ID NO:10). In preferred embodiments of the isolated nucleic acid molecule, wherein the nucleic acid molecules encode human IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 protein. In additional embodiments, the nucleic acid molecules encode mammalian IRTA1 protein. The mammalian IRTA1 protein may be murine IRTA1 protein. In another preferred embodiment, the isolated nucleic acid molecules are operatively linked to a promoter of DNA transcription. In yet another preferred embodiment of the isolated nucleic acid molecule, the promoter comprises a bacterial, yeast, insect, plant or mammalian promoter.

This invention provides a vector comprising any of the above-described isolated nucleic acid molecule encoding IRTA proteins, including but not limited to mammalian IRTA proteins, of which human and murine are preferred.

In an embodiment, the vector is a plasmid.

This invention provides a host cell comprising the above-described vector comprising any of the above-described isolated nucleic acid molecule encoding IRTA proteins. Preferably, the isolated nucleic acid molecules in such vectors are operatively linked to a promoter of DNA transcription. In another embodiment of the host cell, the cell is selected from a group consisting of a

bacterial cell, a plant cell, and insect cell and a mammalian cell.

5 This invention provides a method of producing an IRTA polypeptide (protein) which comprises: (a) introducing a vector comprising an isolated nucleic acid which encodes an immunoglobulin receptor, Immunoglobulin superfamily Receptor Translocation Associated, IRTA, protein into a suitable host cell; and (b) culturing the resulting cell
10 so as to produce the polypeptide. In further embodiments, the IRTA protein produced by the above-described method may be recovered and in a still further embodiment, may be purified either wholly or partially. In an embodiment the IRTA protein may be any of IRTA1, IRTA2, IRTA3, IRTA4, or IRTA5 protein. In further embodiments, any of the IRTA
15 proteins may be mammalian proteins. In still further embodiments, the mammalian proteins may be human or mouse IRTA proteins.

20 IRTA genes (nucleic acid molecules encoding IRTA proteins IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5) are useful for the production of the IRTA proteins encoded thereby. IRTA proteins are useful for production of antibodies; such antibodies are used as reagents for differential diagnosis
25 of lymphoma subtypes in hematopathology. Antibodies directed against IRTA proteins and which bind specifically to IRTA proteins also have therapeutic uses, i.e. to specifically target tumor cells, which may be used and administered similarly to "Rituximab" (an anti-CD20
30 antibody), which is an antibody approved by the FDA for therapy of relapsed CD20-positive lymphomas (Foon K., Cancer J. 6(5):273). Anti-IRTA1, anti-IRTA2, anti-IRTA3,

anti-IRTA4 and anti-IRTA5 antibodies are also useful markers for isolation of specific subsets of B cells in research studies of normal and tumor B cell biology. Moreover, Anti-IRTA1, anti-IRTA2, anti-IRTA3, anti-IRTA4 and anti-IRTA5 antibodies are useful research reagents to experimentally study the biology of signaling in normal and tumor B cells.

Methods of introducing nucleic acid molecules into cells are well known to those of skill in the art. Such methods include, for example, the use of viral vectors and calcium phosphate co-precipitation. Accordingly, nucleic acid molecules encoding IRTA proteins IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5 may be introduced into cells for the production of these IRTA proteins.

Numerous vectors for expressing the inventive proteins IRTA1, IRTA2, IRTA3, IRTA4, and IRTA5, may be employed. Such vectors, including plasmid vectors, cosmid vectors, bacteriophage vectors and other viruses, are well known in the art. For example, one class of vectors utilizes DNA elements which are derived from animal viruses such as bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retroviruses (RSV, MMTV or MoMLV), Semliki Forest virus or SV40 virus. Additionally, cells which have stably integrated the DNA into their chromosomes may be selected by introducing one or more markers which allow for the selection of transfected host cells. The markers may provide, for example, prototrophy to an auxotrophic host, biocide resistance or resistance to heavy metals such as copper. The selectable marker gene can be either directly linked to the DNA sequences to

be expressed, or introduced into the same cell by cotransformation.

Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome binding. Additional elements may also be needed for optimal synthesis of mRNA. These additional elements may include splice signals, as well as enhancers and termination signals. For example, a bacterial expression vector includes a promoter such as the lac promoter and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG. Similarly, a eukaryotic expression vector includes a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such vectors may be obtained commercially or assembled from the sequences described by methods well known in the art, for example the methods described above for constructing vectors in general.

These vectors may be introduced into a suitable host cell to form a host vector system for producing the inventive proteins. Methods of making host vector systems are well known to those skilled in the art.

Suitable host cells include, but are not limited to, bacterial cells (including gram positive cells), yeast cells, fungal cells, insect cells and animal cells. Suitable animal cells include, but are not limited to HeLa cells, Cos cells, CV1 cells and various primary mammalian cells. Numerous mammalian cells may be used as hosts,

including, but not limited to, the mouse fibroblast cell
NIH-3T3 cells, CHO cells, HeLa cells, Ltk⁻ cells and COS
cells. Mammalian cells may be transfected by methods well
known in the art such as calcium phosphate precipitation,
electroporation and microinjection.

This invention provides an isolated nucleic acid molecule
comprising at least 15 contiguous nucleotides capable of
specifically hybridizing with a unique sequence included
within the sequence of the isolated nucleic acid molecule
encoding IRTA protein. In an embodiment, the IRTA protein
may be IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 protein, or
fragment(s) thereof, having the amino acid sequence set
forth in any of Figures 18A, 18B-1-18B-3, 18C-1-18C-2,
18D-1-18D-2 or 18E-1-18E-2, respectively. In other
embodiments, the isolated nucleic acid molecules are
labeled with a detectable marker. In still other
embodiments of the isolated nucleic acid molecules, the
detectable marker is selected from the group consisting of
a radioactive isotope, enzyme, dye, biotin, a fluorescent
label or a chemiluminescent label.

This invention provides a method for detecting a B cell
malignancy or a type of B cell malignancy in a sample from
a subject wherein the B cell malignancy comprises a 1q21
chromosomal rearrangement which comprises: a) obtaining
RNA from the sample from the subject; b) contacting the
RNA of step (a) with a nucleic acid molecule of at least
15 contiguous nucleotides capable of specifically
hybridizing with a unique sequence included within the
sequence of an isolated RNA encoding human IRTA protein
selected from the group consisting of human IRTA1, IRTA2,

IRTA3, IRTA4 and IRTA5, under conditions permitting hybridization of the RNA of step (a) with the nucleic acid molecule capable of specifically hybridizing with a unique sequence included within the sequence of an isolated RNA encoding human IRTA protein, wherein the nucleic acid molecule is labeled with a detectable marker; and c) detecting any hybridization in step (b), wherein detection of hybridization indicates presence of B cell malignancy or a type of B cell malignancy in the sample.

Detection of hybridization of RNA encoding IRTA proteins will indicate that a malignancy is a B cell malignancy. More specifically, detection of hybridization of RNA encoding ITRA1 protein indicates that the B cell malignancy is a Mucosa-Associated-Lymphoid Tissue (MALT) B cell lymphoma. Detection of hybridization of RNA encoding ITRA4 and IRTA5 proteins indicate that the B cell malignancy is a mantle cell lymphoma. In an embodiment of the above-described method, the B cell malignancy comprises a 1q21 chromosomal rearrangement. One of skill will use the above-described method as a diagnostic aid in conjunction with other standard methods of detecting/diagnosing malignancies, e.g. pathology of a tumor sample, which may indicate lymphoma and the above-described method will then narrow the malignancy to a B cell lymphoma or more specifically to MALT) B cell lymphoma or a mantle cell lymphoma as discussed supra.

One of skill is familiar with known methods of detecting of hybridization nucleic acid molecules to nucleic acid oligonucleotides, i.e. nucleic acid probes encoding a protein of interest for diagnostic methods. The nucleic

acid molecules encoding the IRTA proteins of the subject invention are useful for detecting B cell malignancy. One of skill will recognize that variations of the above-described method for detecting a B cell malignancy in a sample include, but are not limited to, digesting nucleic acid from the sample with restriction enzymes and separating the nucleic acid molecule fragments so obtained by size fractionation before hybridization.

In an embodiment of the above-described method for detecting a B cell malignancy in a sample from a subject, wherein the detectable marker is radioactive isotope, enzyme, dye, biotin, a fluorescent label or a chemiluminescent label. In a preferred embodiment, the B cell malignancy is selected from the group consisting of B cell lymphoma, multiple myeloma, Burkitt's lymphoma, marginal zone lymphoma, diffuse large cell lymphoma and follicular lymphoma cells. In a further embodiment, the B cell lymphoma is Mucosa-Associated-Lymphoid Tissue B cell lymphoma (MALT). In another preferred embodiment, the B cell lymphoma is non-Hodgkin's lymphoma.

This invention provides an antisense oligonucleotide having a sequence capable of specifically hybridizing to an mRNA molecule encoding a human ITRA protein so as to prevent overexpression of the mRNA molecule.

In preferred embodiments of the antisense oligonucleotide, the ITRA protein selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5 protein. In further embodiments of any of the above-described oligonucleotides of nucleic acid molecules encoding the

IRTA1, IRTA2, IRTA3, IRTA4 and/or IRTA5 proteins, the nucleic acid may be genomic DNA or cDNA.

One of skill is familiar with conventional techniques for nucleic acid hybridization of oligonucleotides, e.g. Ausubel, F.M. et al. *Current Protocols in Molecular Biology*, (John Wiley & Sons, New York, 1998), for example stringent conditions of 65°C in the presence of an elevated salt concentration. Such conditions are used for completely complementary nucleic acid hybridization, whereas conditions that are not stringent are used for hybridization of nucleic acids which are not totally complementary.

As used herein, the phrase "specifically hybridizing" means the ability of a nucleic acid molecule to recognize a nucleic acid sequence complementary to its own and to form double-helical segments through hydrogen bonding between complementary base pairs. As used herein, a "unique sequence" is a sequence specific to only the nucleic acid molecules encoding the IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5 proteins. Nucleic acid probe technology is well known to those skilled in the art who will readily appreciate that such probes may vary greatly in length and may be labeled with a detectable label, such as a radioisotope or fluorescent dye, to facilitate detection of the probe. Detection of nucleic acid molecules encoding the IRTA1, IRTA2, IRTA3, IRTA4 and/or IRTA5 proteins is useful as a diagnostic test for any disease process in which levels of expression of the corresponding IRTA1, IRTA2, IRTA3, IRTA4 and/or IRTA5 proteins is altered. DNA probe molecules are produced by insertion of

a DNA molecule which encodes mammalian IRTA1, IRTA2, IRTA3, IRTA4 and/or IRTA5 proteins or fragments thereof into suitable vectors, such as plasmids or bacteriophages, followed by insertion into suitable bacterial host cells and replication and harvesting of the DNA probes, all using methods well known in the art. For example, the DNA may be extracted from a cell lysate using phenol and ethanol, digested with restriction enzymes corresponding to the insertion sites of the DNA into the vector (discussed herein), electrophoresed, and cut out of the resulting gel. The oligonucleotide probes are useful for 'in situ' hybridization or in order to locate tissues which express this IRTA gene family, and for other hybridization assays for the presence of these genes (nucleic acid molecules encoding any of the IRTA1-IRTA5 proteins) or their mRNA in various biological tissues. In addition, synthesized oligonucleotides (produced by a DNA synthesizer) complementary to the sequence of a DNA molecule which encodes an IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 protein are useful as probes for these genes, for their associated mRNA, or for the isolation of related genes by homology screening of genomic or cDNA libraries, or by the use of amplification techniques such as the Polymerase Chain Reaction.

This invention provides a purified IRTA1 protein comprising the amino acid sequence set forth in Figure 18A (SEQ ID NO:1). In an embodiment of the purified IRTA1 protein, wherein the IRTA1 protein is human IRTA1.

This invention provides a purified IRTA2 protein comprising the amino acid sequence set forth in Figures

18B-1-18B-3 (SEQ ID NO:3). In an embodiment of the purified IRTA2 protein, the IRTA2 protein is human IRTA2.

5 This invention provides a purified IRTA3 protein comprising the amino acid sequence set forth in Figures 18C-1-18C-2 (SEQ ID NO:5). In an embodiment of the purified IRTA3 protein, the IRTA3 protein is human IRTA3.

10 This invention provides a purified IRTA4 protein comprising the amino acid sequence set forth in Figures 18D-1-18D-2 (SEQ ID NO: 7). In an embodiment of the purified IRTA3 protein, wherein the IRTA4 protein is human IRTA4.

15 This invention provides a purified IRTA5 protein comprising the amino acid sequence set forth in Figures 18E-1-18E-2 (SEQ ID NO: 9). In an embodiment of the purified IRTA5 protein, the IRTA5 protein is human IRTA5.

20 In order to facilitate an understanding of the Experimental Details section which follows, certain frequently occurring methods and/or terms are best described in Sambrook, et al.(1989) and Harlow & Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY: 1988.

25

30 This invention provides an antibody/antibodies directed to an epitope of a purified IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 protein, or fragment(s) thereof, having the amino acid sequence set forth in any of Figures 18A, 18B-1-18B-3, 18C-1-18C-2, 18D-1-18D-2 or 18E-1-18E-2.

As used herein, the term "antibody" includes, but is not limited to, both naturally occurring and non-naturally occurring antibodies. Specifically, the term "antibody" includes polyclonal and monoclonal antibodies, and binding fragments thereof. Furthermore, the term "antibody" includes chimeric antibodies and wholly synthetic antibodies, and fragments thereof. The polyclonal and monoclonal antibodies may be "purified" which means the polyclonal and monoclonal antibodies are free of any other antibodies. As used herein, partially purified antibody means an antibody composition which comprises antibodies which specifically bind to any of the IRTA protein(s) of the subejct invention, and consists of fewer protein impurities than does the serum from which the antibodies are derived. A protein impurity is a protein other than the antibodies specific for the IRTA protein(s) of the subejct invention. For example, the partially purified antibodies may be an IgG preparation.

Polyclonal antibodies (anti-IRTA antibodies) may be produced by injecting a host animal such as rabbit, rat, goat, mouse or other animal with the immunogen(s) of this invention, e.g. a purified human IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5, described infra. The sera are extracted from the host animal and are screened to obtain polyclonal antibodies which are specific to the immunogen. Methods of screening for polyclonal antibodies are well known to those of ordinary skill in the art such as those disclosed in Harlow & Lane, Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratories, Cold Spring Harbor, NY: 1988)

the contents of which are hereby incorporated by reference.

5 The anti-IRTA monoclonal antibodies of the subject invention may be produced by immunizing for example, mice with an immunogen (the IRTA polypeptides or fragments thereof as described herein). The mice are inoculated intraperitoneally with an immunogenic amount of the above-described immunogen and then boosted with similar amounts of the immunogen. Splens are collected from the
10 immunized mice a few days after the final boost and a cell suspension is prepared from the spleens for use in the fusion.

15 Hybridomas may be prepared from the splenocytes and a murine tumor partner using the general somatic cell hybridization technique of Kohler, B. and Milstein, C., Nature (1975) 256: 495-497. Available murine myeloma lines, such as those from the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, USA, may be used in the hybridization.
20 Basically, the technique involves fusing the tumor cells and splenocytes using a fusogen such as polyethylene glycol. After the fusion the cells are separated from the fusion medium and grown in a selective growth medium, such as HAT medium, to eliminate unhybridized parent cells.
25 The hybridomas may be expanded, if desired, and supernatants may be assayed by conventional immunoassay procedures, for example radioimmunoassay, using the immunizing agent as antigen. Positive clones may be
30 characterized further to determine whether they meet the criteria of the invention antibodies.

Hybridomas that produce such antibodies may be grown in vitro or in vivo using known procedures. The monoclonal antibodies may be isolated from the culture media or body fluids, as the case may be, by conventional immunoglobulin purification procedures such as ammonium sulfate precipitation, gel electrophoresis, dialysis, chromatography, and ultrafiltration, if desired.

In the practice of the subject invention any of the above-described antibodies may be labeled with a detectable marker. In one embodiment, the labeled antibody is a purified labeled antibody. The term "antibody" includes, by way of example, both naturally occurring and non-naturally occurring antibodies. Specifically, the term "antibody" includes polyclonal and monoclonal antibodies, and fragments thereof. Furthermore, the term "antibody" includes chimeric antibodies and wholly synthetic antibodies, and fragments thereof. A "detectable moiety" which functions as detectable labels are well known to those of ordinary skill in the art and include, but are not limited to, a fluorescent label, a radioactive atom, a paramagnetic ion, biotin, a chemiluminescent label or a label which may be detected through a secondary enzymatic or binding step. The secondary enzymatic or binding step may comprise the use of digoxigenin, alkaline phosphatase, horseradish peroxidase, β -galactosidase, fluorescein or streptavidin/biotin. Methods of labeling antibodies are well known in the art.

Methods of recovering serum from a subject are well known to those skilled in the art. Methods of partially purifying antibodies are also well known to those skilled

in the art, and include, by way of example, filtration, ion exchange chromatography, and precipitation.

5 The polyclonal and monoclonal antibodies of the invention may be labeled with a detectable marker. In one embodiment, the labeled antibody is a purified labeled antibody. The detectable marker may be, for example, a radioactive or fluorescent marker. Methods of labeling antibodies are well known in the art.

10 Determining whether the polyclonal and monoclonal antibodies of the subject invention bind to cells, e.g. cancer cells, expressing an IRTA protein and form a complex with one or more of the IRTA protein(s) described herein, or fragments thereof, on the surface of said
15 cells, may be accomplished according to methods well known to those skilled in the art. In the preferred embodiment, the determining is accomplished according to flow cytometry methods.

20 The antibodies of the subject invention may be bound to an insoluble matrix such as that used in affinity chromatography. Cells which form a complex, i.e. bind, with the immobilized polyclonal or monoclonal antibody may
25 be isolated by standard methods well known to those skilled in the art. For example, isolation may comprise affinity chromatography using immobilized antibody.

30 Alternatively, the antibody may be a free antibody. In this case, isolation may comprise cell sorting using free, labeled primary or secondary antibodies. Such cell sorting

methods are standard and are well known to those skilled in the art.

This invention provides an antibody directed to a purified IRTA protein selected from the group consisting of IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5. In a preferred embodiment of the anti-IRTA antibody the IRTA protein is human IRTA protein. The IRTA protein may be any mammalian IRTA protein, including a murine IRTA protein. In a further embodiment of any the above-described antibodies, the antibody is a monoclonal antibody. In another embodiment, the monoclonal antibody is a murine monoclonal antibody or a humanized monoclonal antibody. As used herein, "humanized" means an antibody having characteristics of a human antibody, such antibody being non-naturally occurring, but created using hybridoma techniques wherein the antibody is of human origin except for the antigen determinant portion, which is murine. In yet another embodiment, the antibody is a polyclonal antibody.

In preferred embodiments, any of the antibodies of the subject invention may be conjugated to a therapeutic agent. In further preferred embodiments, the therapeutic agent is a radioisotope, toxin, toxoid, or chemotherapeutic agent. The conjugated antibodies of the subject invention may be administered to a subject having a B cell cancer in any of the methods provided below.

This invention provides a pharmaceutical composition comprising an amount of the antibody directed to an IRTA protein effective to bind to cancer cells expressing an IRTA protein selected from the group consisting of human

IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5 so as to prevent growth of the cancer cells and a pharmaceutically acceptable carrier. The anti-IRTA antibody may be directed to an epitope of an IRTA protein selected from the group consisting of IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5. The IRTA proteins may be human or mouse IRTA proteins.

In preferred embodiments of the above-described pharmaceutical composition, the cancer cells are selected from the group consisting of B cell lymphoma, multiple myeloma, a mantle cell lymphoma, Burkitt's lymphoma, marginal zone lymphoma, diffuse large cell lymphoma and follicular lymphoma cells. In another preferred embodiment of the pharmaceutical composition, the B cell lymphoma cells are Mucosa-Associated-Lymphoid Tissue B cell lymphoma (MALT) cells. In another preferred embodiment of the pharmaceutical composition, the B cell lymphoma cells are non-Hodgkin's lymphoma cells.

This invention provides a pharmaceutical composition comprising an amount of any of the above-described oligonucleotides effective to prevent overexpression of a human IRTA protein and a pharmaceutically acceptable carrier capable. In preferred embodiments of the pharmaceutical composition the oligonucleotide is a nucleic acid molecule which encodes an IRTA protein selected from the group consisting of IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5. The IRTA proteins may be human or mouse IRTA proteins.

As used herein, "malignant" means capable of metastasizing. As used herein, "tumor cells" are cells

which originate from a tumor, i.e., from a new growth of different or abnormal tissue. The tumor cells and cancer cells may exist as part of the tumor mass, or may exist as free-floating cells detached from the tumor mass from which they originate.

As used herein, malignant cells include, but are in no way limited to, B cell lymphoma, multiple myeloma, Burkitt's lymphoma, mantle cell lymphoma, marginal zone lymphoma, diffuse large cell lymphoma and follicular lymphoma. The B cell lymphoma is Mucosa-Associated-Lymphoid Tissue B cell lymphoma (MALT) or is non-Hodgkin's lymphoma.

As used herein, "subject" is any animal or artificially modified animal. Artificially modified animals include, but are not limited to, SCID mice with human immune systems. In a preferred embodiment, the subject is a human.

This invention provides a method of diagnosing B cell malignancy which comprises a 1q21 chromosomal rearrangement in a sample from a subject which comprises: a) obtaining the sample from the subject; b) contacting the sample of step (a) with an antibody directed to a purified IRTA protein capable of specifically binding with a human IRTA protein selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5 IRTA protein on a cell surface of a cancer cell under conditions permitting binding of the antibody with human IRTA protein on the cell surface of the cancer cell, wherein the antibody is labeled with a detectable marker; and c) detecting any binding in step (b), wherein detection of

binding indicates a diagnosis of B cell malignancy in the sample.

5 In an embodiment of the above-described method of diagnosing B cell malignancy, the IRTA protein is selected from the group consisting of IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5. In another embodiment of the method the IRTA protein is human or mouse IRTA protein. In a further embodiment IRTA protein is purified. In a preferred
10 embodiment of this method, the B cell malignancy is selected from the group consisting of B cell lymphoma, multiple myeloma, Burkitt's lymphoma, marginal zone lymphoma, diffuse large cell lymphoma and follicular lymphoma. In yet another embodiment of this method, the B cell lymphoma is Mucosa-Associated-Lymphoid Tissue B cell lymphoma (MALT). In another preferred embodiment of this
15 method, the B cell lymphoma is non-Hodgkin's lymphoma.

20 This invention provides a method of detecting human IRTA protein in a sample which comprises: a) contacting the sample with any of any of the above-described anti-IRTA antibodies under conditions permitting the formation of a complex between the antibody and the IRTA in the sample; and b) detecting the complex formed in step (a), thereby
25 detecting the presence of human IRTA in the sample. In an embodiment the IRTA protein detected may be an IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 protein, having an amino acid sequence set forth in any of Figures 18A, 18B-1-18B-3, 18C-1-18C-2, 18D-1-18D-2 or 18E-1-18E-2. As described
30 hereinabove detection of the complex formed may be achieved by using antibody labeled with a detectable marker and determining presence of labeled complex.

Detecting human IRTA protein in a sample from a subject is another method of diagnosing B cell malignancy in a subject. In an embodiment of this method of diagnosis, the B cell malignancy is selected from the group consisting of B cell lymphoma, multiple myeloma, Burkitt's lymphoma, marginal zone lymphoma, diffuse large cell lymphoma and follicular lymphoma. In yet another embodiment of this method, the B cell lymphoma is Mucosa-Associated-Lymphoid Tissue B cell lymphoma (MALT). In another preferred embodiment of this method, the B cell lymphoma is non-Hodgkin's lymphoma.

This invention provides a method of treating a subject having a B cell cancer which comprises administering to the subject an amount of anti-IRTA antibody effective to bind to cancer cells expressing an IRTA protein so as to prevent growth of the cancer cells and a pharmaceutically acceptable carrier, thereby treating the subject. Growth and proliferation of the cancer cells is thereby inhibited and the cancer cells die. In an embodiment of the above-described method, the IRTA protein is selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5. In a preferred embodiment of the above-described method of treating a subject having a B cell cancer, the anti-IRTA antibody is a monoclonal antibody. In another embodiment of the method, the monoclonal antibody is a murine monoclonal antibody or a humanized monoclonal antibody. The antibody may be a chimeric antibody. In a further embodiment, the anti-IRTA antibody is a polyclonal antibody. In an embodiment, the polyclonal antibody may be a murine or human polyclonal antibody. In a preferred embodiment, the B cell cancer is selected from

the group consisting of B cell lymphoma, multiple myeloma, Burkitt's lymphoma, mantle cell lymphoma marginal zone lymphoma, diffuse large cell lymphoma and follicular lymphoma. In another preferred embodiment, the B cell lymphoma is Mucosa-Associated-Lymphoid Tissue B cell lymphoma (MALT). In a further preferred embodiment, the B cell lymphoma is non-Hodgkin's lymphoma. In a preferred embodiment of the above-described method of treating a subject having a B cell cancer, administration of the amount of anti-IRTA antibody effective to bind to cancer cells expressing an IRTA protein is intravenous, intraperitoneal, intrathecal, intralymphatic, intramuscular, intralesional, parenteral, epidural, subcutaneous; by infusion, liposome-mediated delivery, aerosol delivery; topical, oral, nasal, anal, ocular or otic delivery. In another preferred embodiment of the above-described methods, the anti-IRTA antibody may be conjugated to a therapeutic agent. In further preferred embodiments, the therapeutic agent is a radioisotope, toxin, toxoid, or chemotherapeutic agent.

This invention provides a method of treating a subject having a B cell cancer which comprises administering to the subject an amount of an antisense oligonucleotide having a sequence capable of specifically hybridizing to an mRNA molecule encoding a human IRTA protein so as to prevent overexpression of the human IRTA protein, so as to arrest cell growth or induce cell death of cancer cells expressing IRTA protein(s) and a pharmaceutically acceptable carrier, thereby treating the subject.

In an embodiment of the above-described method of treating a subject having a B cell cancer, the IRTA protein is selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5 protein. In a preferred embodiment, B cell cancer is selected from the group consisting of B cell lymphoma, multiple myeloma, Burkitt's lymphoma, marginal zone lymphoma, diffuse large cell lymphoma and follicular lymphoma. In another preferred embodiment, the B cell lymphoma is Mucosa-Associated-Lymphoid Tissue B cell lymphoma (MALT). In a yet another preferred embodiment, the B cell lymphoma is non-Hodgkin's lymphoma. In embodiments of any of the above-described oligonucleotides of nucleic acid molecules encoding the IRTA1, IRTA2, IRTA3, IRTA4 and/or IRTA5 proteins, the nucleic acid may be genomic DNA or cDNA. In a further preferred embodiment of the above-described method of treating a subject having a B cell cancer, administration of the amount of oligonucleotide of effective to prevent overexpression of a human IRTA protein is intravenous, intraperitoneal, intrathecal, intralymphatical, intramuscular, intralesional, parenteral, epidural, subcutaneous; by infusion, liposome-mediated delivery, aerosol delivery; topical, oral, nasal, anal, ocular or otic delivery. In an embodiment of the above-described methods, the oligonucleotide may be conjugated to a therapeutic agent. In further preferred embodiments, the therapeutic agent is a radioisotope, toxin, toxoid, or chemotherapeutic agent.

The invention also provides a pharmaceutical composition comprising either an effective amount of the

oligonucleotides or of the antibodies described above and a pharmaceutically acceptable carrier. In the subject invention an "effective amount" is any amount of an oligonucleotide or an antibody which, when administered to a subject suffering from a disease or abnormality against which the oligonucleotide or antibody are effective, causes reduction, remission, or regression of the disease or abnormality. In the practice of this invention the "pharmaceutically acceptable carrier" is any physiological carrier known to those of ordinary skill in the art useful in formulating pharmaceutical compositions.

Pharmaceutically acceptable carriers are well known to those skilled in the art and include, but are not limited to, 0.01-0.1M and preferably 0.05M phosphate buffer or 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like.

In one preferred embodiment the pharmaceutical carrier may be a liquid and the pharmaceutical composition would be in the form of a solution. In another equally preferred embodiment, the pharmaceutically acceptable carrier is a solid and the composition is in the form of a powder or tablet. In a further embodiment, the pharmaceutical carrier is a gel and the composition is in the form of a suppository or cream. In a further embodiment the compound may be formulated as a part of a pharmaceutically acceptable transdermal patch.

A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier

such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by for example, intramuscular, intrathecal, epidural, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. The compounds may be prepared as a sterile solid composition which may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium. Carriers are intended to include necessary and inert binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.

The pharmaceutical composition comprising the oligonucleotide or the antibody can be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents, for example, enough saline or glucose to make the solution isotonic, bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like.

The pharmaceutical composition comprising the oligonucleotide or the antibody can also be administered orally either in liquid or solid composition form. Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.

Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular inhibitor in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition or abnormality. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject age, weight, gender, diet, and time of administration.

This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific

methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

EXPERIMENTAL DETAILS

First Series of Experiments

Molecular analysis of chromosomal translocations associated with multiple myeloma (MM) has indicated that the pathogenesis of this malignancy may be heterogeneous, being associated with several distinct oncogenes including BCL-1, MUM-1 and FGFR3. Structural abnormalities of chromosome 1q21, including translocations with chromosome 14q32, represent frequent cytogenetic aberrations associated with multiple myeloma. In order to identify the genes involved in these translocations, the breakpoint regions corresponding to both derivatives of a t(1;14)(q21;q32) detectable in the FR4 human plasmacytoma cell line were cloned. Analysis of the breakpoint sequences showed that they involved a reciprocal recombination between the Immunoglobulin heavy chain (IgH) locus on 14q32 and unknown sequences on 1q21. The normal locus corresponding to the 1q21 region involved in the translocation was cloned and the genes adjacent to the breakpoint region were identified by an exon-trapping strategy. Two genes were found, located within a 20 Kb distance from each other, in the region spanning the breakpoint on 1q21. The first gene, called MUM-2 (multiple myeloma-2) is expressed as a 2.5 Kb mRNA transcript detectable in spleen and lymph nodes. Cloning and sequencing of the full-length MUM-2cDNA predicts a 515 amino acid cell surface glycoprotein containing four extracellular Ig-type domains, a transmembrane and a cytoplasmic domain and sharing a 37% identity (51%homology) with Fc gamma receptor I over its first three extracellular domains. In FR4 cells, the

translocation breakpoints interrupt the MUM-2 coding domain and juxtapose it to the IgH locus in the same transcriptional orientation. As a consequence, structurally abnormal FR4-specific MUM-2 transcripts (3.0, 5.2 and 6.0 Kb) in lymph nodes and spleen and encodes a protein with an extracellular domain containing six Ig-type domains homologous to members of the Fc gamma and Ig-type adhesion receptor families. The structure of the MUM-2 and MUM-3 genes and their direct involvement in a MM-associated translocation suggest that these genes code for novel cell surface receptors important for normal lymphocyte function and B cell malignancy.

Second Series of Experiments

Experimental Procedures

Cell Lines

The MM cell lines used in this study (FR4, U266, JJN3, EJM, SKMM1, RPMI-8226, XG1, XG2, XG4, XG6, XG7) have been previously reported (Tagawa et al., 1990), (Jernberg et al., 1987), (Hamilton et al., 1990; Jackson et al., 1989), (Eton et al., 1989), (Zhang et al., 1994). The FR4 cell line was established in the laboratory of one of the authors (S.T). The U266, JJN3, and EJM cell lines were gifts from Dr. K. Nilsson (University of Uppsala, Uppsala, Sweden) and the SKMM-1 cell line was a gift of A.N. Houghton (Memorial Sloan Kettering Cancer Center, New York, NY). The five XG cell lines were obtained from Dr. Bernard Klein and cultured in the presence of 1 ng/ml human recombinant IL-6 as described previously (Zhang et al., 1994). The BL cell lines with 1q21 abnormalities

have been previously described (Polito et al., 1995), (Magrath et al., 1980) and were grown in RPMI, 10% FCS.

Genomic and cDNA library screening and DNA sequence analysis

Two genomic libraries were constructed from FR4 genomic DNA either by BamHI complete digestion or by Sau3AI partial digestion and subsequent ligation of gel-purified fractions into the lDASH-II phage vector (Stratagene). The BamHI library was screened with a 4.2 kb XhoI-BamHI probe derived from the Ca locus and the Sau3AI library was screened with a 5'Sa probe previously described (Bergsagel et al., 1996). A human placental DNA library (Stratagene) was screened with probe 1.0EH (Figures 8A-8C) to obtain the germline 1q21 locus. Library screening and plaque isolation were performed according to established procedures (Sambrook et al., 1989). *IRTA1* and *IRTA2* cDNA clones were isolated from an oligo-dT/random-primed cDNA library constructed from normal human spleen RNA (Clontech). The *IRTA1* cDNA probe used for library screening was obtained from RT-PCR of human spleen cDNA using primers flanking exons 1 and 3. DNA sequencing was performed on an ABI 373 automated sequencer (Applied Biosystems). Sequence homology searches were carried out through the BLAST e-mail server at the National Center for Biotechnology Information, Bethesda, MD.

PAC and YAC isolation and exon trapping

Human PAC clones were obtained by screening a human PAC library spotted onto nylon membranes (Research Genetics), with the 1.0 EH probe (Figures 8A-8C). The Zeneca

(formerly ICI) human YAC library (Anand et al., 1990) obtained from the United Kingdom Human Genome Mapping Resource Center (UK-HGMP) was screened using a PCR-based pooling strategy. Exon trapping was performed using the exon trapping system (Gibco BRL), according to the manufacturer's instructions.

Isolation of PAC/YAC end clones, pulsed-field gel electrophoresis (PFGE) and fluorescence *in situ* hybridization (FISH) analysis

PAC DNA extraction was performed according to standard alkaline lysis methods (Drakopoli N et al., 1996). A vectorette-PCR method was used to isolate PAC and YAC end probes (Riley et al., 1990), as previously described (Iida et al, 1996). PFGE analysis was performed according to standard protocols (Drakopoli N et al., 1996) using the CHEF Mapper system (BioRad, Hercules, CA). Biotin labeling of PAC DNA, chromosome preparation and FISH were performed as previously described (Rao et al., 1993).

Southern and Northern blot analyses, RACE and RT-PCR

Southern and northern blot analyses were performed as described previously (Neri et al, 1991). For Northern blot analyses total RNA was prepared by the guanidium thiocyanate method and poly(A) RNA was selected using poly(T)-coated beads (Oligotex Kit by Quigen). For Northern blots, 2 mg of poly(A) RNA were loaded per lane. Multiple tissue Northern filters were obtained from Clontech. RACE was performed using the Marathon cDNA Amplification kit (Clontech) and Marathon-Ready spleen

cDNA. First strand cDNA synthesis was performed using the Superscript RT-PCR system (Gibco BRL)

***In situ* hybridization**

5 Digoxigenin-containing antisense and sense cRNA probes were transcribed with T3 and T7 RNA polymerase, respectively, from linearized pBluescript KS+ plasmids containing coding region of cDNAs (nucleotides 62 to 1681 of IRTA1 and 18 to 2996 of IRTA2.) Hyperplastic human tonsillar tissue surgically resected from children in Babies' Hospital, Columbia Presbyterian Medical Center was snap frozen in powdered dry ice. Cryostat sections were stored for several days at -80 degrees C prior to processing. Non-radioactive *in situ* hybridization was performed essentially as described (Frank et al., 1999), except that fixation time in 4% paraformaldehyde was increased to 20 minutes, and proteinase K treatment was omitted. The stringency of hybridization was 68 degrees C, in 5X SSC, 50% formamide. Alkaline phosphatase-conjugated anti-digoxigenin antibody staining was developed with BCIP/NBT substrate.

Transfection, immunoprecipitation and Western Blotting

25 293 cells (ATCC), grown in DMEM, 10% FCS were transiently transfected, according to the standard calcium phosphate method, with pMT2T and pMT2T-IRTA1/Ca transient expression constructs. The latter was generated using the IRTA1/Ca RT-PCR product from FR4. Cells (2×10^6 of transfectants and 2×10^7 of remaining cell lines) were solubilized in Triton X-100 lysis buffer (150 mM NaCl, 10 mM Tris-HCl [pH 7.4], 1% Tx-100, 0.1% BSA) in the presence of a protease inhibitors cocktail (Roche Biochemicals).

Lysates were incubated at 4°C for 2 hours with 4 mg/ml of the monoclonal antibody #117-332-1 (Yu et al., 1990) (Tanox Biosystems, Inc, Houston, Texas) that was raised against the extracellular portion of the IgA membrane peptide. Immune complexes were isolated with protein G-Sepharose (Pharmacia) prior to electrophoresis on 10-20% Tris-HCl gradient gels (Biorad) and immunoblotting, using 15 mg/ml of the #117-332-1 antibody. Results were visualized by ECL (Amersham).

RESULTS

Molecular Cloning of the t(1;14)(q21;q32)

Chromosomal translocations involving the Ig heavy-chain (IGH) locus often occur within or near IgH switch regions as a result of "illegitimate" switch recombination events (Dalla-Favera et al., 1983; Chesi et al., 1996; Chesi et al., 1998). The breakpoints can be detected by Southern-blot hybridization assays as rearranged alleles in which the IGH constant (C_H) region sequences have lost their syntenic association with IGH joining (J_H) and 5' switch region (S) sequences (Dalla-Favera et al., 1983; Neri et al., 1988; Neri et al., 1991; Bergsagel et al., 1996). This assay has led to the identification of several chromosomal partners for the IgH locus in B-NHL and MM (Taub et al., 1982; Dalla-Favera et al., 1983; Neri et al., 1988; Neri et al., 1991; Ye et al., 1993; Chesi et al., 1996; Richelda et al., 1997; Iida et al., 1997; Dyomin et al., 1997; Dyomin et al., 2000). We employed the same strategy in order to clone the 1q21 breakpoint region in FR4, a myeloma cell line carrying a t(1;14)(q21;q32), as determined by cytogenetic analysis

(Tagawa et al., 1990; Taniwaki M, unpublished results). Two "illegitimately" rearranged fragments were identified within the C α heavy-chain locus in FR4 by Southern blot hybridization analysis (data not shown), and were cloned from phage libraries constructed from FR4 genomic DNA. Restriction mapping, Southern blot hybridization and partial nucleotide sequencing of two genomic phages (clones λ FR4B-5 and λ FR4S-a, Figure 8A) demonstrated that they contained the chromosomal breakpoints of a reciprocal balanced translocation between the C α_1 locus on 14q32 and non-IGH sequences. A probe (1.0EH) representing these non-IgH sequences (Figure 8A) was then used to clone the corresponding normal genomic locus from phage, P1 artificial chromosome (PAC), and yeast artificial chromosome (YAC) human genomic libraries. Fluorescence *in situ* hybridization (FISH) analysis of normal human metaphase spreads using the 100-kb non-chimaeric PAC clone 49A16 which spans the breakpoint region (see below, Figure 13), identified the partner chromosomal locus as derived from band 1q21 (Figure 8C). Mapping to a single locus within chromosome 1 was confirmed by hybridization of two non-repetitive probes to DNA from a somatic-cell hybrid panel representative of individual human chromosomes (data not shown). These results were consistent with the cloning of sequences spanning the t(1;14)(q21;q32) in FR4.

Sequence analysis of the breakpoint regions on the derivative chromosomes and alignment with the germline 14q32 and 1q21 loci revealed that the breakpoint had occurred in the intron between the CH3 and the

transmembrane exon of $C\alpha_1$ on chromosome 14. Although the breakpoint region was devoid of recombination signal sequences (RSS) or switch signal sequences (Kuppers et al., 1999), the sequence CTTAAC (underlined on Figure 8B) was present in both germline chromosomes 14 and 1 at the breakpoint junction. One copy of this sequence was present in each of the derivative chromosomes, with a slight modification in the der(1) copy (point mutation in the last nucleotide: C to G). The nucleotides AT preceding CTTAAC on chromosome 1 were also present in both derivative chromosomes (Figure 8B). The translocation did not result in any loss of chromosome 1 sequences. On the other hand, in the chromosome 14 portion of der(1) we observed two deletions upstream of the breakpoint junction: a 16 nucleotide deletion (GGCACCTCCCCTTAAC) and a 4 nucleotide deletion (TGCA) 6 nucleotides upstream (Figure 8B). These observations indicate that the t(1;14)(q21;q32) in FR4 cells represents a balanced reciprocal translocation possibly facilitated by the presence of homologous sequences (CTTAAC) on both chromosomes.

The 1q21 breakpoint region contains genes coding for novel members of the Immunoglobulin Receptor Superfamily

We next investigated whether the region of chromosome 1q21 spanning the translocation breakpoint in FR4 contains a transcriptional unit. DNA from partially overlapping PAC clones 49A16 and 210K22 (Figure 13) was "shotgun" cloned in plasmids, sequenced and analyzed for homology to known genes in human genome databases. In parallel, candidate

genes on the 49A16 PAC were sought by an exon trapping strategy (Church et al., 1994).

Mapping of the candidate exons on the 1q21 genomic clones revealed that the FR4 breakpoint had occurred between two trapped exons (see below, Figure 13), which belonged to the same transcript since they could be linked by RT-PCR using spleen RNA. This RT-PCR product was then used as a probe to screen a spleen cDNA library in order to isolate full-length clones corresponding to this transcript. Two sets of cDNA clones were identified, belonging to two distinct transcripts and sharing a 76% mRNA sequence identity within the 443 bp probe region. Full length cDNA clones for both transcripts were obtained by rapid amplification of cDNA ends (RACE) on human spleen cDNA that generated 5' and 3' extension products.

The schematic structure of the cDNA representing the first transcript is depicted in Figure 9A. Alternate usage of three potential polyadenylation sites in its 3' untranslated region gives rise to three mRNA species of 2.6, 2.7 and 3.5 kb, encoding the same putative 515-amino acid protein (Figure 9A). The predicted features of this protein include a signal peptide, in accordance with the [-3, -1] rule (von Heijne, 1986), four extracellular Ig-type domains carrying three potential asparagine (N)-linked glycosylation sites (Figure 9A), a 16 amino acid transmembrane and a 106 amino acid cytoplasmic domain with three putative consensus Src-homology 2 (SH2)-binding domains (Unkeless and Jin, 1997) (Figure 10B). These (SH2)-binding domains exhibit features of both ITAM (Immune-receptor Tyrosine-based Activation Motif

-D/EX₇D/EX₂YXXL/IX₆₋₈YXXL/I; where X denotes non-conserved residues) (Reth, 1989) and ITIM motifs (Immune-receptor Tyrosine-based Inhibition Motif - S/V/L/IYXXL/V where X denotes non-conserved residues) (Unkeless and Jin, 1997). As shown in Figure 10B, the first two SH2-binding domains are spaced 8 aminoacids apart, consistent with the consensus ITAM motif. Diverging from the consensus, the glutamate residue (E) is positioned four rather than two aminoacids before the first tyrosine (Y) (Figure 10B), and the +3 position relative to tyrosine (Y) is occupied by valine (V) rather than leucine (L) or isoleucine (I) (Cambier, 1995). All three domains conform to the ITIM consensus and each is encoded by a separate exon, as is the case for ITIM. Thus their arrangement may give rise to three ITIM or possibly to one ITAM and one ITIM. The overall structure of this protein suggests that it represents a novel transmembrane receptor of the Ig superfamily and it was therefore name IRTA1 (Immune Receptor Translocation Associated gene 1).

The second cDNA shares homology to *IRTA1* (68% nucleotide identity for the length of the *IRTA1* message encoding its extracellular domain) and was named *IRTA2*. The *IRTA2* locus is more complex than *IRTA1* and is transcribed into three major mRNA isoforms (*IRTA2a*, *IRTA2b*, *IRTA2c*) of different molecular weight (2.8, 4.7 and 5.4 kb respectively), each with its own unique 3' untranslated region (Figure 9B). In addition, a 0.6 kb transcript (Figure 12A) arises from the usage of an early polyadenylation signal at nucleotide 536 of *IRTA2*. The three predicted *IRTA2* protein isoforms encoded by these

transcripts share a common aminoacid sequence until residue 560, featuring a common signal peptide and six extracellular Ig-type domains (Figure 9B). IRTA2a encodes for a 759 aa secreted glycoprotein with eight Ig-type domains followed by 13 unique, predominantly polar aminoacids at its C-terminus. IRTA2b diverges from IRTA2a at amino acid residue 560, and extends for a short stretch of 32 additional residues, whose hydrophobicity is compatible with its docking to the plasma membrane via a GPI-anchor (Ferguson and Williams, 1988). IRTA2c is the longest isoform whose sequence deviates from IRTA2a at aminoacid 746. It encodes a 977 aa type I transmembrane glycoprotein with nine extracellular Ig-type domains, harboring eight potential N-linked glycosylation sites, a 23 aminoacid transmembrane and a 104 aminoacid cytoplasmic domain with three consensus SH2-binding motifs (Figure 10B). Each of the SH2-binding sites in IRTA2c agrees with the ITIM consensus (Figure 10B) and is encoded by a separate exon. These features suggest that IRTA2c is a novel transmembrane receptor of the Ig superfamily with secreted and GPI-linked isoforms.

Homology between the IRTA proteins and Immunoglobulin Superfamily Receptors

Amino acid alignment of the entire extracellular domains of the IRTA1 and IRTA2 proteins to each other and to other Ig superfamily members revealed a remarkable homology between them (47% identity and 51% similarity) and a lower, but striking homology to the Fc gamma receptor family of proteins. This homology was stronger in the aminoacid positions conserved among the different classes

of Fc receptors. Among Fc receptors, the high affinity IgG receptor FCGRI (CD64) shared the highest levels of homology with the first three Ig-domains of IRTA1 and IRTA2 (37% identity and 50% similarity) throughout its entire extracellular portion (Figure 10A). Lower levels of homology were observed between the IRTA proteins and the extracellular domains of other cell surface molecules, including human platelet endothelial cell adhesion molecule (PECAM1), B-lymphocyte cell adhesion molecule (CD22) and Biliary Glycoprotein 1 (BGP1) (22-25% identity, 38-41% homology).

No homology is apparent between the IRTAs and members of the Fc receptor family in their cytoplasmic domains. In contrast, significant aminoacid homology is present between IRTA1 and PECAM1 (31% aminoacid identity and 45% homology), IRTA2c and BGP1 (30% identity, 35% homology) and IRTA2c and PECAM1 (28% identity, 50% homology) (Figure 10B). These homologies suggest employment of similar downstream signaling pathways by these different proteins.

IRTA1 and IRTA2 are normally expressed in specific subpopulations of B cells

The normal expression pattern of the *IRTA1* and *IRTA2* mRNAs was first analyzed by Northern blot hybridization of RNA derived from different normal human tissues and from human cell lines representing different hematopoietic lineages and stages of B-cell development.

IRTA1 expression was detected at a very low level in human spleen and lymph node RNA (Figure 11A, left panel) and was undetectable in all other human tissues analyzed, including fetal liver, bone marrow, lung, placenta, small intestine, kidney, liver, colon, skeletal muscle, heart and brain (data not shown). Among B cell lines, IRTA1 expression was absent in cell lines representing pre-B and germinal center B-cells, plasma cells and cells of erythroid, T-cell and myeloid origin (data not shown, see Materials and Methods). Expression was detectable at very low levels only in EBV-immortalized lymphoblastoid cell lines (LCL), which represent a subpopulation (immunoblasts) positioned downstream of germinal center B cells in B-cell differentiation. However, expression was induced in estrogen-deprived ER/EB cells which, being immortalized by a recombinant EBV genome in which the EBNA2 gene is fused to the estrogen receptor, proliferate in the presence of estrogen while they arrest in the G₀/G₁ phase upon estrogen deprivation (Kempkes et al., 1995). IRTA1 expression was barely detectable in these cells in the presence of estrogen, but was induced (10-fold) upon their G₀/G₁ arrest following estrogen withdrawal (Figure 11A, right panel). Taken together, these results suggest that IRTA1 is expressed in a lymphoid subpopulation present in spleen and lymph nodes and presumably represented by resting B cells.

To further investigate the phenotype and tissue distribution of the cells expressing IRTA1, we performed *in situ* hybridization on human tonsillar tissue using a IRTA1 antisense cDNA probe (Figure 11B). Serial sections were processed for *in situ* hybridization with a control

sense cDNA probe (Panel # 1 in Figure 11B), an antisense cDNA probe (Panel # 2) and hematoxylin and eosin (H&E) staining (Panel # 3) to outline the architecture of the lymphoid tissue. The *IRTA1* hybridization signal was excluded from the germinal center and the mantle zone of the follicles and was characteristically concentrated in the perifollicular zone with infiltrations in the intra-epithelial region (Figures 11B-2, 11B-4). In this region, only B cells were positive as documented by staining with B cell specific markers (IgD, not shown), and by immunohistochemical analysis with anti-*IRTA1* and anti-B (CD20, PAX5), anti-T (CD3), and anti-monocyte (CD68) antibodies (not shown; G. Cattoretti et al., manuscript in preparation). This perifollicular area is the "marginal zone" equivalent of the tonsil, representing a functionally distinct B-cell compartment that contains mostly memory B-cells and monocytoïd B-cells (de Wolf-Peeters et al., 1997). Together with the Northern blot analysis of normal tissues and cell lines, these results indicate that *IRTA1* is expressed in a subpopulation of resting mature B-cells topographically located in the perifollicular and intraepithelial region, sites rich in memory B cells.

In the case of *IRTA2*, Northern blot analysis detected all alternatively spliced species in human lymph node, spleen, bone marrow and small intestine mRNA, with relative preponderance of the *IRTA2a* isoform (Figure 12A, left panel). Among the hematopoietic cell lines of lymphoid and non-lymphoid origin tested, *IRTA2* expression was restricted to B-cell lines with an immunoblastic, post-germinal center phenotype (Figure 12A, right panel). Similarly to *IRTA1*, it was absent from cell lines derived

from pre-B cells, germinal center centroblasts, plasma cells, T-cells, erythroid cells and myeloid cells (Figure 12A, right panel).

5 *In situ* hybridization analysis of human tonsillar tissue, using the *IRTA2c* cDNA as a probe, was consistent with the results of the Northern blot analysis. The *IRTA2* mRNA was largely excluded from the mantle zone of the germinal center, with the exception of a few positive cells (Figures 12B-2, 12B4). Within the germinal center, the dark zone, represented by centroblasts, appeared negative for *IRTA2*, while the light zone, rich in centrocytes, was strongly positive (Figures 12B-2, 12B-4). Finally, *IRTA2* mRNA was detected in the "marginal zone" equivalent region outside germinal center follicles and in the intraepithelial and interfollicular regions of the tonsil. This pattern is consistent with specificity of *IRTA2* for centrocytes and post-germinal center B cells. Comparing their expression patterns, we conclude that both are specific for mature B cells, but *IRTA2* has a broader pattern of expression that includes centrocytes and interfollicular B cells, while *IRTA1* is restricted to marginal zone B cells, most likely memory cells.

25 **Genomic organization of the *IRTA1* and *IRTA2* genes**

To understand the consequences of 1q21 abnormalities on *IRTA1* and *IRTA2* gene structure and expression, we first determined the organization of their genomic loci. The *IRTA1* gene contains 11 exons with a total genomic size of 24.5 kb (Figure 13). The *IRTA2* locus was found to span a genomic region of approximately 40 kb (Figure 13). The three *IRTA2* alternatively spliced products share their

first 8 exons, at which point *IRTA2b* does not utilize the next splicing site, and terminates by entering its 3'UTR region. *IRTA2a* and *2c* isoforms splice into exon 9, with *IRTA2a* entering into its 3'UTR after exon 11 and *IRTA2c* splicing into exon 12 and extending until exon 18 (Figure 13).

Based on sequencing data, we determined that the *IRTA1* and *IRTA2* genes are located 21 kb distant from each other, juxtaposed in the same transcriptional orientation (Figure 13) that extends from the telomere (5') towards the centromere (3'). At the 1q21 locus, they are tightly linked to each other as well as to three additional genes we recently cloned through their homology to the *IRTAs* (I.M, manuscript in preparation). All five genes are contiguous, covering a ~300 kb region at 1q21. This region is located at the interval between previously reported 1q21 breakpoints. Based on the distance between genomic clones harboring the respective genes on the Whitehead Institute Radiation Hybrid map, the *IRTA1-2* locus is estimated to lie approximately 0.8 Mb away from the *MUC1* locus towards the telomere (N.P, unpublished data; Dyomin et al., 2000; Gilles et al., 2000) and less than or equal to 7 Mb away from the *FCGRIIB* locus towards the centromere (N.P, unpublished data).

The t(1;14)(q21;q32) translocation generates an *IRTA1/Ca₁* fusion protein in the FR4 myeloma cell line

Comparative restriction and nucleotide sequence analysis of germline versus rearranged sequences from the *Ca₁* and *IRTA1* loci showed that the translocation had fused

sequences within intron 2 of the *IRTA1* gene to the intronic sequences between the *CH3* and the transmembrane exon of Ca_1 in the same transcriptional orientation (Figure 14A). This suggested that, if *IRTA1* sequences were expressed in the translocated locus, the intact donor site at the 3' border of the *IRTA1* exon and the intact acceptor site at the 5' of Ca_1 could be used to generate a fusion *IRTA1/Ca₁* mRNA, and possibly a *IRTA1/Ca₁* fusion protein.

In order to test this prediction, we analyzed *IRTA1* mRNA expression in FR4 by Northern blot analysis using an *IRTA1* cDNA probe derived from exon 1 (Figure 14A). This probe detected a 0.8 kb message in FR4 that was absent from other B-cell lines, and was shorter than the normal 2.5 kb message detectable in ER/EB cells (Figure 14B). We cloned this transcript by RT-PCR of FR4 mRNA using primers derived from sequences at the 5' border of *IRTA1* exon 1 and the 3' border of the Ca_1 cytoplasmic exon (Figure 14A). An RT-PCR product was obtained from FR4, but not from the DAKIKI cell line expressing wild-type surface IgA, or other cell lines lacking a t(1;14) translocation (data not shown). Direct sequencing analysis of the PCR product indicated that splicing had precisely linked *IRTA1* and Ca_1 at canonical splicing sites and determined that the fusion transcript was 820 bp long.

Analysis of the predicted protein product indicated that the *IRTA1/Ca₁* splicing had resulted in a fusion between the *IRTA1* signal peptide and first two extracellular aminoacids, with the 32-amino acid long extracellular spacer, transmembrane domain and cytoplasmic tail of the

membrane IgA₁ (mIgA₁) receptor (Figure 14C). To assay for the expression of this fusion protein in FR4 protein extracts, we used an antibody directed against extracellular aminoacid residues specific for the transmembrane isoform of Cα₁ (Yu et al., 1990) for immunoprecipitation, followed by Western blotting. Our results demonstrated that FR4 cells, but not a control cell line (DAKIKI) expressing wild-type surface IgA, express a 9.8kDa protein consistent with the predicted size of IRTA1/Cα₁ fusion protein (Figure 14D). These results show that the translocated allele encodes a fusion protein, composed of the signal peptide and first two extracellular residues of IRTA1 (17 aminoacids) fused to the Cα₁ encoded transmembrane and cytoplasmic domains (71 aminoacids). In contrast to IRTA1/Cα₁ overexpression on der(14), no expression was detected in FR4 for the reciprocal Cα₁/IRTA1 transcript or for the intact IRTA2 gene on der(1).

With the exception of FR4, IRTA1 mRNA expression was not detected in any other myeloma or lymphoma cell line, regardless of the status of its chromosomal band 1q21 (data not shown). Thus, the IRTA1/Cα fusion represents a rare event in 1q21 aberrations.

Frequent deregulation of IRTA2 expression in cell lines carrying 1q21 abnormalities

In order to establish the physical relationship between other 1q21 breakpoints and the IRTA1/2 locus, we performed FISH analysis with the PAC 49A16 on our panel of BL and MM cell lines. Among ten BL cell lines analyzed, seven with

dup(1)(q21q32) and three with 1q21 translocations (AS283A, BL104, BL136), we detected three signals corresponding to the *IRTA1/IRTA2* locus in seven of the former and two of the latter, consistent with dup(1)(q21q32) in the first case and dup(1)(q21q32) followed by a translocation breakpoint at 1q21 in the second. (Table 1). FISH analysis of AS283A and BL136, using probes spanning the *IRTA* locus and with neighboring genomic clones, placed the breakpoint of the derivative chromosomes outside the *IRTA* locus in both cell lines, at a distance of >800 kb towards the centromere in AS283A and >800 kb towards the telomere in BL136 (N.P, unpublished results). Consistent with this finding, analysis of 30 cases of MM primary tumors by interphase FISH with the 300-kb YAC 23GC4 (Figure 13), showed that 15 cases (50% of total analyzed) had more than two interphase FISH signals (data not shown), while double color FISH with two PAC clones flanking the YAC centromeric and telomeric borders detected no split of these two probes in any of the cases. These results indicate that, with the exception of FR4, the breakpoints of 1q21 aberrations in BL or MM are not within or in close proximity to the genomic region defined by *IRTA1* and *IRTA2*. However, the consistent outcome of either dup(1)(q21q32) (see Table 1) or dup(1)(q21q32) followed by unbalanced translocations (AS283A, BL136, XG2, XG7 in Table 1) is partial trisomy or tetrasomy of the region of 1q21 containing the *IRTA* genes.

Table 1. Summary of karyotypic and FISH data on *IRTA1*/*IRTA2* locus

Tumour type	Cytogenetics	PAC 49A16	Copy number of IRTA locus by FISH	<i>IRTA2</i> mRNA expression
Burkitt Lymphoma				
AS283A	der(4) t (1;4)(q21;q35)	der(4), normal 1	3	++++++
MC116	dup1q21	dup1q21	3	+++
CA46	dup1q21	dup1q21	3	+++
PA682	dup1q21	dup1q21	3	++
Brg1gA	dup1q21	dup1q21	3	++
BL32	dup1q21	dup1q21	3	-
BL92	dup1q21	dup1q21	3	++
BL103	invdup1q21	dup1q21	3	+
BL104	t(1;3)(q21;p25)	der(1)	2	+
BL136	der(1)(qpter1q21::q21)	der(1)	3	++
Multiple Myeloma				
XG2	der(1) t(1;?)(q21;?) der 19 t (1;19)(q12;?)	der(1), normal 1 der(19)	3	++++
XG7	der(9) t (1;9)(q12;?) der(19) t (1;19)(q12;?) der(1) t(1;?)(q21;?) x2	der(9) der(19) der(1) x2	4	-

We then investigated whether these aberrations had an effect on *IRTA2* mRNA expression. To this end, we used a cDNA probe corresponding to the *IRTA2* 5' untranslated region to screen a Northern blot with a panel of B-NHL and MM cell lines lacking or displaying 1q21 chromosomal abnormalities. The results show that most (ten out of twelve) BL lines with normal 1q21 chromosomes essentially lack *IRTA2* expression, consistent with the fact that BL derive from GC centroblasts which normally lack *IRTA2* expression (Figure 15A, left panel). In contrast, most BL lines carrying 1q21 abnormalities (ten out of twelve) clearly display *IRTA2* mRNA upregulation (Figure 15A, right panel), ranging from 2 to 50 fold over baseline levels detected in BL with normal 1q21. Among myeloma cell lines, *IRTA2* was overexpressed in one out of three lines displaying 1q21 abnormalities (XG2), while it was expressed in none out of seven with normal 1q21 (Figure 15B).

These results show a strong correlation between the presence of 1q21 chromosomal aberrations and deregulation of *IRTA2* mRNA expression in BL and suggest that trisomies of the *IRTA2* locus may deregulate its expression in this lymphoma subtype (see Discussion).

Discussion

Efforts described herein to identify genes involved in chromosomal aberrations affecting band 1q21 in Multiple Myeloma and B cell lymphoma, led to the discovery of *IRTA1* and *IRTA2*, two founding members of a novel subfamily of related receptors within the immunoreceptor family; full length nucleic acid sequences encoding *IRTA1* and *IRTA2*

proteins are provided herein, as are the amino acid sequences of the encoded IRTA1 and IRTA2 proteins. Subsequently three additional genes of members of this subfamily of related receptors were isolated, *IRTA3*, *IRTA4*, and *IRTA5*, the full length nucleic acid sequences of which are provided herein, as are the amino acid sequences of the encoded IRTA3, IRTA4, and IRTA5 proteins. These results have implications for the normal biology of B cells as well as for the role of 1q21 aberrations in lymphomagenesis.

IRTA1 and IRTA2 are founding members of a new subfamily within the Ig superfamily

Several features shared between the two IRTA genes and their encoded proteins suggest that they form a new subfamily within the immunoreceptor superfamily. First, they share a higher degree of homology with each other in their extracellular domains than with other superfamily members both in their mRNA (68% identity) and protein (47% identity) sequence. Second, they share homology in their cytoplasmic domains, marked by the presence of ITAM-like and ITIM signaling motifs in the context of homologous aminoacid sequences. Third, IRTA1 and IRTA2 belong to a larger subfamily of five genes displaying higher intrafamily homology and tight clustering within a ~300 kb region at 1q21 (I.M. et al., manuscript in preparation). Their genomic organization suggests that a common ancestral gene may have given rise to this subfamily, by a process of duplication and sequence divergence, similar to the mechanism proposed for the Fc receptor family (Qiu et al., 1990).

In their extracellular domain, the *IRTA* proteins are closely related to the Fc receptor subfamily based on the high degree of aminoacid homology shared especially with the high affinity FCGRI receptor (37-45% aminoacid

identity). A common evolutionary origin with Fc receptors is also suggested by the position of the *IRTA* family locus in the interval between the *FCGR1* locus on 1q21 and the *FCERI* and *FCGR11-III* loci on 1q21-q23. Finally, the *IRTA* and *FCR* genes share a similar exon/intron organization of the gene portion that encodes their signal peptide, in particular the two 5' leader exons with the sequences encoding the signal peptidase site located within the second 21-bp exon.

Based on their cytoplasmic ITIM-like motifs, the *IRTA* proteins can be considered members of the Inhibitory Receptor Superfamily (IRS), a group of receptors that block activation of many cell types in the immune system (Lanier, 1998). Such members include *FCGR11B* and *CD22* in the human (DeLisser et al., 1994) and *PIR-B* in the mouse (Kubagawa et al., 1997). Analogous to IRS members, the ITIM of *IRTA1* and *IRTA2* are encoded by individual exons. A feature that many IRS members share is the existence of corresponding activating receptor isoforms whose cytoplasmic domains are devoid of ITIM (reviewed in Ravetch and Lanier, 1998). It is possible that the secreted isoform of *IRTA2*, which lacks ITIM-like motifs, fulfills an analogous role by counteracting the effect of the transmembrane isoform.

Significant homology in the sequence and overall organization of their extracellular portion is shared among the *IRTA1* and *IRTA2* proteins and the Cell Adhesion Molecule (CAM) subfamily members *PECAM1*, *CD22* and *BGP1*. In addition, the ability of *IRTA2* to generate three protein isoforms with distinct subcellular localization (a transmembrane, a GPI-linked or a secreted protein) by differential splicing is shared by *NCAM*, another member of the CAM subfamily (Dickson et al., 1987; Gower et al., 1988). Thus, the *IRTA* family is also related to the CAM family, as has been previously suggested for a member of the Fc receptor family (murine *FCGR11*) because of its

homology to PECAM1 (CAM, IRS family) (Daeron, 1991; Newman et al., 1990; Stockinger et al., 1990).

In conclusion, the IRTA family may represent an intersection among the Fc, IRS and CAM families, combining features from all three. Accordingly, IRTA proteins may have a role in the regulation of signal transduction during an immune response (like Fc receptors), intercellular communication (like members of the IRS and CAM families) and cell migration (like CAM family members) (DeLisser et al., 1994; Ravetch and Lanier, 2000). Initial experiments indicate that IRTA1 can weakly bind heat aggregated IgA, while IRTA2c can specifically bind heat aggregated human serum IgG (with higher affinity for IgG₁ and IgG₂), but not monomeric human IgG, IgA, IgM and IgE (data not shown). These initial data lend support to a functional relationship between the IRTA and the Fc receptor families, but do not exclude functions dependent on other ligands for the IRTA proteins.

Differential pattern of expression of IRTA genes in mature B cells

The IRTA genes display a specific pattern of expression in various normal B cell compartments. IRTA1 is topographically restricted to B cells within the perifollicular region, which was originally named marginal zone in the spleen, but is also detectable in most lymphoid organs (de Wolf-Peeters et al., 1997). The *in situ* hybridization data presented here have been confirmed by immunohistochemical analysis using anti-IRTA1 antibodies which show that the IRTA1 protein is selectively expressed in marginal zone B cells, and, among NHL, in marginal zone lymphoma, the tumors deriving from these cells (G. Cattoretti et al., manuscript in preparation). On the other hand, IRTA2 has a broader pattern of expression that includes GC centrocytes, as well as a broad spectrum of perifollicular cells, which

may include immunoblasts and memory cells. Initial data suggest that the pattern of expression of *IRTA3* is analogous to *IRTA2*, while *IRTA4* and *IRTA5* are selectively expressed in mantle zone B cells (I. Miller et al., manuscript in preparation), the pre-GC compartment of mature B cells (MacLennan, I. C., 1994). This topographic restriction of *IRTA* gene expression in lymphoid organs suggests that the *IRTA* molecules may play a role in the migration or activity of various B cell subpopulations in specific functional B cell compartments. In addition, *IRTA* expression should be useful for the differential diagnosis of NHL subtypes deriving from various B cell compartments, particularly *IRTA1* in the diagnosis of marginal zone lymphoma.

***IRTA1* locus and 1q21 abnormalities in MM**

In the FR4 cell line, the consequence of the t(1;14) translocation is the formation of an *IRTA1/C α_1* fusion gene. Despite the fact that this gene is driven by the *IRTA1* promoter region, which is normally silent in plasma cells, its expression is high in FR4, presumably due to the influence of the *C α_1* 3' LCR, which is retained downstream of the *C α_1* locus. The fusion gene encodes a *IRTA1/C α_1* fusion protein which contains only the signal peptide and first two amino acids of *IRTA1* linked to the surface IgA receptor. The latter has been almost completely deprived of its extracellular domain, but retains all its transmembrane and intracellular domains. This structure indicates that the *IRTA1/C α_1* fusion protein, though probably unable to bind any ligand, may retain the potential for dimerization and signaling. In particular, the membrane (m) IgA-derived extracellular portion contains a cysteine residue, which can be involved in disulphide bonds between two α -chains or between α -chains and associated proteins, such as the auxilliary surface receptor CD19 (Leduc et al., 1997). The fusion protein also carries the intact, 14 amino acid mIgA cytoplasmic

domain, which is highly conserved in evolution (Reth, 1992) and may play an essential role in the proliferation, survival and differentiation of mature B-cells, analogous to the role of mIgG and mIgE (Kaisho et al., 1997). Thus, the emergence of the IRTA1/Ca₁ protein in FR4 may have provided the cells with a proliferative and survival advantage during tumor development through ligand (antigen)-independent activation of the BCR pathway. This fusion event however, appears to be rare in B-cell malignancy, since so far we were able to detect it only in FR4 cells.

IRTA2 locus and 1q21 abnormalities in MM and BL

Abnormal expression of *IRTA2* is a frequent consequence of 1q21 abnormalities. Although this gene is not expressed normally either in centroblasts, the presumed normal counterparts of BL (Kuppers et al., 1999), or in BL with normal 1q21, its levels are upregulated on average by 10-fold in BL cell lines with 1q21 abnormalities. This deregulation appears to be specific for *IRTA2* since all the other 4 *IRTA* genes present within 300 kb on 1q21 are either not expressed in BL (*IRTA1*), or their pattern of expression does not correlate with the presence of 1q21 abnormalities (*IRTA3*, 4, 5, not shown). The mechanism by which this deregulation occurs is difficult to ascertain in the absence of structural lesions within or adjacent to the *IRTA2* gene. Since the heterogeneous aberrations that affect 1q21 all cause an excess copy number of the *IRTA* locus, it is possible that this may lead to regulatory disturbances, as is the case for low level amplification of *BCL2* in FL lacking (14;18) translocations (Monni et al., 1997), *REL* in diffuse large cell lymphoma (Houldsworth et al., 1996; Rao et al., 1998) and deregulation of Cyclin D1 in some MM cases with trisomy 11 (Pruneri et al., 2000). On the other hand, 1q21 abnormalities, including translocations and duplications, change the genomic context of the *IRTA* locus and may lead

to deregulation of *IRTA2* by distant cis-acting enhancer chromatin organizing elements acting on its promoter as is the case for *MYC* in endemic BL (Pelicci et al., 1986) and MM (Shou et al., 2000) and for *CCND1* in mantle cell lymphoma (Bosch et al., 1994; Swerdlow et al., 1995) and MM (Pruneri et al., 2000).

The biological consequences of deregulated *IRTA2* expression are difficult to predict at this stage. The observation that *IRTA2* has homology with CAM adhesion receptors, together with its specific distribution in the light zone of the GC suggest that its ectopic expression in centroblasts may cause a disruption in the GC development and architecture. On the other hand, our initial observations that *IRTA2* can bind IgG immune complexes comparably to bona fide Fc receptors suggest that its inappropriate expression may perturb the dynamics of cell surface regulation of B cell immunological responses, possibly leading to clonal expansion. Deregulated expression of *FCGR2B* as a result of the t(1;14)(q21;q32) in follicular lymphoma has been proposed to contribute to lymphomagenesis in this tumor type (Callanan et al., 2000), by a mechanism involving escape by tumor cells of anti-tumor immune surveillance through their Fc binding and inactivation of tumor specific IgG. Similar evasion mechanisms have been observed in cells infected by Fc-encoding herpesviruses (Dubin et al., 1991). The role of *IRTA2* deregulation needs to be tested in "gain of function" transgenic mice constitutively expressing *IRTA2* in the GC.

References for Second Series of Experiments

Anand, R., Riley, J. H., Butler, R., Smith, J. C., and Markham, A. F. (1990). A 3.5 genome equivalent multi access YAC library: construction, characterisation, screening and storage. *Nucleic Acids Res* 18, 1951-6.

Avet-Loiseau, H., Andree-Ashley, L. E., Moore, D., 2nd, Mellerin, M. P., Feusner, J., Bataille, R., and Pallavicini, M. G. (1997). Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. *Genes Chromosomes Cancer* 19, 124-33.

Bakhshi, A., Jensen, J. P., Goldman, P., Wright, J. J., McBride, O. W., Epstein, A. L., and Korsmeyer, S. J. (1985). Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. *Cell* 41, 899-906.

Berger, R., Bernheim, A. (1985). Cytogenetics of Burkitt's lymphoma-leukaemia: a review. *IARC Sci Publ* 60, 65-80.

Bergsagel, P. L., Chesi, M., Nardini, E., Brents, L. A., Kirby, S. L., and Kuehl, W. M. (1996). Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. *Proc Natl Acad Sci U S A* 93, 13931-6.

Bosch, F., Jares, P., Campo, E., Lopez-Guillermo, A., Piris, M. A., Villamor, N., Tassies, D., Jaffe, E. S., Montserrat, E., Rozman, C. et al. (1994). PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. *Blood* 84, 2726-32.

Callanan, M. B., Le Baccon, P., Mossuz, P., Duley, S.,
Bastard, C., Hamoudi, R., Dyer, M. J., Klobeck, G.,
Rimokh, R., Sotto, J. J., and Leroux, D. (2000). The IgG
Fc receptor, FcgammaRIIB, is a target for deregulation by
chromosomal translocation in malignant lymphoma. *Proc Natl
Acad Sci U S A* 97, 309-14.

Cambier, J. C. (1995). Antigen and Fc receptor signaling.
The awesome power of the immunoreceptor tyrosine-based
activation motif (ITAM). *J Immunol* 155, 3281-5.

Chesi, M., Bergsagel, P. L., Brents, L. A., Smith, C. M.,
Gerhard, D. S., and Kuehl, W. M. (1996). Dysregulation of
cyclin D1 by translocation into an IgH gamma switch region
in two multiple myeloma cell lines [see comments]. *Blood*
88, 674-81.

Chesi, M., Bergsagel, P. L., Shonukan, O. O., Martelli, M.
L., Brents, L. A., Chen, T., Schrock, E., Ried, T., and
Kuehl, W. M. (1998). Frequent dysregulation of the c-maf
proto-oncogene at 16q23 by translocation to an Ig locus in
multiple myeloma. *Blood* 91, 4457-63.

Chesi, M., Nardini, E., Brents, L. A., Schrock, E., Ried,
T., Kuehl, W. M., and Bergsagel, P. L. (1997). Frequent
translocation t(4;14)(p16.3;q32.3) in multiple myeloma is
associated with increased expression and activating
mutations of fibroblast growth factor receptor 3. *Nat
Genet* 16, 260-4.

Church, D. M., Stotler, C. J., Rutter, J. L., Murrell, J.
R., Trofatter, J. A., and Buckler, A. J. (1994). Isolation

of genes from complex sources of mammalian genomic DNA using exon amplification. *Nat Genet* 6, 98-105.

Cigudosa, J. C., Parsa, N. Z., Louie, D. C., Filippa, D. A., Jhanwar, S. C., Johansson, B., Mitelman, F., and Chaganti, R. S. (1999). Cytogenetic analysis of 363 consecutively ascertained diffuse large B- cell lymphomas. *Genes Chromosomes Cancer* 25, 123-33.

Daeron, M. (1991). Fc receptors, or the elective affinities of adhesion molecules. *Immunol Lett* 27, 175-81.

Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R.C., and Croce, C.M.: The human c-myc onc-gene is located on the region of chromosome 8 which is translocated in Burkitt lymphoma cells. *Proc. Nat. Acad. Sci. USA* 79:7824-7827, 1982.

Dalla-Favera, R., Martinotti, S., Gallo, R. C., Erikson, J., and Croce, C. M. (1983). Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. *Science* 219, 963-7.

de Wolf-Peeters, C., Pittaluga, S., Dierlamm, J., Wlodarska, I., and Van Den Berghe, H. (1997). Marginal zone B-cell lymphomas including mucosa-associated lymphoid tissue type lymphoma (MALT), monocytoid B-cell lymphoma and splenic marginal zone cell lymphoma and their relation to the reactive marginal zone. *Leuk Lymphoma* 26, 467-78.

DeLisser, H. M., Newman, P. J., and Albelda, S. M. (1994).
Molecular and functional aspects of PECAM-1/CD31. *Immunol
Today* 15, 490-5.

5 Dickson, G., Gower, H. J., Barton, C. H., Prentice, H. M.,
Elsom, V. L., Moore, S. E., Cox, R. D., Quinn, C., Putt,
W., and Walsh, F. S. (1987). Human muscle neural cell
adhesion molecule (N-CAM): identification of a muscle-
specific sequence in the extracellular domain. *Cell* 50,
10 1119-30.

Dierlamm, J., Pittaluga, S., Wlodarska, I., Stul, M.,
Thomas, J., Boogaerts, M., Michaux, L., Driessen, A.,
Mecucci, C., Cassiman, J. J., and et al. (1996). Marginal
zone B-cell lymphomas of different sites share similar
15 cytogenetic and morphologic features [see comments]. *Blood*
87, 299-307.

Dracopoli, C. N., Haines, J. L., Korf, B. R., Morton, C.
20 C., Seidman, C. E., Seidman, J.G., Smith, D. R. (1997).
Current Protocols in Human Genetics (New York: Wiley &
Sons)

Dubin, G., Socolof, E., Frank, I., Friedman, H. M. (1991).
25 Herpes simplex virus type 1 Fc receptor protects infected
cells from antibody-dependent cellular cytotoxicity.
Journal of Virology 65, 7046-50.

Dyomin, V. G., Palanisamy, N., Lloyd, K. O., Dyomina, K.,
30 Jhanwar, S. C., Houldsworth, J., and Chaganti, R. S.
(2000). MUC1 is activated in a B-cell lymphoma by the

t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood 95, 2666-71.

5 Dyomin, V.G., Rao, P.H., Dalla-Favera, R., Chaganti, R.S.K. (1997). *BCL8*, a novel gene involved in translocations affecting band 15q11-13 in diffuse large-cell lymphoma. Proc Natl Acad Sci USA 94, 5728-32.

10 Eton, O., Scheinberg, D. A., and Houghton, A. N. (1989). Establishment and characterization of two human myeloma cell lines secreting kappa light chains. Leukemia 3, 729-35.

15 Ferguson, M. A., and Williams, A. F. (1988). Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures. Annu Rev Biochem 57, 285-320.

20 Frank, D., Mendelsohn, C. L., Ciccone, E., Svensson, K., Ohlsson, R., and Tycko, B. (1999). A novel pleckstrin homology-related gene family defined by Ipl/Tssc3, TDAG51, and Tih1: tissue-specific expression, chromosomal location, and parental imprinting. Mamm Genome 10, 1150-1159.

25 Gaidano, G., and Dalla-Favera, R. (1997). Molecular Biology of Lymphomas. In: Principles and Practice of Oncology, Fifth Ed, DeVita, VT, Hellman, S., Rosenberg SA (eds) JB Lippincott Co (publ.), 2131-2145.

30 Gilles, F., Goy, A., Remache, Y., Shue, P., and Zelenetz, A. D. (2000). MUC1 dysregulation as the consequence of a

tt(1;14)(q21;q32) translocation in an extranodal lymphoma.
Blood 95, 2930-2936.

5 Gower, H. J., Barton, C. H., Elsom, V. L., Thompson, J.,
Moore, S. E., Dickson, G., and Walsh, F. S. (1988).
Alternative splicing generates a secreted form of N-CAM in
muscle and brain. Cell 55, 955-64.

10 Hamilton, M. S., Ball, J., Bromidge, E., Lowe, J., and
Franklin, I. M. (1990). Characterization of new IgG lambda
myeloma plasma cell line (EJM): a further tool in the
investigation of the biology of multiple myeloma. Br J
Haematol 75, 378-84.

15 Houldsworth, J., Mathew, S., Rao, P. H., Dyomina, K.,
Louie, D. C., Parsa, N., Offit, K., Chaganti, R. S.
(1996). REL proto-oncogene is frequently amplified in
extranodal diffuse large cell lymphoma. Blood 87, 25-9.

20 Iida, S., Rao, P. H., Butler, M., Corradini, P.,
Boccardo, M., Klein, B., Chaganti, R. S., and Dalla-
Favera, R. (1997). Deregulation of MUM1/IRF4 by
chromosomal translocation in multiple myeloma. Nat Genet
17, 226-30.

25 Jackson, N., Lowe, J., Ball, J., Bromidge, E., Ling, N.
R., Larkins, S., Griffith, M. J., and Franklin, I. M.
(1989). Two new IgA1-kappa plasma cell leukaemia cell
lines (JJN-1 & JJN-2) which proliferate in response to B
30 cell stimulatory factor 2. Clin Exp Immunol 75, 93-9.

Jernberg, H., Zech, L., and Nilsson, K. (1987).
Cytogenetic studies on human myeloma cell lines. *Int J*
Cancer 40, 811-7.

5 Juliusson, G., Oscier, D. G., Fitchett, M., Ross, F. M.,
Stockdill, G., Mackie, M. J., Parker, A. C., Castoldi, G.
L., Guneo, A., Knuutila, S., and et al. (1990). Prognostic
subgroups in B-cell chronic lymphocytic leukemia defined
by specific chromosomal abnormalities. *N Engl J Med* 323,
10 720-4.

Kaisho, T., Schwenk, F., and Rajewsky, K. (1997). The
roles of gamma 1 heavy chain membrane expression and
cytoplasmic tail in IgG1 responses. *Science* 276, 412-5.

15 Kempkes, B., Spitkovsky, D., Jansen-Durr, P., Ellwart, J.
W., Kremmer, E., Delecluse, H. J., Rottenberger, C.,
Bornkamm, G. W., and Hammerschmidt, W. (1995). B-cell
proliferation and induction of early G1-regulating
proteins by Epstein-Barr virus mutants conditional for
20 EBNA2. *Embo J* 14, 88-96.

Kornblau, S. M., Goodacre, A., Cabanillas, F. (1991).
Chromosomal abnormalities in adult non-endemic Burkitt's
25 lymphoma and leukemia: 22 new reports and a review of 148
cases from the literature. *Hematol Oncol* 9, 63-78.

Kubagawa, H., Burrows, P. D., and Cooper, M. D. (1997). A
novel pair of immunoglobulin-like receptors expressed by B
30 cells and myeloid cells [see comments]. *Proc Natl Acad Sci*
U S A 94, 5261-6.

Kuppers, R., Klein, U., Hansmann, M. L., and Rajewsky, K. (1999). Cellular origin of human B-cell lymphomas. *N Engl J Med* 341, 1520-9.

5 Lanier, L. L. (1998). NK cell receptors. *Annu Rev Immunol* 16, 359-93.

Leduc, I., Drouet, M., Bodinier, M. C., Helal, A., and Cogne, M. (1997). Membrane isoforms of human immunoglobulins of the A1 and A2 isotypes: structural and functional study. *Immunology* 90, 330-6.

10 MacLennan, I. C. (1994). Germinal Centers. *Annu Rev Immunol* 12, 117-39.

15 Magrath, I. T., Pizzo, P. A., Whang-Peng, J., Douglass, E. C., Alabaster, O., Gerber, P., Freeman, C. B., and Novikovs, L. (1980). Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. I. Physical, cytogenetic, and growth characteristics. *J Natl Cancer Inst* 64, 465-76.

20 Monni, O., Joensuu, H., Franssila, K., Klefstrom, J., Alitalo, K., and Knuutila, S. (1997). BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. *Blood* 90, 1168-74.

25 Neri, A., Barriga, F., Knowles, D. M., Magrath, I. T., and Dalla-Favera, R. (1988). Different regions of the immunoglobulin heavy-chain locus are involved in

chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. *Proc Natl Acad Sci U S A* 85, 2748-52.

5 Neri, A., Chang, C. C., Lombardi, L., Salina, M., Corradini, P., Maiolo, A. T., Chaganti, R. S., and Dalla-Favera, R. (1991). B cell lymphoma-associated chromosomal translocation involves candidate oncogene *lyt-10*, homologous to NF-kappa B p50. *Cell* 67, 1075-87.

10 Newman, P. J., Berndt, M. C., Gorski, J., White, G. C. d., Lyman, S., Paddock, C., and Muller, W. A. (1990). PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. *Science* 247, 1219-22.

15 Offit, K., Louie, D. C., Parsa, N. Z., Roy, P., Leung, D., Lo Coco, F., Zelenetz, A., Dalla-Favera, R., Chaganti, R. S. (1995). BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma. *Leuk Lymphoma* 20, 85-9.

20 Pelicci, P. G., Knowles, D. M. d., Magrath, I., and Dalla-Favera, R. (1986). Chromosomal breakpoints and structural alterations of the *c-myc* locus differ in endemic and sporadic forms of Burkitt lymphoma. *Proc Natl Acad Sci U S A* 83, 2984-8.

25 Polito, P., Cilia, A. M., Gloghini, A., Cozzi, M., Perin, T., De Paoli, P., Gaidano, G., and Carbone, A. (1995). High frequency of EBV association with non-random abnormalities of the chromosome region 1q21-25 in AIDS-related Burkitt's lymphoma-derived cell lines. *Int J Cancer* 61, 370-4.

30

Pruneri, G., Fabris, S., Baldini, L., Carboni, N., Zagano, S., Colombi, M. A., Ciceri, G., Lombardi, L., Rocchi, M., Buffa, R., Maiolo, A. T., Neri, A. (2000). Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). *Am J Pathol* 156, 1505-13.

Qiu, W. Q., de Bruin, D., Brownstein, B. H., Pearce, R., Ravetch, J. V. (1990). Organization of the human and mouse low-affinity Fc gamma R genes: duplication and recombination. *Science* 248, 732-5.

Rao, P. H., Houldsworth, J., Dyomina, K., Parsa, N. Z., Cigudosa, J. C., Louie, D. C., Popplewell, L., Offit, K., Jhanwar, S. C., and Chaganti, R. S. (1998). Chromosomal and gene amplification in diffuse large B-cell lymphoma. *Blood* 92, 234-40.

Rao, P. H., Murty, V. V., Gaidano, G., Hauptschein, R., Dalla-Favera, R., and Chaganti, R. S. (1993). Subregional localization of 20 single-copy loci to chromosome 6 by fluorescence *in situ* hybridization. *Genomics* 16, 426-30.

Ravetch, J. V., and Lanier, L. L. (2000). Immune inhibitory receptors [In Process Citation]. *Science* 290, 84-9.

Reth, M. (1989). Antigen receptor tail clue [letter]. *Nature* 338, 383-4.

Reth, M. (1992). Antigen receptors on B lymphocytes. *Annu Rev Immunol* 10, 97-121.

Richelda, R., Ronchetti, D., Baldini, L., Cro, L.,
Viggiano, L., Marzella, R., Rocchi, M., Otsuki, T.,
Lombardi, L., Maiolo, A. T., Neri, A. (1997). A novel
chromosomal translocation t(4; 14)(p16.3; q32) in multiple
myeloma involves the fibroblast growth-factor receptor 3
gene [see comments]. *Blood* 90, 4062-70.

Riley, J., Butler, R., Ogilvie, D., Finniear, R., Jenner,
D., Powell, S., Anand, R., Smith, J. C., and Markham, A.
F. (1990). A novel, rapid method for the isolation of
terminal sequences from yeast artificial chromosome (YAC)
clones. *Nucleic Acids Res* 18, 2887-90.

Ronchetti, D., Finelli, P., Richelda, R., Baldini, L.,
Rocchi, M., Viggiano, L., Cuneo, A., Bogni, S., Fabris,
S., Lombardi, L., Maiolo, A. T., and Neri, A. (1999).
Molecular analysis of 11q13 breakpoints in multiple
myeloma. *Blood* 93, 1330-7.

Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E.,
Tsujiimoto, Y., Harris, N. L., and Arnold, A. (1991).
PRAD1, a candidate BCL1 oncogene: mapping and expression
in centrocytic lymphoma. *Proc Natl Acad Sci U S A* 88,
9638-42.

Sawyer, J. R., Tricot, G., Mattox, S., Jagannath, S., and
Barlogie, B. (1998). Jumping translocations of chromosome
1q in multiple myeloma: evidence for a mechanism involving
decondensation of pericentromeric heterochromatin. *Blood*
91, 1732-41.

Sawyer, J. R., Waldron, J. A., Jagannath, S., Barlogie, B. (1995). Cytogenetic findings in 200 patients with multiple myeloma. *Cancer Genet Cytogenet* 82, 41-9.

5 Shou, Y., Martelli, M. L., Gabrea, A., Qi, Y., Brents, L. A., Roschke, A., Dewald, G., Kirsch, I. R., Bergsagel, P. L., and Kuehl, W. M. (2000). Diverse karyotypic abnormalities of the c-myc locus associated with c- myc dysregulation and tumor progression in multiple myeloma. *Proc Natl Acad Sci U S A* 97, 228-33.

10 Stockinger, H., Gadd, S. J., Eher, R., Majdic, O., Schreiber, W., Kasinrerker, W., Strass, B., Schnabl, E., and Knapp, W. (1990). Molecular characterization and functional analysis of the leukocyte surface protein CD31. *J Immunol* 145, 3889-97.

15 Swerdlow, S. H., Yang, W. I., Zukerberg, L. R., Harris, N. L., Arnold, A., Williams, M. E. (1995). Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/cyclin D1 gene. *Hum Pathol* 26, 999-1004.

20 Tagawa, S., Doi, S., Taniwaki, M., Abe, T., Kanayama, Y., Nojima, J., Matsubara, K., and Kitani, T. (1990). Amylase-producing plasmacytoma cell lines, AD3 and FR4, with der(14)t(8;14) and dic(8)t(1;8) established from ascites. *Leukemia* 4, 600-5.

25 Taub, R., Kirsch, I., Morton, C., Lenoir, G., Swan, D., Tronick, S., Aaronson, S., Leder, P. (1982). Translocation of the c-myc gene into the immunoglobulin heavy chain

locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 79, 7837-41.

Thompson, J. D., Higgins, D. G., Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22, 4673-80.

Tusnady, G. E., Simon, I. (1998). Principles governing amino acid composition of integral membrane proteins: application to topology prediction. J Mol Bio 283, 489-506.

Unkeless, J. C., and Jin, J. (1997). Inhibitory receptors, ITIM sequences and phosphatases. Curr Opin Immunol 9, 338-43.

von Heijne, G. (1986). A new method for predicting signal sequence cleavage sites. Nucleic Acids Res 14, 4683-90.

Whang-Peng, J., Knutsen, T., Jaffe, E. S., Steinberg, S. M., Raffeld, M., Zhao, W. P., Duffey, P., Condron, K., Yano, T., Longo, D. L. (1995). Sequential analysis of 43 patients with non-Hodgkin's lymphoma: clinical correlations with cytogenetic, histologic, immunophenotyping, and molecular studies. Blood 85, 203-16.

Willis, T. G., Zalcborg, I. R., Coignet, L. J., Wlodarska, I., Stul, M., Jadayel, D. M., Bastard, C., Treleaven, J. G., Catovsky, D., Silva, M. L., and Dyer, M. J. (1998). Molecular cloning of translocation tt(1;14)(q21;q32)

defines a novel gene (BCL9) at chromosome 1q21. Blood 91, 1873-81.

Ye, B. H., Lista, F., Lo Coco, F., Knowles, D. M., Offit, K., Chaganti, R. S., and Dalla-Favera, R. (1993). Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large- cell lymphoma. Science 262, 747-50.

Yu, L. M., Peng, C., Starnes, S. M., Liou, R. S., and Chang, T. W. (1990). Two isoforms of human membrane-bound alpha Ig resulting from alternative mRNA splicing in the membrane segment. J Immunol 145, 3932-6.

Zhang, X. G., Gaillard, J. P., Robillard, N., Lu, Z. Y., Gu, Z. J., Jourdan, M., Boiron, J. M., Bataille, R., and Klein, B. (1994). Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83, 3654-63.

Third Series of Experiments

Chromosome 1q21 is frequently altered by translocations and duplications in several types of B cell malignancy, including multiple myeloma, Burkitt lymphoma, marginal zone lymphomas, and follicular lymphoma. To identify the genes involved in these aberrations, cloned was the chromosomal breakpoint of a t(1;14)(q21;q32) in the myeloma cell line FR4. A 300kb region spanning the breakpoint contains at least five highly related adjacent genes which encode surface receptor molecules that are members of the immunoglobulin gene superfamily, and thus called IRTA (Immunoglobulin Receptor Translocation

Associated). The various IRTA molecules have from three to nine extracellular immunoglobulin superfamily domains and are related to the Fc gamma receptors. They have transmembrane and cytoplasmic domains containing ITIM-like and ITAM-like (ITRA-1, IRTA-3, IRTA-4) signaling motifs. In situ hybridization experiments show that all IRTA genes are expressed in the B cell lineage with distinct developmental stage-specific patterns: IRTA-1 is expressed in a marginal B cell pattern. IRTA-2 is expressed in centrocytes and more mature B cells. As a result of the translocation in FR4, IRTA-1 is broken and produces a fusion transcript with the immunoglobulin locus. The IRTA-2 gene, normally silent in centroblasts, is overexpressed in multiple myeloma and in Burkitt lymphoma cell lines carrying 1q21 abnormalities. The data here suggests that IRTA genes are novel B cell regulatory molecules that may also have a role in lymphomagenesis.

What is claimed is:

1. An isolated nucleic acid molecule which encodes immunoglobulin receptor, Immunoglobulin superfamily Receptor Translocation Associated, IRTA, protein.
2. The isolated nucleic acid molecule of claim 1, wherein the IRTA protein is IRTA1 protein comprising the amino acid sequence set forth in Figure 18A (SEQ ID NO:1).
3. The isolated nucleic acid molecule of claim 1, wherein the IRTA protein is IRTA2 protein comprising the amino acid sequence set forth in Figures 18B-1-18B-3 (SEQ ID NO:3).
4. The isolated nucleic acid molecule of claim 1, wherein the IRTA protein is IRTA3 protein comprising the amino acid sequence set forth in Figures 18C-1-18C-2 (SEQ ID NO:5).
5. The isolated nucleic acid molecule of claim 1, wherein the IRTA protein is IRTA4 protein comprising the amino acid sequence set forth in Figures 18D-1-18D-2 (SEQ ID NO: 7).
6. The isolated nucleic acid molecule of claim 1, wherein the IRTA protein is IRTA5 protein comprising the amino acid sequence set forth in Figures 18E-1-18E-2 (SEQ ID NO: 9).

7. An isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is DNA.
8. The isolated DNA molecule of claim 2, wherein the DNA is cDNA.
9. The isolated DNA molecule of claim 2, wherein the DNA is genomic DNA.
10. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule is an RNA molecule.
11. The isolated DNA molecule of claim 2, wherein the DNA molecule is cDNA having the nucleotide sequence set forth in Figure 18A (SEQ ID NO:2).
12. The isolated DNA molecule of claim 2, wherein the DNA molecule is cDNA having the nucleotide sequence set forth in Figure 18A (SEQ ID NO:4).
13. The isolated DNA molecule of claim 2, wherein the DNA molecule is cDNA having the nucleotide sequence set forth in Figure 18A (SEQ ID NO:6).
14. The isolated DNA molecule of claim 2, wherein the DNA molecule is cDNA having the nucleotide sequence set forth in Figure 18A (SEQ ID NO:8).
15. The isolated DNA molecule of claim 2, wherein the DNA molecule is cDNA having the nucleotide sequence set forth in Figure 18A (SEQ ID NO:10).

16. The isolated nucleic acid molecule of claim 1, wherein the nucleic acid molecule encodes a human IRTA1 protein.

5 17. The isolated nucleic acid molecule of claim 1 operatively linked to a promoter of DNA transcription.

10 18. The isolated nucleic acid molecule of claim 17, wherein the promoter comprises a bacterial, yeast, insect, plant or mammalian promoter.

15 19. A vector comprising the nucleic acid molecule of claim 17.

20 20. The vector of claim 19, wherein the vector is a plasmid.

21. A host cell comprising the vector of claim 20.

22. The host cell of claim 21, wherein the cell is selected from a group consisting of a bacterial cell, a plant cell, and insect cell and a mammalian cell.

25 23. An isolated nucleic acid molecule comprising at least 15 contiguous nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of the isolated nucleic acid molecule encoding IRTA1 protein of claim 1.

30 24. The isolated nucleic acid molecule of claim 23 labeled with a detectable marker.

25. The nucleic acid molecule of claim 24, wherein the detectable marker is selected from the group consisting of a radioactive isotope, enzyme, dye, biotin, a fluorescent label or a chemiluminescent label.

26. A method for detecting a B cell malignancy or a type of B cell malignancy in a sample from a subject wherein the B cell malignancy comprises a 1q21 chromosomal rearrangement which comprises:

- a) obtaining RNA from the sample from the subject;
- b) contacting the RNA of step (a) with a nucleic acid molecule of at least 15 contiguous nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of an isolated RNA encoding human IRTA protein selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5, under conditions permitting hybridization of the RNA of step (a) with the nucleic acid molecule capable of specifically hybridizing with a unique sequence included within the sequence of an isolated RNA encoding human IRTA protein, wherein the nucleic acid molecule is labeled with a detectable marker; and
- c) detecting any hybridization in step (b), wherein detection of hybridization indicates presence of B cell malignancy or a type of B cell malignancy in the sample.

27. The method of claim 26, wherein the detectable marker is radioactive isotope, enzyme, dye, biotin, a fluorescent label or a chemiluminescent label.

28. The method of claim 26, wherein the B cell malignancy is selected from the group consisting of B cell lymphoma, multiple myeloma, Burkitt's lymphoma, marginal zone lymphoma, diffuse large cell lymphoma and follicular lymphoma cells.

29. The method of claim 28, wherein the B cell lymphoma is Mucosa-Associated-Lymphoid Tissue B cell lymphoma (MALT).

30. The method of claim 28, wherein the B cell lymphoma is non-Hodgkin's lymphoma.

31. An antisense oligonucleotide having a sequence capable of specifically hybridizing to an mRNA molecule encoding a human ITRA protein so as to prevent overexpression of the mRNA molecule.

32. The antisense oligonucleotide of claim 31, wherein the ITRA protein selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5 protein.

33. A purified IRTA1 protein comprising the amino acid sequence set forth in Figure 18A (SEQ ID NO:1).

34. The purified IRTA1 protein of claim 33, wherein the IRTA1 protein is human IRTA1.

35. A purified IRTA2 protein comprising the amino acid sequence set forth in Figures 18B-1-18B-3 (SEQ ID NO:3).

36. The purified IRTA2 protein of claim 35, wherein the IRTA2 protein is human IRTA2.

37. A purified IRTA3 protein comprising the amino acid sequence set forth in Figures 18C-1-18C-2 (SEQ ID NO:5).

38. The purified IRTA3 protein of claim 37, wherein the IRTA3 protein is human IRTA3.

39. A purified IRTA4 protein comprising the amino acid sequence set forth in Figures 18D-1-18D-2 (SEQ ID NO:7).

40. The purified IRTA3 protein of claim 39, wherein the IRTA4 protein is human IRTA4.

41. A purified IRTA5 protein comprising the amino acid sequence set forth in Figures 18E-1-18E-2 (SEQ ID NO:9).

42. The purified IRTA5 protein of claim 41, wherein the IRTA5 protein is human IRTA5.

43. An antibody directed to a purified IRTA protein selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5.

44. The antibody of claim 43, wherein the IRTA protein is human IRTA protein.
45. The antibody of claim 43, wherein the antibody is a monoclonal antibody or a polyclonal antibody.
46. The antibody of claim 43, wherein the monoclonal antibody is a murine monoclonal antibody or a humanized monoclonal antibody.
47. The antibody of claim 43, wherein the antibody is conjugated to a therapeutic agent, wherein the therapeutic agent is selected from the group consisting of a radioisotope, a toxin, a toxoid, or a chemotherapeutic agent.
48. A pharmaceutical composition comprising an amount of the antibody of claim 43 effective to bind to cancer cells expressing an IRTA protein selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5 so as to prevent growth of the cancer cells and a pharmaceutically acceptable carrier.
49. The pharmaceutical composition of claim 48, wherein the cancer cells are selected from the group consisting of B cell lymphoma, a mantle cell lymphoma multiple myeloma, Burkitt's lymphoma, marginal zone lymphoma, diffuse large cell lymphoma and follicular lymphoma cells.

50. The pharmaceutical composition of claim 49, wherein the B cell lymphoma cells are Mucosa-Associated-Lymphoid Tissue B cell lymphoma (MALT) cells.

5 51. The pharmaceutical composition of claim 49, wherein the B cell lymphoma cells are non-Hodgkin's lymphoma cells.

10 52. A pharmaceutical composition comprising an amount of the oligonucleotide of claim 31 effective to prevent overexpression of a human IRTA protein and a pharmaceutically acceptable carrier.

15 53. A method of diagnosing B cell malignancy which comprises a 1q21 chromosomal rearrangement in a sample from a subject which comprises:

- 20 a) obtaining the sample from the subject;
- b) contacting the sample of step (a) with the antibody of claim 43 capable of specifically binding with a human IRTA protein selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5 IRTA protein on a cell surface of a cancer cell under conditions permitting binding of the antibody with human IRTA protein on the cell surface of the cancer cell, wherein the antibody is labeled with a detectable marker; and
- 25 c) detecting any binding in step (b), wherein detection of binding indicates a diagnosis of B cell malignancy in the sample.
- 30

54. The method of claim 53, wherein the B cell malignancy is selected from the group consisting of B cell lymphoma, multiple myeloma, Burkitt's lymphoma, mantle cell lymphoma, marginal zone lymphoma, diffuse large cell lymphoma and follicular lymphoma.

55. The method of claim 54, wherein the B cell lymphoma is Mucosa-Associated-Lymphoid Tissue B cell lymphoma (MALT).

56. The method of claim 54, wherein the B cell lymphoma is non-Hodgkin's lymphoma.

57. A method of treating a subject having a B cell cancer which comprises administering to the subject an amount of anti-IRTA antibody effective to bind to cancer cells expressing an IRTA protein selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5 so as to prevent growth of the cancer cells and a pharmaceutically acceptable carrier, thereby treating the subject.

58. The method of claim 57, wherein the anti-IRTA antibody is a monoclonal antibody.

59. The method of claim 58, wherein the monoclonal antibody is a murine monoclonal antibody or a humanized monoclonal antibody.

60. The method of claim 57, wherein the anti-IRTA antibody is a polyclonal antibody.

61. The method of claim 57, wherein the B cell cancer is selected from the group consisting of B cell lymphoma, multiple myeloma, mantle cell lymphoma, Burkitt's lymphoma, marginal zone lymphoma, diffuse large cell lymphoma and follicular lymphoma.
62. The method of claim 61, wherein the B cell lymphoma is Mucosa-Associated-Lymphoid Tissue B cell lymphoma (MALT).
63. The method of claim 61, wherein the B cell lymphoma is non-Hodgkin's lymphoma.
64. A method of treating a subject having a B cell cancer which comprises administering to the subject an amount of the oligonucleotide of claim 31 effective to prevent overexpression of a human IRTA protein, so as to arrest cell growth or induce cell death of cancer cells expressing IRTA protein(s) and a pharmaceutically acceptable carrier, thereby treating the subject.
65. The method of claim 64, wherein the IRTA protein is selected from the group consisting of human IRTA1, IRTA2, IRTA3, IRTA4 and IRTA5 protein.
66. The method of claim 64, wherein the B cell cancer is selected from the group consisting of B cell lymphoma, mantle cell lymphoma, multiple myeloma, Burkitt's lymphoma, marginal zone lymphoma, diffuse large cell lymphoma and follicular lymphoma.

- 5

68. The method of claim 66, wherein the B cell lymphoma is non-Hodgkin's lymphoma.


ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-
TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF
LYMPHOMA/MELANOMA

5 Abstract of the Disclosure

10 This invention provides an isolated nucleic acid molecule
which encodes immunoglobulin receptor, Immunoglobulin
superfamily Receptor Translocation Associated, IRTA,
protein. Provided too, are the IRTA proteins encoded by
the isolated nucleic acid molecules, IRTA1, IRTA2, IRTA3,
15 IRTA4 or IRTA5 proteins, having the amino acid sequences
set forth in any of Figures 18A, 18B-1-18B-3, 18C-1-18C-2,
18D-1-18D-2 or 18E-1-18E-2. Oligonucleotides of the
isolated nucleic acid molecules are provided. Antibodies
20 directed to an epitope of a purified IRTA1, IRTA2, IRTA3,
IRTA4 or IRTA5 proteins are also provided, as are
pharmaceutical compositions comprising such antibodies or
oligonucleotides. Methods for detecting a B cell
malignancy in a sample from a subject; diagnosing B cell
malignancy in a sample from a subject; detecting human
IRTA protein in a sample; and treating a subject having a B
cell cancer are also provided.

FIGURE 1

FIG. 1A



1/34

FIG. 1B

Chr 1 GGGCCGTGACAGCAACTTTTCTTCTACTAGTTTCATCTTAACTTTATCCTGGTAACTGGCGAGACAACTGTCTTAAGTAACTGAAGGGAAA
 |||||
 der14 GGGCCGTGACAGCAACTTTTCTTCTACTAGTTTCATCTTAACTTTATCCTGGTAACTGGCGAGACAACTGTCTTAAGTAACTGAAGGGAAA
 |||||
 Chr 14 TCCCACTGACGCATGCAGGAAGGGACCTTCCCTTTAACTGCTCTGTACGGGGCACGTGGGCACAGGTGCACACTCACA
 |||||

[illegible]

PACs(2)

YAC(3)

23GC4

CEN




FIGURE 4




FIGURE 5

1 CTCAATCAGCTTTATGCAGAGAAGAAGCTTACTGAGCTCACTGCTGGTGTGGTGTAGGCAAGTGTGCTTTGGCAA
 M L L W A S
 78 TCTGGGCTGACCTGGCTTGTCTCCTCAGAACTCCTTCTCAACCCCTGGAGCAGGCTTCCATGCTGCTGTGGGCGTCC
 L L A F A P V C G Q S A A A H K P V I S V H P P W T 32
 155 TTGCTGGCCTTTGCTCAGCTCTGACACTGCAGCTGCACACAAACCTGTGATTTCCGTCCATCCTCCATGGAC
 T F F K G E R V T L T C N G F Q F Y A T E K T T W Y 58
 232 CACATTCTTCAAAGGAGAGAGAGTACTCTGACTTGAATGGATTTCAGTTCTATGCAACAGAGAAAACACATGGT
 H R H Y W G E K L T L T P G N T L E V R E S G L Y 83
 309 ATCATCGGCACTACTGGGGAGAAAAGTTGACCCCTGACCCAGGAAACACCCCTCGAGGTTCCGGAATCTGGACTGTAC
 R C Q A R G S P R S N P V R L L F S S D S L I L Q A 109
 386 AGATGCCAGGCCCCGGGCTCCCCACGAAGTAACCCCTGTGCGCTTGTCTTTCTTCAGACTCCTTAATCCTGCAGGC
 P Y S V F E G D T L V L R C H R R R K E K L T A V K 135
 463 ACCATATTCTGTGTTGAAGGTGACACATTGGTCTGAGATGCCACAGAAGAAGGAAAGAGAAATTGACTGCTGTGA
 Y T W N G N I L S I S N K S W D L L I P Q A S S N 160
 540 AATATACTTGAATGGAACATTCTTCCATTCTAATAAAAGCTGGGATCTTCTTATCCCAAGCAAGTTCAAAT
 N N G N Y R C I G Y G D E N D V F R S N F K I I K I 186
 617 AACAAATGGCAATTATCGATGCATTGGATATGGAGATGAGAATGATGTATTTAGATCAAATTTCAAATAATTAAT
 Q E L F P H P E L K A T D S Q P T E G N S V N L S C 212
 694 TCAAGAACTATTTCCACATCCAGAGCTGAAAGCTACAGACTCTCAGCCTACAGAGGGGAATTCTGTAAACCTGAGCT
 E T Q L P P E R S D T P L H F N F F R D G E V I L 237
 771 GTGAAACACAGCTTCTCCAGAGCGGTACAGACACCCCACTTCACTTCACTTCTTCAGAGATGGCGAGGTCATCCTG
 S D W S T Y P E L Q L P T V W R E N S G S Y W C G A 263
 848 TCAGACTGGAGCAGCTACCCGGAACCTCAGCTCCCAACCGTCTGGAGAGAAAACCTCAGGATCCTATTGTTGTGGTGC
 E T V R G N I H K H S P S L Q I H V Q R I P V S G V 289
 925 TGAACAGCTGAGGGTAACATCCACAGCAGTCCCTCGCTACAGATCCATGTGCAGCGGATCCCTGTGTCTGGG
 L L E T Q P S G G Q A V E G E M L V L V C S V A E 314
 1002 TGCTCCTGGAGACCCAGCCCTCAGGGGGCCAGGCTGTTGAAGGGGAGATGCTGGTCTTGTCTGCTCCGTGGCTGAA
 G T G D T T F S W H R E D M Q E S L G R K T Q R S L 340
 1079 GGCACGGGTATACCATTCTCTGGCACCAGAGGACATGCAGGAGAGTCTGGGGAGGAAAACCTCAGCGTTCCT
 R A E L E L P A I R Q S H A G G Y Y C T A D N S Y G 366
 1156 GAGAGCAGAGCTGGAGCTCCCTGCCATCAGACAGAGCCATGCAGGGGATACTACTGTACAGCAGACAACAGCTACG
 P V Q S M V L N V T V R E T P G N R D G L V A A G 391
 1233 GCCCTGTCCAGAGCATGGTGTCTGAATGTCACTGTGAGAGAGACCCAGGCAACAGAGATGGCCTTGTCCCGCGGGA
 A T G G L L S A L L A V A L L F H C W R R R K S G 417
 1310 GCCACTGGAGGGCTGCTCAGTGTCTTCTCCTGGCTGTGGCCCTGCTGTTCACTGCTGGCGTCGGAGGAAGTCAGG
 V G F L G D E T R L P P A P G P G E S S H S I C P A 443
 1387 AGTTGGTTTCTTGGGAGACGAAACCAGGCTCCCTCCCGCTCCAGGCCAGGAGAGTCTCCCATTCATCTGCCCTG
 Q V E L Q S L Y V D V H P K K G D L V Y S E I Q T 468
 1464 CCCAGGTGGAGCTTCAGTCGTTGTATGTTGATGTACACCCAAAAGGGAGATTGGTATACTCTGAGATCCAGACT
 T Q L G E E E E A N T S R T L L E D K D V S V V Y S 494
 1541 ACTCAGCTGGGAGAAGAAGAGGAAGCTAATACCTCCAGGACACTTCTAGAGGATAAGGATGTCTCAGTTGTCTACTC
 E V K T Q H P D N S A G K I S S K D E E S * 515
 1618 TGAGGTAAAGACACAACACCCAGATAACTCAGCTGGAAGATCAGCTCTAAGGATGAAGAAAGTTAAGAGAATGAAA
 1695 AGTTACGGGAACGTCTACTCATGTGATTTCTCCCTTGTCCAAAGTCCCAGGCCAGTGCAGTCTTGGCGCACCTG
 1772 GAATGATCAACTCATTCCAGCTTTCTAATTTCTTCTCATGCATATGCATTCACTCCAGGAATACTCATTCTGCTACT
 1849 CTGATGTTGGGATGGAATGGCCTCTGAAAGACTTCACTAAATGACCAGGATCCACAGTTAAGAGAAGACCCCTGTAG
 1926 TATTTGCTGTGGGCTGACCTAATGCATTCCCTAGGGTCTGCTTTAGAGAGGGGGATAAAGAGAGAGAGGACTGT
 2003 TATGAAAAACAGAAGCACAATTTTGGTGAATTTGGGATTTGCAGAGATGAAAAAGACTGGGTGACCTGGATCTCTGC
 2080 TTAATACATCTACACCATTTGTCTCACTGGAGACTCACTGCATCAGTTTGTAACTGTGAGTGGCTGCACAGGCA
 2157 CTGTGCAAAACATGAAAAGCCCTTCACTTCTGCCTGCACAGCTTACACTGTCAAGATTCAAGTTGAGATTAAAGAA
 2234 CCCATCTGGAATGTTTACAGAGAGAGGAATTTAAAGAGGACATCAGAAGAGCTGGAGATGCAAGCTCTAGGCTGC
 2311 GCTTCCAAAAGCAAATGATAATTATGTTAATGTCAATTAGTGACAAAGATTGCAACATTAGAGAAAAGACACAAA
 2388 TATAAATTAATACTTAAGTACCAACTCTCCAAAATAAATTTGAACCTTAAATATTAGTATAAATCATAATAA
 2465 CTCTGCCTTTAAATAAAAAAAAAAAAAAAAAAAAAA

FIGURE 6a

1 CGGTGCAGTGTCTCTGACTGTAAGATCAAGTCCAAACCTGTTTTGGAATTGAGGAAACTTCTCTTTTGATCTCAGCCCTTG
 M L L W V I L L V L A P V S G Q F A R T P R 22
 81 GTGGTCCAGGTCTTCTATGCTGCTGTGGGTGATATTACTGGTCTCTGGCTCTGTGAGTGGACAGTTTGAAGGACACCCAG
 P I I F L Q P P W T T V F Q G E R V T L T C K G F R F 49
 161 GCCCATTTATTTCTCCAGCCTCCATGGACCACAGTCTTCCAAGGAGAGAGAGTGACCCTCACTTGCAAGGGATTTCGCT
 Y S P Q K T K W Y H R Y L G K E I L R E T P D N I L 75
 241 TCTACTCACCACAGAAAACAAAATGGTACCATCGGTACCTTGGGAAAGAAATACTAAGAGAAACCCAGACAATATCCTT
 E V Q E S G E Y R C Q A Q G S P L S S P V H L D F S S 102
 321 GAGGTTCAGGAATCTGGAGAGTACAGATGCCAGGCCAGGGCTCCCTCTCAGTAGCCCTGTGCACTTGGAATTTTCTTC
 A S L I L Q A P L S V F F E G D S V V L R C R A K A E V 129
 401 AGCTTCGCTGATCCTGCAAGCTCCACTTTCTGTGTTTGAAGGAGACTCTGTGGTTCTGAGGTGCCGGGCAAAGCGGAG
 T L N N T I Y K N D N V L A F L N K R T D F H I P H 155
 481 TAACACTGAATAATACTATTTACAAGAATGATAATGTCTGGCATTCTTAATAAAGAACTGACTTCCATATTCCTCAT
 A C L K D N G A Y R C T G Y K E S C C P V S S N T V K 182
 561 GCATGCTCAAGGACAATGGTGATATCGCTGTACTGGATATAAGGAAAGTTGTTGCCCTGTTTCTTCCAATACAGTCAA
 I Q V Q E P F T R P V L R A S S F Q P I S G N P V T 209
 641 AATCCAAGTCCAAGAGCCATTTACACGTCCAGTGCTGAGAGCCAGCTCCTTCCAGCCCATCAGCGGGAACCCAGTGACCC
 T C E T Q L S L E R S D V P L R F R F F R D D Q T L 235
 721 TGACCTGTGAGACCCAGCTCTCTCTAGAGAGGTGAGATGTCCCGCTCCGGTTCCGCTTCTTCTCAGAGATGACCAGACCCCTG
 G L G W S L S P N F Q I T A M W S K D S G F V A 262
 801 GGATTAGGCTGGAGTCTCTCCCGAATTCCAGATTACTGCCATGTGGAGTAAAGATTGAGGGTTCTACTGGTGTAAGGC
 A T M P H S V I S D S P R S W I Q V Q I P A S H P V 289
 881 AGCAACAATGCCTCAGCGTCATATCTGACAGCCGAGATCTTGATACAGGTGACAGATCCCTGCATCTCATCCTGTCC
 T L S P E K A L N F E G T K V T L H C E T Q E D S L 315
 961 TCACTCTCAGCCCTGAAAAGGCTCTGAATTTTGAAGGAACCAAGGTGACACTTCACTGTGAAACCCAGGAAGATTCTCTG
 R T L Y R F Y H E G V P L R A S S V R C E R G A S I S 342
 1041 CGCACTTTGTACAGGTTTTATCATGAGGGTGTCCCCCTGAGGCACAAGTCAGTCCGCTGTGAAAGGGGAGCATCCATCAG
 F S L T T E N S G N Y Y C T A D N G L G A K P S K A 369
 1121 CTTCTCACTGACTACAGAGAATTGAGGAATCTACTGACAGCTGACAATGGCCTTGGCGCCAAGCCAGTAAGGCTG
 S L S V T V P V S H P V L N L S S P E D L I F E G A 395
 1201 TGAGCCTCTCAGTCACTGTTCCTGTCTCATCTGTCTCCTGAGGACCTGATTTTTGAGGGAGCC
 K V T L H C E A Q R G S L P I L Y Q F H H E D A A L E 422
 1281 AAGGTGACACTTCACTGTGAAGCCAGAGAGGTTCACTCCCATCTGTACCAGTTTCATCATGAGGATGCTGCCCTGGA
 R R S A N S A G G V A I S F S L T A E H S G N Y S C 449
 1361 GCGTAGGTCGGCAACTCTGCAGGAGGTGGCCCTCAGCTTCTCTGACTGCAGAGCATTGAGGAATCACTACTGCA
 A D N G F G P Q R S K A V S L S I T V P V S H P V L 475
 1441 CAGCTGACAATGGCTTTGGCCCCCAGCGCAGTAAGCGGTGAGCCTCTCCATCACTGTCCCTGTCTCATCTGTCTC
 T L S S A E A L T F E G A T V T L H C E V Q R G S P Q 502
 1521 ACCCTCAGCTCTGCTGAGGCCCTGACTTTTGAAGGAGCCACTGTGACACTTCACTGTGAAGTCCAGAGAGTTCCCCACA
 I L Y Q F Y H E D M P L W S S S T P S V G R V S F S 529
 1601 AATCCTATACCAGTTTTATCATGAGGACATGCCCCCTGTGGAGCAGCTCAACACCCTCTGTGGGAAGAGTGTCTTCAGCT
 S L T E G H S G N Y Y C T A D N G F G P Q R S E V V 555
 1681 TCTCTCTGACTGAAGGACATTCAGGGAATTACTACTGCACAGCTGACAATGGCTTTGGTCCCCAGCGCAGTGAAGTGGTG
 S L F V T V P V S R P I L T L R V P V A Q D A L 582
 1761 AGCCTTTTTGTCTCACTGTCTCGCCCCCATCTCACCCTCAGGGTTCCAGGGCCAGGCTGTGGTGGGGGACCT
 L E L H C E A P R G S P P I L Y W F Y H E D V T L G 609
 1841 GCTGGAGCTTCACTGTGAGGCCCGAGAGGCTCTCCCCCAATCTGTACTGGTTTTATCATGAGGATGTCACCCTGGGGA
 S S A P S G G E A S F N L S L T A E H S G N Y S C E 635
 1921 GCAGCTCAGCCCCCTCTGGAGGAGAAGCTTTTCAICTCTCTGACTGCAGAACATTCTGGAACCTACTCATGTGAG
 A N N G L V A Q H S D T I S L S V I V P V S R P I L T 662
 2001 GCCAACAATGGCCTAGTGGCCAGCAGTGACACAATATCACTCAGTGTATAGTTCAGTATCTCGTCCCATCCTCAC
 F R A P R A Q A V V G D L L E L H C E A L R G S S P 689
 2081 CTTTCAGGGCTCCCAGGGCCAGGCTGTGGTGGGGGACCTGCTGGAGCTTCACTGTGAGGCCCTGAGAGGCTCCTCCCCAA
 L Y W F Y H E D V T L G K I S A P S G G G A S F N L 715
 2161 TCCTGTGATGGTTTTATCATGAGATGTACCCCTGGGTAAGATCTCAGCCCCCTCTGGAGGAGGGGCTCCTTCAACCTC
 S L T T E H S G I Y S C E A D N G L E A Q R S E M V T 742
 2241 TCTCTGACTACAGAACATTCTGGAATCTACTCTGTGAGGCAGACAATGGTCTGGAGGCCAGCGCAGTGAGATGGTGAC
 L K V A G E W A L P T S S T S E N * 759
 2321 ACTGAAAGTTGACAGGTGAGTGGGCCCTGCCACAGCAGACATCTGAGAAGTCACTGTGCCTGTTCTCCCTGCAGCTGA
 2401 AAATGGAGCCACAGAGCTCCTCAGGGCTGTTTTGCTGTGTGGCATCCAGCACACTTCTGCCTGCAGAACCTCCCTGTG
 2481 AAAGTCTCGGATCCTTTGTGGTATGGTCCAGGAATCTGATGTTTCCAGCAGTCTTCTTGAAGATGATCAAAGCACCTC
 2561 ACTAAAAATGCAATAAGACTTTTTAGAACATAAACTATATCTGAACTGAAATTATTACATGAAAATGAAACCAAGA
 2641 ATTCTGAGCATATGTTTCTCTGCCGTAGAAAGGATTAAGCTGTTTCTGTCCGGATTCTTCTCTCATTGACTTCTAAGAA
 2721 GCCTCTACTCTTGAGTCTCTTTCATTACTGGGGATGTAAATGTTCCCTTACATTCCACATTAAAAATCCTATGTTAACGA
 AAAAA

FIGURE 6b

1 CGGTGCAGTGTCTGACTGTAAGATCAAGTCCAAACCTGTTTGGAAATTGAGGAAACTTCTCTTTGATCTCAGCCCTTG
 M L L W V I L L V L A P V S G Q F A R T P R 22
 81 GTGGTCCAGGTCTTCTGCTGCTGGGTGATATTACTGGTCTGGCTCCTGTCAGTGGACAGTTTGAAGGACACCCAG
 P I I F L Q P P W T T V F Q G E R V T L T C K G F R F 49
 161 GCCCATTTATTTCTCCAGCCTCCATGGACCACAGTCTTCCAAGGAGAGAGTACCCTCACTTGCAAGGGATTTCGCT
 Y S P Q K T K W Y H R Y L G K E I L R E T P D N I L 75
 241 TCTACTCACCACAGAAAACAAATGGTACCATCGGTACCTTGGGAAAGAAATACTAAGAGAAAACCCAGACAATATCCTT
 E V Q E S G E Y R C Q A Q G S P L S S P V H L D F S S 102
 321 GAGGTTTCAGGAATCTGGAGGTACAGATGCCAGGCCAGGGCTCCCTCTCAGTAGCCCTGTGCAGTTGGATTCTTCTT
 A S L I L Q A P L S V F E G D S V V L R C R A K A E V 129
 401 AGCTTCGCTGATCCTGCAAGCTCCACTTTCTGTGTTTGAAGGAGACTCTGTGGTTCTGAGGTGCCGGGCAAAGGCGGAAG
 T L N N T I Y K N D N V L A F L N K R T D F H I P H 155
 481 TAACACTGAATAATACTATTACAGAATGATAATGCTGGCATTCTTAATAAAAGAACTGACTTCCATATTCCTCAT
 A C L K D N G A Y R C T G Y K E S C C P V S S N T V K 182
 561 GCATCTCTCAAGDACAATGGTGCATATCGCTGTACTGGATATAAGGAAAGTTGTTGCCCTGTTTCTTCCAATACAGCAA
 I Q V Q E P F T R P V L R A S S S F Q P I S G N P V T L 209
 641 AATCCAAGTCCAAGAGCCATTTACACGTCCAGTGCTGAGAGCCAGCTCCTTCCAGCCCATCAGCGGGAACCCAGTGACCC
 T C E T Q L S L E R S D V P L R F R F F R D D Q T L 235
 721 TGACCTGTGAGACCCAGCTCTCTCTAGAGAGGTACAGATGCCCGCTCCGGTCCGCTTCTTCTCAGAGATGACCAGACCCCTG
 G L G W S L S P N F Q I T A M W S K D S G F Y W C K A 262
 801 GGATTAGCTGGAGTCTCTCCCGAATTTCCAGATTACTGCCATGTGGAGTAAAGATTACGGGTTCTACTGGTGAAGGC
 A T M P H S V I S D S P R S W I Q V Q I P A S H P V L 289
 881 AGCAACAATGCTCACAGCGTCATATCTGACAGCCGAGATCCTGGATACAGGTGCAGATCCCTGCATCTCATCTCTGTCC
 T L S P E K A L N F E G T K V T L H C E T Q E D S L 315
 961 TCACTCTCAGCCCTGAAAAGGCTCTGAATTTTGGGGACCAAGGTGACACTTCACTGTGAAACCCAGGAAGATTCTCTG
 R T L Y R F Y H E G V P L R H K S V R C E R G A S I S 342
 1041 CGCAGTTTGTACAGGTTTTATCATGAGGGTGTCCCCCTGAGGCACAAGTCAGTCCGCTGTGAAAGGGGAGCATCCATCAG
 F S L T T E N S G N Y Y C T A D N G L G A K P S K A V 369
 1121 CTTCTCACTGACTACAGAGAATTCAGGGAAGTACTACTGCACAGCTGACAATGGCCTTGGCGCCAGCCAGTAAAGGCTG
 S L S V T V P V S H P V L N L S S P E D L I F E G A 395
 1201 TGAGCCTCTCAGTCACTGTCTCCGCTGTCTCATCTCTCAACCTCAGCTCCTCTGAGGACCTGATTCTTGGAGGAGCC
 K V T L H C E A Q R G S L P I L Y Q F H H E D A A L E 422
 1281 AAGGTGACACTTCACTGTGAAGCCAGAGAGGTTCACTCCCCATCTGTACCAGTTTCATCATGAGGATGCTGCCCTGGA
 R R S A N S A G V A I S F S L T A E H S G N Y Y C T 449
 1361 GCGTAGGTGCGGCAACTCTGCAGGAGGAGTGGCCATCAGCTTCTCTGACTGCAGAGCATTACAGGAACTACTACTGCA
 A D N G F G P Q R S K A V S L S I T V P V S H P V L 475
 1441 CAGCTGACAAATGGCTTTGGCCCCAGCGCAGTAAGCGGTGAGCCTCTCCATCACTGCTCCCTGTGTCTCATCTCTGCTC
 T L S S A E A L T F E G A T V T L H C E V Q R G S P Q 502
 1521 ACCCTCAGCTCTGCTGAGGCGCTGACTTTTGAAGGAGGCACTGTGACACTTCACTGTGAAGTCCAGAGAGTTCSCCACA
 I L Y Q F Y H E D M P L W S S S T P S V G R V S S F 529
 1601 AATCCTATACAGTTTATCATGAGGACATGCCCTGTGGAGCAGCTCAACACCCCTCTGTGGGAAGAGTGTCTTTCAGCT
 S L T E G H S G N Y Y C T A D N G F G P Q R S E V V 555
 1681 TCTCTGACTGAAGGACATTACAGGAATTAATACTGCACAGCTGACAATGGCTTTGGTCCCCAGCGCAGTGAAGTGGTG
 S L F V T G K C W V L A S H P L A E F S L T H S F K 582
 1761 AGCCTTTTGTCACTGGTAAGTGCTGGGTCTTGGCAGTCACCCACCCCTGGCTGAGTTCTCTCTACCCATTCTCTTAA
 N L F A L S S F L P * stop 592
 1841 AATCTGTTTGCAGCTGTCAGTTTCTCCCTTAATCACTTAATCCCCTTCTGGCTTCTCCTCAACTAACTAGCTGGG
 1921 GTTTTCCGTACTCATAAGTCTTGGCTCAGCCAGACCCCTAAAACAGCTCAGTAGATTCCCAGCTTTTACCAAATGAATT
 2001 TATTTATTTGATTTTCTCCTCATTCTCTGTATGTTTCAACAGTACGCCAATTTTCTTGTATGCACGGAGCGTGTCTTACT
 2081 TCTCTACTGACATTTACATATTAAGTCTAGCTACAGCAGCTTATAGATAAATATTTGGTCAAGACCTTAAATTTCTCCA
 2161 AAGGATTTCCAATCTTATGGTAGATTGGAGAAAGCTGCTGGTGAACAAAGGGGAAATGGCTCCCTAGGAACCACTCC
 2241 TCAAACTCTCGGAGTTTTATGATCCCTGTTTCTCACTGCTAAAATCAGTATCATTTTATTGTATTATTTTAAAAA
 2321 ACTATTGTTGAAGTATGACATACATTCAAGAAACGTGTGCAAAATTTGTATGTGTACGATTGGTGTCTTTTAGGAGCTAA
 2401 GTTGCTTCTGTTTTACTTGAATCTTTGTTTATAGAACTGGGGAAAGTTTACTTTCTTTTTCAGAGAAGCCAAATGGTA
 2481 TGATAGAAAAATCTTGAGCCTGATGTGTGACACATGCCCTAGCATAACTTGTGTAGTAAAGAGGTTATTTTAAATGT
 2561 GAATGTTCTGAGACTACTCAAAGTCAGAGCCAAATCTACTAGGAAGCTTCTAGACTTCACTCATTCTGCTACCTTTAC
 2641 TATCTTTTATTCATGTTTACTTTCTTCTCATATTCAAGCAGCATCTTAAGCCTCTTATTTTCTGTTTCTTGTACTGCTA
 2721 CCTTAATGCCAGTAGAATGTAAGCTTCATGAGAACAGAACTGCATCCATCTTGGTCTTCAACAATCCCTGTGCTTACT
 2801 CAGTGTGTTGGCACACAGTAGGTCCTCAGTCAACATTTGTAATTTAGTGGACAGATGATATGACAAGATGATAAGAGGGGA
 2881 TTTAAAAAATCATCTAGCAAGCCCAAGAGGAAAAAACAAGCTATTTTAGAAATGAAATACCAATTTGAAGCAGTA
 2961 AGAATAGATTGGATATCTTTGAAAACCATTAATTTGAATGAAGAACCAATTTGAGAAAACATACAGAATGCAAGTAGAA
 3041 AGATACAGAAATAAGGCAAAAGTTATAATATGGAATCAGACAATGGATTGTCTGTATCCAGTTATGTGGATAATTA
 3121 AATGGAGACCTCAGAAAATGAACCGAAGAGTAAATGAACCTCAAAAATGTAGTAGAAATTTGGGGAAGTAAAGAAA
 3201 ACTTGAATATGTAGATCAGAACATATATGTTGATGACGTTATTGACTTTGAGGTTAAAAATATATATGTGCTTATGAT
 3281 TATGGGAAAAAAGCAGTCGCTCTCAGAAAAGAAAAACATCAAGTTAGTCTTAGACTTTGCAGTGCACCTCAGTACCAAGAG
 3361 AGAGAGGCCAGACTGGACCTGCGAGGGAAGAATAATAACCGAAAAATTTATATCAATTCAAAAAGACATTTGCAAAA
 3441 TACAGGGATTACAGAACTGAGAATGCACTAAGCCTTCTGAAAAAACACCTAATGACAAAATCTAGCCCAACAGATGT
 3521 AATGAATATAAAGGACTCATAATGAGGAACCGCATATGACTGGCTCTCAACCCCTGGCCGCATATAGACTCGTCAAA
 3601 GACCTTTGTAAAAGGTCACACATTGACTCGTCAAGCCCTCTCCAGACTAATTCATTCAGAATCTCAGAGATGGGGCC
 3681 ACAGAACTCAGTATTTTGTACACAACCTCAAGTGAGAATATTGTGTAGACAAGATTGGAAACCACTGATTTAGATATAGA
 3761 AACAAAGGCTAATCAACTGTGAGAATTATGGTCACAGATAGAAAGTAACTATTATGAACACTGAAAATGTAATAAATA
 3841 GTAACAAAGAAAAATAGTTAGAGGAAGGAGAGGAAGTAAAGGAACAATCTTTCTCATGATTATTATTATTTACAGATA
 3921 AATTGTGAGTTATTTACAAATCAAAAAGATGGACTGTTTAAAAAATAGTAAATAGATTTCAAAATGTCCATTTTGTGA
 4001 AATCGTTTCTGAATACTTTGTCAACAGTTACTCATCATTAATGGCTTATACTTCACTAAAATTCATGGAACCAACTA
 4081 GTAGCCTGTAGAGTCACATAGGAGAGAACAAAGTGAATCTTTGGGTGGCGCAAGCATAGATGTTAGGACTGACAAAAA
 4161 AATAATAAAAAATAAACCCTGTGATTTGATATGATCACAATGATCAGGGAAGAGGAAACAGAACTCTCATACGCCATTA
 4241 TTACAAGGTAAATTTGGTTCAACCTTTTCGTTTAAATTGACACATTGTAATTGTATATATTTATGGAAGCACAGTTTGT
 4321 ATTTTGTATATACATACATGATATATAACGATCAAAATAGGATATTTAATGTACCATCATCTCATGCAATTTATCATTTCT
 4401 TTGGAATAAA AACATTCAAA AGCCAAAAA AAAAAA AAAAAA

FIGURE 6c-1

1 CGGTGCAGTGTCTGACTGTAAGATCAAGTCCAAACCTGTTTTGGAATTGAGGAACTTCTCTTTTGATCTCAGCCCTTG
 81 GTGGTCCAGGTCTTTCATGCTGTGGGTGATATTACTGGTCTGGCTCCTGTGAGTGGACAGTTTGCAAGGACACCCAG 22
 P I I F L Q P P W T T V F Q G E R V T L T C K G F R F 49
 161 GCCCATTATTTTCTCCAGCCTCCATGGACCACAGTCTTCCAAGGAGAGAGAGTACCCTCACTTGCAAGGGATTTCCGT
 Y S P Q K T K W Y H R Y L G K E I L R E T P D N I L 75
 241 TCTACTCACCACAGAAAACAAATGGTACCATCGGTACCTTGGGAAAGAAATACTAAGAGAAACCCAGACAATATCCTT
 E V Q E S G E Y R C Q A Q G S P L S S P V H L D F S S 102
 321 GAGGTTTCAGGAATCTGGAGAGTACAGATGCCAGGCCAGGGCTCCCTCTCAGTAGCCCTGTGCACTTGGATTTCCTTC
 A S L I L Q A P L S V F E G D S V V L R C R A K A E V 129
 401 AGCTTCGCTGATCCTGCAAGCTCCACTTTCTGTGTTTGAAGGAGACTCTGTGGTTCTGAGGTGCCGGGCAAGGCCGAAG
 T L N N T I Y K N D N V L A F L N K R T D F H I P H 155
 481 TAACACTGAATAATACTATTACAGAATGATAATGTCTGGCATTCTTAATAAAAGAACTGACTTCCATATTCCTCAT
 A C L K D N G A Y R C T G Y K E S C C P V S S N T V K 182
 561 GCATGCTCAAGGACAATGGTGCATATCGCTGTACTGGATATAAGGAAAGTTGTTGCCCTGTTTCTTCCAATACAGTCAA
 I Q V Q E P F T R P V L R A S S F Q P I S G N P V T L 209
 641 AATCCAAGTCCAAGAGCCATTACAGTCCAGTGTGAGAGCCAGTCTCTCCAGCCCATCAGCGGGAACCCAGTGACCC
 T C E T Q L S L E R S D V P L R F R F F R D D Q T L 235
 721 TGACCTGTGAGACCCAGCTCTCTCTAGAGAGGTACAGTGTCCCGCTCCGCTTCTTCAGAGATGACCAAGCCCTG
 G L G W S L S P N F Q I T A M W S K D S G F Y W C K A 262
 801 GGATTAGCTGGAGTCTCTCCCGAATTTCCAGATTACTGCCATGTGGAGTAAAGATTCAAGGGTTCTACTGGTGAAGGC
 A T M P H S V I S D S P R S W I Q V Q I P A S H P V L 289
 881 AGCAACAATGCCCTCACAGCGTCATATCTGACAGCCGAGATCCTGGATACAGGTGCAGATCCCTGCATCTCATCTGTCC
 T L S P E K A L N F E G T K V T L H C E T Q E D S L 315
 961 TCACTCTCAGCCCTGAAAAGGCTCTGAATTTGAGGGAACCAAGTGACACTTCACTGTGAAACCCAGGAAGATCTCTG
 R T L Y R F Y H E G V P L R H K S V R C E R G A S I S 342
 1041 CGCACTTTGTACAGGTTTATCATGAGGGTGTCCCCCTGAGGCACAGTCACTCCGCTGTGAAAGGGGAGCATCCATCAG
 F S L T T E N S G N Y Y C T A D N G L G A K P S K A V 369
 1121 CTTCTCACTGACTACAGAGAATTCAGGGAACACTACTGCACAGCTGACAATGGCCTTGGCGCCCAAGCCCAAGGCTG
 S L S V T V P V S H P V L N L S S P E D L I F E G A 395
 1201 TGAGCCTCTCAGTGTCTCCCGTGTCTCCTGTCTCAACCTCAGCTCTCCTGAGGACCTGATTTTGGAGGAGCC
 K V T L H C E A Q R G S L I L Y Q F H H E D A L E 422
 1281 AAGGTGACACTTCACTGTGAAGCCAGAGAGGTTCACTCCCATCCTGTACCAGTTTCATCATGAGGATGCTGCCCTGGA
 R R S A N S A G G V A I S F S L T A E H S G N Y Y C T 449
 1361 GCGTAGGTGCGGCCAATCTGCAGGAGGAGTGGCCATCAGCTTCTCTGACTGCAGAGCATTGAGGGAACCTACTACTGCA
 A D N G F G P Q R S K A V S L S I T V P V S H P V L 475
 1441 CAGCTGACAATGGCTTTGGCCCCCAGCGCAGTAAGGCGGTGAGCCTCTCCATCACTGTCCCTGTGTCTATCCTGTCTC
 T L S S A E A L T F E G A T V T L H C E V Q R G S P Q 502
 1521 ACCCTCAGCTCTGCTGAGGCCCTGACTTTTGAAGGAGCCACTGTGACACTTCACTGTGAAGTCCAGAGAGGTTCCCCACA
 I L Y Q F Y H E D M P L W S S S T P S V G R V S F S F 529
 1601 AATCCTATACCACTTTTATCATGAGGACATGCCCTGTGGAGCAGTCAACACCCCTCTGTGGGAAGAGTGTCTTCAGCT
 S L T E G H S G N Y Y C T A D N G F G P Q R S E V V 555
 1681 TCTCTGACTGAAGGACATTCAAGGAATTAATCACTGCACAGCTGACAATGGCTTTGGTCCCCAGCGCAGTGAAGTGGTG
 S L F V T V P V S R P I L T L R V P R A Q A V V G D L 582
 1761 AGCCTTTTGTCACTGTTCCAGTGTCTCGCCCCATCCTCACCTCAGGGTTCCAGGGGCCAGGCTGTGGTGGGGGACCT
 L E L H C E A P R G S P P I L Y W F Y H E D V T L G S 609
 1841 GCTGGAGCTTCACTGTGAGGCCCGGAGAGGCTCTCCCAATCCTGTACTGGTTTATCATGAGGATGTCAACCCTGGGGA
 S A P S G E A S F S L T A E H S G N Y S C E 635
 1921 GCAGCTCAGCCCCCTCTGGAGGAGAAGCTTCTTCAACCTCTCTCTGACTGCAGAACATTCTGGAACCTACTCACTGTGAG
 A N N G L V A Q H S D T I S L S V I V P V S R P I L T 662
 2001 GCCAACAAATGGCCTTGGGCCAGCAGTACAGACATCACTCAGTGTATAGTTCCAGTATCTCGTCCCATCCTCAC
 F R A P R A Q A V V G D L L E L H C E A L R G S S P I 689
 2081 CTTCAGGGCTCCAGGGGCCAGGCTGTGGTGGGGGACCTGCTGGAGCTTCACTGTGAGGCCCTGAGAGGCTCTCCCCAA
 L Y W F Y H E D V T L G K I S A P S G G G A S F N L 715
 2161 TCCTGTACTGGTTTTATCATGAAGATGTCAACCTGGGTAAAGATCTCAGCCCCCTCTGGAGGAGGGGCTCCTTCAACCTC
 S L T A T E H S G I Y S C E A D N G L E A Q R S E M V T 742
 2241 TCTCTGACTACAGACATTCTGGAATCTACTCCTGTAGGCGAGACAATGGTCTGGAGGCCAGCGCAGTGAAGTGGTAC
 L K V A V P V S R P V L T L R A P G T H A A V G D L L 769
 2321 ACTGAAAGTTGCACTTCCGGTGTCTCGCCCGGTCTCACCTCAGGGCTCCCGGGGACCCATGCTGCGGTGGGGGACCTGC
 E L H C E A L R G S P L I L Y R F F H E D V T L G N 795
 2401 TGGAGCTTCACTGTGAGGCCCTGAGAGGCTCTCCCTGTACTGCTACCGGTTTTTTCATGAGGATGTCAACCTAGGAAT
 R S S P S G G A S L N L S L T A E H S G N Y S C E A D 822
 2481 AGGTGCTCCCCCTCTGGAGGAGCGTCTTAACCTCTCTCTGACTGCAGAGCACTCTGGAACCTACTCCTGTGAGGCCGA
 N G L G A Q R S E T Y T L Y I T G L T A N R S G P F A 849
 2561 CAATGGCTCCGGGCCCCAGCGCAGTGAACAGTGAACATTTATATCACAGGGCTGACCCGGAACAGAGTGGCCCTTTTG
 T G V A G G G L L S I A G L A A G A L L Y C W I S R 875
 2641 CCACAGGAGTGCAGCGGGGCTGTGCTAGCATAGCAGGCTTGTCTCGGGGGCACTGCTGCTTACTGCTGGCTCTCGAGA
 K A G R K P A S D P A R S P S D S D S Q E P T Y H N V 902
 2721 AAAGCAGGGAAGAGCCTGCCTCTGACCCCGCCAGGAGCCCTTCAAGCTCGGACTCCCAAGAGCCCACTATCACAAATGT
 P A W E L Q P V Y T N A N P R G E N V V Y S E V T I 929
 2801 ACCAGCCTGGGAAGAGCTGCAACCAAGTGTACACTAATGCAATCTAGAGGAGAAAATGTGGTTTACTCAGAAGTACGGA
 I Q E K K K H A V A S D P R H L R N K G S P I I Y S 955
 2981 TCATCCAAGAGAAAAAGAAATGCACTGAGTGGCTCTGACCCAGGCATCTCAGGAACAAGGGTTCCCTTATCATCTACTCT



10/34

FIGURE 6c-2

E V K V A S T P V S G S L F L A S S A P H R * stop 977

2961 GAAGTTAAGGTGGCGTCAACCCCGGTTTCCGGATCCCTGTTCTTGGCTTCCTCAGCTCCTCACAGATGAGTCCACACGTC
3041 TCTCCAACTGCTGTTTCAGCCTCTGCACCCCAAAGTTCCTTGGGGGAGAAGCAGCATTGAAGTGGGAAGATTTAGGCT
3121 GCCCCAGACCATATCTACTGGCCTTTGTTTCACATGTCTCATTCTCAGTCTGACCAGAATGCAGGGCCCTGCTGGACTG
3201 TCACCTGTTTCCCAAGTTAAAGCCCTGACTGGCAGGTTTTTAATCCAGTGGCAAGGTGCTCCCACTCCAGGGCCAGCAC
3281 ATCTCCTGGATTCTTCTAGTGGGCTTCAGCTGTGGTGTCTGCTGAGTACTGCTCTCATCACACCCCCACAGAGGGGTC
3361 TTACCACACAAAGGGAGAGTGGGCTTCAGGAGATGCCGGGCTGGCCTAACAGCTCAGGTGCTCCTAAACTCCGACACAG
3441 AGTTCCTGCTTTGGGTGGATGCATTCTCAATTGTCTCAGCCTGGTGGGGCTACTGCAGTGTGCTGCCAAATGGGACAG
3521 CACACAGCCTGTGCACATGGGACATGTGATGGGTCTCCCCACGGGGGCTGCATTTACACTCCTCCACCTGTCTCAAACCT
3601 CTAAGGTGGGCACTTGACACCAAGGTAACCTCTCTCCTGCTCATGTGTCTCAGTGTCTACCTGCCCAAGTAAGTGGCTTTCA
3681 TACACCAAGTCCCGAAGTTCTTCCCATCTAACAGAAGTAACCCAGCAAGTCAAGGCCAGGAGGACCAGGGGTGCAGACA
3761 GAACACATACTGGAACACAGGAGGTGCTCAATTACTATTGACTGACTGACTGAATGAATGAATGAATGAGGAAGAAAAC
3841 TGTGGGTAAATCAAACCTGGCATAAATCCAGTGCCTCCCTAGGAAATCCGGGAGGTATTCTGGCTTCTTAAGAAACAACG
3921 GAAGAGAAGGAGCTTGGATGAAGAACTGTTGAGCAAGAAGAGGGCTTCTTCACTTTTATGTGCTTGTGGATCACCT
4001 GAGGATCTGTGAAAAATACAGATACTGATTGAGTGGGTCTGTGTAGAGCCTGAGACTGCCATTCTAACATGTTCCAGGGG
4081 ATGCTGATGCTGCTGGCCCTGGGACTGCACTGCATGTCATGTGAAGCCCTATAGGTCTCAGCAGAGGCCCATGGAGAGGGA
4161 ATGTGTGGCTCTGGCTGCCCCAGGGCCCACTCGGTTACACGGATCGTGCTGCTCCCTGGCCAGCCTTTGGCCACAGCAC
4241 CACCAGCTGCTGTTGCTGAGAGAGCTTCTTCTGTGACATGTGGCTTTCATCAGCCACCTGGGAAGCGGAAAGTAGC
4321 TGCCACTATCTTTGTTTCCCCACCTCAGGCCTCACACTTTCCCATGAAAAGGGTGAATGTATATAACCTGAGCCCTCTCC
4401 ATTCAGAGTTGTTCTCCCATCTCTGAGCAATGGGATGTTCTGTTCCGCTTTTATGATATCCATCACATCTTATCTTGATC
4481 TTTGCTCCCACTGGATTGTACAGTGTGACTTTTAAAGCCCAAGGCCCTGAAATAAAATCCTTCCAAGGGCATTGGAAGC
4561 TCACTCCACCTGAACCATGGCTTTTTCATGCTTCCAAGTGTGAGGGCCTTGCCAGATAGACAGGGCTGACTCTGCTGCCC
4641 CAACCTTTCAAGGAGGAAACCAGACCTGAGACAGGAGCCTGTATGCAGCCAGTGCAGCCTTGACAGAGGACAAGGCTG
4721 GAGGCATTGTCTACTACAGATATGCAACTAAATAGACGTGGAGCAAGAGAAATGCATTCCACCGAGGCCGCTTTT
4801 TTAGGCCTAGTTGAAAGTCAAGAAGGACAGCAGCAAGCATAGGCTCAGGATTAAAGAAAAAATCTGCTCACAGTCTGTT
4881 CTGGAGGTCACATCACCAACAAGCTCACGCCCTATGCAGTCTGAGAAGGTGGAGGACCAGGCTCAAAGAGGAAATT
4961 TAGAATTTCTCATTTGGGAGAGTAAGGTACCCCATCCCAAGATGATAACTGCACAGTGGCAGAACAACTCCACCTAAT
5041 GTGGGTGGACCCCATCCAGTCTGTTGAAGGCCTGAATGTAAACAAAAGGGCTTATTCTTCTCAAGTAAGGGGAACTCCT
5121 GCTTTGGGCTGGGACATAAGTTTTCTGCTTTCAGACGCAAACTGAAAAATGGCTCTTCTTGGGTCTTGAGCTTGTGCG
5201 ATATGGACTGAAAGAACTATGCTATTGGATCTCCTGGATCTCCAGCTTGCTGACTGCAGATCTTGAGATATGTGAGCCT
5281 CTACAGTCACAAGAGCTAATTCATTCTAATAAACCAATCTTTC

FIG. 7A

[illegible]

12/34

FIGURE 8A




FIGURE 9

FIG. 9A




FIG. 9B




FIGURE 10

FIG.10A


FCGRIIA (1) MAMETQMSQNVCPRNWMLQPEIVVILLIILAGIDECAGAAEPRAVADLPPPIIIVAGCEPVTIVVCEARSPEPIIOGFHNGKIPPHQSYRFPKANNNDPT
 FCGRIIA (1) -----EQOGLPTALILIKAGKMTEDLEKAMFLEPOVRYVTEKSEVILKCEAYSBEENSTOMPHEHIIQOISYFIDANTVADK
 FCERIA (1) -----MAP-AGESPTICALEFAPDEVLVQCKEYENPPNRRPFGNGVTHNGNNMFYSEYKPHNGNISTSEYSLVNAKFEEDR
 FCGRIA (1) -----IVRLVILLIMPPVDEGV-DTKRAVISLQPPVEVQCEAVVHHEVLHFGSGSTOMFLMGATSSPPYRTSASNDAR
 IRTA1 (1) -----MLWASGGAAPVCQGSAAHKVVISVHPPTTFKSHRVTHNGFCQYAEKTTTHHYWGHLLLPNGT-LEVKER
 IRTA2 (1) -----MLLWILLIMAPVSEQFARVETVIFLQPPPTAVPOSHRVTHNGCFREYQKNTNKHVILGKILIREPDNI-LEVQV
 FCGRIIA (101) EVTCTQISADIVATVLEWVILQTHLEQKQWVTHCHSRRKPEVVKVTASQNKQKPSLLETHITANHSSEVVTGNVYTL-SEK
 FCGRIIA (86) EVRCCTRLTSLSDIVQLEVHIENILLQAPRWVKEEDTHHCHSMKNTATPAKVTYIQNGKRRKQVHSDYIPKQAKDESYVRELSKN-VSE
 FCERIA (90) EVKCHQVNESEPVDENFEMWLLQAAEVNMEGEPHILCHGKQVWDVSKVAYKCEZALITVJENHNSITANAVEDSCVYVTEKMQLD-KZE
 FCGRIA (82) EVRCORLIGRDEHQLTEHREMLLOVSNVTTGSPILACHAMKRLANWVYRCKHKKHNNWVAILKAPSSANCTATTEWCHR-KA
 IRTA1 (82) LMECCAGCPGRNPPVRIILFSESLQAPYSVF-EGDALALCHRRRSEKLTAKVTMGNILLESKMDLILPAAISNANVYKIEYGENDVREN
 IRTA2 (82) EVRCQACCPLESPVHILFSSASLEQAPLSVF-EGDSVYLRGRKAAVTLANVYKMDNVILAPKKADEHIEPAAWKONGVRCVTCYKESCCPVSSN
 FCGRIA (172) EKHR--KTSAGSVTVKLEPPAPVNASVMSLEFENLVTISCTEKLLOQPGLOTPSHMGSLV-RENVSEKQILTAREDDKPAWPAWIEDGN
 IRTA1 (171) EENDVFRSNFKIKTOLEPHHEKAYDQI-TEGNSVNSCTECPERSITALEMNERIGEVLSDNISTYPILOPPTVRRNKSVMCAPVRAN
 IRTA2 (170) KSSCCPSSNTKLOVOPPTPRPVIRASFOI-SNPVITACETQISERSIVETREFRITDOINGLISLHNFOIDAMSKDKFVWKAAVMPHS
 FCGRIA (269) VAKRSELEKQVLCQOIPVWFWHLGYLAVGEMLVNIVVILIRKEARKKADTISIASHKKTSLQDRHFEELKQCE-KKEQLQEVVH
 IRTA1 (270) HTHHSEIQIHVERIPVSGV-TEVQSPGSAVEEMVIVASVAEGDITTEVVRDQESIRKQRIIRALLPAAVQSHAT-GYVCADNSY-
 IRTA2 (269) VASDSERSWLOVC-IPASHGV-LTISERKALNFECTKVULHGMQEDSIRIVIRVHDE--PIRHSVRCERASFSCTTENG-NYYCADDNGTCA

FIG.10B

ITAM: E DXXXXXXXXX E DXX--YXXLXXXXXXXXX I I XXXL
 IRTA1: ESSHSICPAQVELQSLYVDVHPKKG-DLVYSEIQTTTLEEEREAANTSRTLLEDKDVSVVYSEV
 PECAM: DNKEPLNSDVQYTEVQVSSAEWSHK-----DLGKKDTEVYSEV
 IRTA2C: DSDSQ-----EPTXHNVPAAWELQPVYT-----NANPRGENVVYSEV
 BG1: ASDQR---DLTEHKPSVSNTQDHSN-----DPPNKMNEVYSTL
 ITIM: SXXXXL SXXXXL SXXXXL
 V V V V V
 L L L L L
 I I I I I
 X⁽²⁴⁾ I I YSEVK
 X⁽²¹⁾ I I YSEVK

11A

FIGURE 11A



11B1-4






FIGURE 12A

FIGURE 12B1-B4




FIGURE 13




FIGURE 14

FIG.14A




FIG.14B




FIG.14D




FIG.14C




FIGURE 15

FIG.15A





FIG.15B



Cell line	IRTA2
Burkitt Lymphoma	
Normal 1q21	2/12
Abnormal 1q21	10/12
Multiple Myeloma	
Normal 1q21	0/7
Abnormal 1q21	1/3

Summary of IRTA2 expression

FIGURE 16-1~16-4
IRTA1 expression in normal lymphoid tissue




FIGURE 17

IRTA1 expression in a stomach Mucosa-Associated-Lymphoid Tissue B cell lymphoma




FIGURE 18A

1 CTCAATCAGCTTTATGCAGAGAAGAAGCTTACTGAGCTCACTGCTGGTGTGGTGTAGGCAAGTGCTGCTTTGGCAA
 M L L W A S 6
 78 TCTGGGCTGACCTGGCTTGTCTCCTCAGAACTCCTTCTCCAACCTGGAGCAGGCTTCCATGCTGCTGTGGGCGTCC
 L L A F A P V C G Q S A A A H K P V I S V H P P W T 32
 155 TTGCTGGCCTTTGTCTCAGTCTGTGGACAATCTGCAGCTGCACACAAACCTGTGATTTCGGTCCATCTCCATGGAC
 T F F K G E R V T L T C N G F Q F Y A T E K T T W Y 58
 232 CACATTCTTCAAAGGAGAGAGAGTGAATGCTGACTTGAATGGATTTCAGTTCTATGCAACAGAGAAAACAACATGGT
 H R H Y W G E K L T L T P G N T L E V R E S G L Y 83
 309 ATCATCGGCACTACTGGGGAGAAAAGTTGACCTGACCCAGGAAACACCTCGAGGTTCGGGAATCTGGACTGTAC
 R C Q A R G S P R S N P V R L L F S S D S L I L Q A 109
 386 AGATGCCAGGCCCCGGGCTCCCCACGAAGTAACCTGTGCGCTTGTCTCTTTTCTTCAGACTCCTTAATCCTGCAGGC
 P Y S V F E G D T L V L R C H R R R K E K L T A V K 135
 463 ACCATATTCTGTGTTTGAAGCTGACACATTGGTTCTGAGATGCCACAGAAGAAGGAAAGAGAAATTGACTGCTGTGA
 Y T W N G S I S N K S W D L L I P Q A S S N 160
 540 AATATACTTGAATGGAACATTCTTTCCATTCTAATAAAGCTGGGATCTTCTTATCCACAAGCAAGTTCAAAT
 N N G N Y R C I G Y G D E N D V F R S N F K I I K I 186
 617 AACAAATGGCAATTATCGATGCATTGGATGGAGATGAGAATGATGATTTAGATCAAATTTCAAAATAAATTAAT
 Q E L F P H P E L K A T D S Q P T E G N S V C 212
 694 TCAAGAACTATTTCCACATCCAGAGCTGAAAGCTACAGACTCTCAGCCTACAGAGGGGAATTCTGTAACCTGAGCT
 E T Q L P P E R S D T P L H F N F F R D G E V I L 237
 771 GTGAACACAGCTTCTCCAGAGCGGTGACACACCCCACTTCACTTCACTTCTTCAGAGATGGCGAGGTCTCCTG
 S D W S T Y P E L Q L P T V W R E N S G S Y W C G A 263
 848 TCAGACTGGAGCAGTACCCGGAACCTCAGCTCCCAACCGTCTGGAGAGAAAACCTCAGGATCCTATTGGTGTGGTGC
 E T V R G N I H K H S P S L Q I H V Q R I P V S G V 289
 925 TGAAACAGTGAGGGGTAACATCCACAAGCACAGTCCCTCGCTACAGATCCATGTGCAGCGGATCCCTGTGTCTGGGG
 L L E T Q P S G G Q A V E G E M L V L V C S V A E 314
 1002 TGCTCTGGAGACCCAGCCTCAGGGGGCCAGGCTGTGAAGGGGAGATCTGGTCTGTCTGCTCCGTGGCTGAA
 G T G D T T F S W H R E D M Q E S L G R K T Q R S L 340
 1079 GGCACAGGGGATACCACTTCTCCTGGCACCAGAGGACATGCAGGAGAGTCTGGGGAGGAAAACCTCAGCGTTCCCT
 R A E L E L P A I R Q S H A G G Y Y C T A D N S G 366
 1156 GAGAGCAGAGCTGGAGCTCCCTGCCATCAGACAGGCCATCAGGGGGATACTACTGTACAGCAGACAACAGCTACG
 P V Q S M V L V R E T P G N R D G L V A A G 391
 1233 GCCCTGTCCAGAGCATGGTGTCTGAATGTCACTGTGAGAGAGACCCAGGCAACAGAGATGGCCTTGTCTCGCCGGGA
 A T G G L L S A L L L A V A L L F H C W R R R K S G 417
 1310 GCCACTGGAGGGCTGCTCAGTGTCTTCTCCTGGCTGTGGCCCTGCTGTTTCACTGCTGGCGTCGGAGGAAGTCAGG
 V G F L G D E T R L P P A P G P G E S S H S I C P A 443
 1387 AGTTGGTTTCTTGGGAGACGAAACAGGCTCCCTCCCGCTCCAGGCCAGGAGAGTCCCTCCATCTCCATCTGCCCTG
 Q V E L Q S L Y V D V H P K K G D L V Y S E I Q T 468
 1464 CCCAGGTGGAGCTTCACTCGTTGTATGTTGATGTACACCCCAAAAAGGGAGATTGGTATACTCTGAGATCCAGACT
 T Q L G E E E E A N T S R T L L E D K D V S V V Y S 494
 1541 ACTCAGCTGGGAGAAGAAGAGGAAGCTAATACCTCCAGGACACTTCTAGAGGATAAGGATGTCTCAGTTGTCTACTC
 E V K T Q H P D N S A G K I S S K D E E S * 515
 1618 TGAGGTAAAGACACACACCCAGATAACTCAGCTGGAAAGATCAGCTCTAAGGATGAAGAAAGTTAAGAGAATGAAA
 1695 AGTTACGGGAACGTCCTACTCATGTGATTCTCCCTTGTCCAAAGTCCCAGGCCAGTGCAGTCTTGGCGCACCTG
 1772 GAATGATCAACTCATTCAGCTTTCTAATTCTTCTCATGCATATGCATTCACTCCAGGAATACTCATTCGTCTACT
 1849 CTGATGTTGGGATGGAATGGCCTCTGAAAGACTTCACTAAAATGACCAGGATCCACAGTTAAGAGAAGACCCCTGTAG
 1926 TATTTGCTGTGGGCTGACCTAATGCATTCCCTAGGGTCTGCTTTAGAGAAGGGGATAAAGAGAGAGAAGGACTGT
 2003 TATGAAAAACAGAAGCACAATTTTGGTGAATTGGGATTTGCAGAGATGAAAAAGACTGGGTGACCTGGATCTCTGC
 2080 TTAATACATCTACAACCATTTGTCTCACTGGAGACTCACTTGCATCAGTTTGTTTAACTGTGAGTGGCTGCACAGGCA
 2157 CTGTGCAAAACATGAAAAGCCCCCTCACTTCTGCCTGCACAGCTTACACTGTCAAGATTCACTTGCAGATTAAAGAA
 2234 CCCATCTGGAATGGTTTACAGAGAGAGGAATTTAAAAGAGGACATCAGAAGAGCTGGAGATGCAAGCTCTAGGCTGC
 2311 GCTTCCAAAAGCAAATGATAATTATGTTAATGTCTAGTGACAAAGATTGCAACATTAGAGAAAAGAGACAAAA
 2388 TATAAAATTAATACTTAAGTACCAACTCTCCAAAACATAAATTGAACTTAAATATAGTATAAACTATAATAAA
 • CTCTGCCTTTAAATAAAAAAAAAAAAAAAAAAAAAA

IRTA1 cDNA and protein sequence

FIGURE 18B-1

IRTA2A
IRTA2C
IRTA2B

```

1 CGGTGCAGTGTCTGACTGTAAGATCAAGTCCAAACCTGTTTGGAAATTGAGGAACTTCTCTTTTGATCTCAGCCCTTG
  M L L W V I L L V L A P V S G Q F A R T P R
81 GTGGTCCAGGTCTTCATGCTGCTGTGGGTGATATTACTGGTCTGGCTCCTGTCAGTGGACAGTTTGCAAGGACACCCAG
  P I I F L Q P P W T T V F Q G E R V T L T C K G F R F
161 GCCATTATTTTCTCCAGCCTCCATGGACCACAGTCTTCCAAGGAGAGAGAGTGACCCTCACTTGCAAGGGATTTCGCT
  Y S P Q K T K W Y H R Y L G K E I L R E T P D N I L
241 TCTACTCACCACAGAAACAAATGGTACCATCGGTACCTTGGGAAAGAAATACTAAGAGAAACCCAGACAATATCCTT
  E V Q E S G E Y R C Q A Q G S P L S S P V H L D F S S
321 GAGGTTCAGGAATCTGGAGAGTACAGATGCCAGGCCAGGGCTCCCTCTCAGTAGCCCTGTGCATTGGATTTCCTTC
  A S L I L Q A P L S V F E G D S V V L R C R A K A E V
401 AGCTTCGCTGATCTGCAAGCTCCACTTCTGTGTTTGAAGGAGACTCTGTGGTTCTGAGGTGCCGGGCAAAGCGGAAG
  T L N I Y K N D N V L A F L N K R T D F H I P H
481 TAACACTGAAATACTATTACAAGAATGATAATGCTCTGGCATTCTTAATAAAAGAACTGACTTCCATATTCCTCAT
  A C L K D N G A Y R C T G Y K E S C C P V S S N T V K
561 GCATGCTCAAGGACAATGGTGCATATCGCTGTACTGTAGGAAAGTTGTTGCCCTGTTTCTTCCAATACAGTCAA
  I Q V Q E P F T R P V L R A S S F Q P I S G N P V T L
641 AATCCAAGTCCAAGAGCCATTTACACGTCCAGTGCTGAGAGCCAGTCTTCCAGCCCATCAGCGGGAACCCAGTGACCC
  T C E T Q L S L E R S D V P L R F R F F R D D Q T L
721 TGACCTGTGAGACCCAGCTCTCTAGAGAGGTGATGCTCCCGCTCCGCTTCTTTCAGAGATGACCAGACCCCTG
  G L G W S L S P N F Q I T A M W S K D S G F Y W C K A
801 GGATTAGGCTGGAGTCTCTCCCGAATTTCCAGATTACTGCCATGTGGAGTAAAGATTGAGGGTCTACTGGTGTAAGGC
  A T M P H S V I S D S P R S W I Q V Q I P A S H P V L
881 AGCAACAATGCTCACAGGCTCATATCTGACAGCCGAGATCCTGGATACAGGTGCAGATCCCTGCATCTCATCTGTCC
  T L S P E K A L N F E G T K V T L H C E T Q E D S L
961 TCACCTCTCAGCCCTGAAAAGCTCTGAATTTTGAGGGAACCAAGGTGACACTTCACTGTGAAACCCAGGAAGATTCTCTG
  R T L Y R F Y H E G V P L R H K S V R C E R G A S I S
1041 CGCACTTTGTACAGGTTTATCATGAGGTTGTCCTCCCTGAGGCACAAGTCAGTCCGCTGTGAAAGGGGAGCATCCATCAG
  F S L T E N S G N Y Y C T A D N G L G A K P S K A V
1121 CTTCTCACTGACTACAGAGAATTACAGGAACTACTACTGCACAGCTGACAATGGCCTTGGCGCCAAGCCAGTAAAGCTG
  S L S V T V P V S H P V L N L S S P E D L I F E G A
1201 TGAGCCTCTCAGTCAGTGTCCCGTGTCTCATCTCACTCACTCTCTCTGAGGACCTGATTTTGAGGGAGCC
  K V T L H C E A Q R G S L P I L Y Q F H H E D A L E
1281 AAGGTGACACTTCACTGTGAAGCCAGAGAGGTTCACTCCCATCCTGTACCAGTTTCATCATGAGGATGTCGCCCTGGA
  R R S A N S A G G V A I S F S L T A E H S G N Y Y C T
1361 GCGTAGGTGCGCAACTCTGCAGGAGGAGTGCCCATCAGCTCTCTCTGACTGCAGAGCATTGAGGAACTACTGCA
  A D N G F G P Q R S K A V S L S I T V P V S H P V L
1441 CAGCTGACAATGGCTTTGGCCCCCAGCGCAGTAAGGCGGTGAGCCTCTCCATCACTGTCCCTGTGTCTCATCTGTCTC
  T L S S A E A L T F E G A T V T L H C E V Q R G S S P Q
1521 ACCCTCAGCTCTGCTGAGGCCCTGACTTTTGAAGGAGCCACTGTGACACTTCACTGTGAAGTCCAGAGAGGTTCCCCACA
  I L Y Q F Y H E D M P L W S S S T P S V G R V S F S F
1601 AATCCTATACCACTTTTATCATGAGGACATGCCCTGTGGAGCAGCTCAACACCCCTCTGTGGGAAGAGTGTCTCAGCT
  S L T E G H S G N Y Y C T A D N G F G P Q R S E V V
1681 TCTCTCTGACTGAAGGACATTACAGGAATTACTACTGCACAGCTGACAATGGCTTTGGTCCCCAGCGAGTGAAGTGGTG

S L F V T V P V S R P I L T L R V P R A Q A V V G D L
2A,2C1761 AGCCTTTTGTGCTACTGTCCAGTGTCTCGCCCCATCCTCACCCCTCAGGGTTCCAGGGCCAGGCTGTGGTGGGGGACCT
  G K C W V L A S H P P L A E F S L T H S F K
2B 1761 -----GGTAAGTGTGGGTTCTTGCCAGTCAACCCACCCCTGGCTGAGTCTCTCTCAACCATCTCTTAA

L E L H C E A P R G S P P I L Y W F Y H E D V T L G S
2A,2C1841 GCTGGAGCTTCACTGTGAGGCCCGAGAGGCTCTCCCCAATCCTGTACTGGTTTATCATGAGGATGTCAACCTGGGGA
  N L F A L S S F L P * stop
2B 1841 AAATCTGTTTGCACTGTCCAGTTTCTCCCTAATCAACTTAATCCCTTCTTGGCTTCTCTCAACTAAGTCTGGG

S S A P S G G E A S F L T A E H S G C E
2A,2C1921 GCAGCTCAGCCCCCTCTGGAGGAGAAGCTTCTTTCAACCTCTCTCTGACTGCAGAACATTCTGGAACCTACTCATGTGAG
  GTTTTCCGTACTCATAAGTCTGGCTCAGCCAGACCCCTAAACAGCTCAGTAGATTCCCCAGCTTTTACCAAATGAATT
2B 1921

A N N G L V A Q H S D T I S L S V I V P V S R P I L T
2A,2C2001 GCCAACAAATGGCCTAGTGGCCAGCACAGTACACAATCACTCAGTGTATAGTTCAGTATCTCGTCCCATCCTCAC
  TATTTATTGTATTTTCTCTCATCTCTGTATGTTCACAGTACGCCAATTTTCTTGATGCACGGAGCGGTCTACT
2B 2001

F R A P R A Q A V V G D L L E L H C E A L R G S S P I
2A,2C2081 CTTCAGGGCTCCAGGGCCAGGCTGTGGTGGGGGACCTGTGGAGCTTCACTGTGAGGCCCTGAGAGGCTCCTCCCAA
  TCTCTACTGACATTTACATATTAAGTCTAGCTACAAGCACAGTCTTATAGATAAATATTGGTCAAGACCTTAAATCTCCA
2B 2081

```

FIGURE 18B-2

L Y W F Y H E D V T L G K I S A P S G G G A S F N L 715
 2A, 2C2161 TCCTGTACTGGTTTTATCATGAAGATGTCACCTGGGTAAGATCTCAGCCCCCTCTGGAGGAGGGGCCCTCCTTCAACCTC
 2B 2161 AAGGATTTCCAATCTTATGGTAGATTTGGAGAAAGCTGCTGGTGAACAAGGGGAAATGGCTCCCTAGGAACCAACTCC

L T T E H S G I Y S C E A D N G L E A Q R S E M V T 742
 2A, 2C2241 TCTCTGACTACAGAACATCTGGAATCTACTCTGTGAGGCAGACAATGGTCTGGAGGCCAGCGCAGTGAGATGGTGAC
 2B 2241 TCAAACCTCTGGAGTTTTATGATCCCTTGTTTTCTAACCTGCTAAATCAGTATCATTATTATTGATTATTTTAAAAA

L K V A V P V S R P V L T L R A P G T H A A V G D L L 769
 2C 2321 ACTGAAAGTTGCAGTTCGGGTGTCTCGCCCGGTCTCACCCTCAGGGCTCCCGGACCCATGCTGCGGTGGGGACCTGC
 -----G E W A L P T S S T S E N * 759
 2A 2321 -----GGTGAGTGGGCCCTGCCACCAGCAGCACATCTGAGAACTGACTGTGCCTGTTCTCCCTGCAGCTGA
 2B 2321 ACTATGTGTGAAGTATGACATACATTCAAGAACGTGTGCAATTGTATGTGTACGATTGGTGTCTTTTAGGAGCTAA

E L H C E A L R G S P L I L Y R F F H E D V T L G 795
 2C 2401 TGGAGCTTCACTGTGAGGCCCTGAGAGGCTCTCCCTGATCCTGTACCGGTTTTTTCATGAGGATGTCAACCTAGGAAT
 2A 2401 AAATGGAGCCACAGAGCTCCTCAGGGCTGTTTGCTTGTGTGGCATCCAGCACACTTCTGCCTGCAGAACCTCCCTGTG
 2B 2401 GTTGCTTCTGTTTTACTTGAATCTTTGTTTATAGAACTGGGGGAAAGTTACTTTCTTTTCAGAGAAGCCAAATGGTA

S P S G G A S L L T A E H S G C E A D 822
 2C 2481 AGGTCGTCCCTCTGGAGGAGCGTCTTAACCTCTCTGACTGCAGAGCACTCTGAACTACTCTGTGAGGCCGA
 2A 2481 AAAGTCTCGGATCCTTTGTGGTATGGTTCAGGAATCTGATGTTCCAGCAGTCTTCTTGAAGATGATCAAGACCTC
 2B 2481 TGATAGAAATCTTGAGCCTGATGTGTGATGATGCTCCCTAGCATAACTTGTGAGTAAAGAGTTATTTTAAATGT

N G L G A Q R S E T V T L Y I T G L T A R S G P F A 849
 2C 2561 CAATGGCCTCGGGGCCAGCGCAGTGAGACAGTGAACCTTATATCACAGGGCTGACCGCGAACAGAGTGGCCCTTTG
 2A 2561 ACTAAAAATGCAATAAGACTTTTTAGAACATAAACTATATTCTGAAGTAAATATTACATGAAATGAAACCAAGA
 2B 2561 GAATGTTCTGAGACTACTCCAAAGTCAAGCCAAATCTACTAGGAAGCTTCTAGACTCACTCATTCTGCATCCCATAC

T G V A G G L L S I A G L A A G A L L L Y C W L S R 875
 2C 2641 CCACAGGAGTCCGCGGGGGCTGCTCAGCATAGCAGGCTTGTGCGGGGGCACTGCTGCTCTACTGCTGGCTCTCGAGA
 2A 2641 ATTCTGAGCATATGTTTCTCTGCCGTAGAAAGGATTAAGCTGTTTCTTGTCCGATTCTTCTCTCATTGACTCTAAGAA
 2B 2641 TATCTTTTATCCATGTTTTACTTTCTTCTCATATTTCAGCAGCATCTTAAGCCTCTTTATTTTCTGTTTCTGACTGTCA

K A G R K P A S D P A R S P S D S D S Q E P T Y H N V 902
 2C 2721 AAAGCAGGGAGAAAGCCTGCCTCTGACCCGCCAGGAGCCCTTCAGACTCGGACTCCCAAGAGCCCACTATCACAATGT
 2A 2721 GCCTCTACTCTTGAGTCTCTTTCATTACTGGGGATGTAATGTTCCCTTACATTCCACATTAATAATCTATGTTAACGA
 2B 2721 CCCTTAATGCCAGTAGAATGTAAGCTTCATGAGAACAGAACTGCATCCATCTTGGTCTTCACACATCCCTGTGCCTACT

P A W E E L Q P V Y T N A N P R G E N V V Y S E V R I 929
 2C 2801 ACCAGCCTGGGAAGAGCTGCAACCAAGTGTACACTAATGCAATCCTAGAGGAGAAAATGTGGTTTACTCAGAGTACGGA
 2A 2801 AAAAA
 2B 2801 CAGTGTGTCACACAGTAGGTCCTCAGTCAACATTGTAAATTTAGTGGACAGATGATATGACAAGATGATAAGAGGGGA

I Q E K K K H A V A S D P R H L R N K G S P I I Y S 955
 2C 2881 TCATCCAAGAGAAAAAGAACATGCAAGTGGCCTCTGACCCAGGCATCTCAGGAACAAGGGTTCCCTATCATCTACTCT
 2B 2881 TTTAAAAAATCATCTAGCAAGCCCAAGAGGAAAAAACAAGCTATTTTAGAAATGAAATACCAATTTGAAGCAGTA

E V K V A S T P V S G S L F L A S S A P H R * stop 977
 2C 2961 GAAGTTAAGGTGGCGTCAACCCCGGTTTCCGGATCCCTGTTCTTGGCTTCTCAGCTCCTCAGATGAGTCCACACGTC
 2B 2961 AGAATAGATTGGATATCTTTGAAAACCATTAATTGAATGAAGAACAATTTGAGAAAACAATACAGAAATGCAAGTAGAA

2C 3041 TCTCAACTGCTGTTTCAGCCTCTGCACCCAAAGTTCCCTTGGGGGAGAAGCAGCATGAAGTGGGAAGATTTAGGCT
 2B 3041 AGATACAGAAATAAAGGCAAAAGTTATAATATGGAATCAGACAATGGATTTGTCTGTATCCAGTTATGTGGATAATTAA

2C 3121 GCCCCAGACCATATCTACTGGCCTTTGTTTCACATGTCTCATTCTCAGTCTGACCAGAATGCAGGGCCTGCTGGACTG
 2B 3121 AATGGAGACCTCAGAAAATGAACCGAAGAGTAAATGAACTCAAAAATGTAGTAGAAATGTTGGGAAGTAAAGAAA

2C 3201 TCACCTGTTTCCAGTTAAAGCCCTGACTGGCAGGTTTTTTAATCCAGTGGCAAGGTGCTCCCACTCCAGGGCCAGCAC
 2B 3201 ACTTGAATATGTAGATCAGAACATATATGTTGATGACGTATTGACTTTGAGGTTAAAAATATATATATGTGCTATGAT

2C 3281 ATCTCCTGGATTCTTTAGTGGGCTTCAGCTGTGGTGTCTGTTCTGAGTACTGCTCTCATCACACCCCCACAGAGGGGTC
 2B 3281 TATGGGAAAAAAGCAGTCGCTCAGAAAAGAAACATCAAGTTAGTCTTAGACTTTGAGTGCACCTCAGTACCAAGAG

3361 TTACCACACAAAGGGAGAGTGGCCCTCAGGAGATGCCGGGCTGGCCTAACAGCTCAGTGTCTCTAACTCCGACACAG
 3441 AGTTCCTGCTTTGGGTGGATGCATTTCTCAATTGTCTATCAGCCTGGTGGGGCTACTGCAGTGTGCTGCCAAATGGGACAG
 3521 CACACAGCCTGTGCACATGGGACATGTGATGGGTCTCCCCACGGGGGCTGCATTTACACTCCTCCACCTGTCTCAACT
 3601 CTAAGGTCCGCACCTTGACACCAAGGTAACCTCTCTCCTGCTCATGTGTGAGTGTCTACCTGCCAAGTAAAGTGGCTTTCA
 3681 TACACCAAGTCCCGAAGTTCTTCCATCCTAACAGAAGTAACCCAGCAAGTCAAGGCCAGGAGGACAGGGGTGCAGACA
 3761 GAACACATACTGGAACACAGGAGGTGCTCAATTACTATTGACTGACTGACTGAATGAATGAATGAATGAGGAAGAAAAAC
 3841 TGTGGGTAATCAAACTGGCATAAAACTCAGTGCACTCCCTAGGAAATCCGGGAGGTATCTGGCTTCTTAAGAAACAACG
 3921 GAAGAGAAGGAGCTTGGATGAAGAACTGTTTCAGCAAGAAGAAGGGCTTCTTCACACTTTTATGTGCTGTGGATCACCT
 4001 GAGGATCTGTGAAATACAGATACTGATTCAAGTGGGTCTGTGTAGAGCTGAGACTGCCATTCTAACATGTTCCAGGGG

FIGURE 18B-3

4081 ATGCTGATGCTGCTGGCCCTGGGACTGCACTGCATGTCATGTGAAGCCCTATAGGTCTCAGCAGAGGCCCATGGAGAGGGA
4161 ATGTGTGGCTCTGGCTGCCCAGGGCCCAACTCGGTTTACACGGATCGTGCTGCTCCCTGGCCAGCCTTTGGCCACAGCAC
4241 CACCAGCTGCTGTTGCTGAGAGAGCTTCTTCTCTGTGACATGTTGGCTTTCATCAGCCACCCTGGGAAGCGGAAAGTAGC
4321 TGCCACTATCTTTGTTTCCCCACCTCAGGCCTCACACTTTCCTATGAAAAGGGTGAATGTATATAACCTGAGCCCTCTCC
4401 ATTCAGAGTTGTTCTCCCATCTCTGAGCAATGGGATGTTCTGTTCCGCTTTTATGATATCCATCACATCTTATCTTGATC
4481 TTTGCTCCCACTGGATTGTACAGTGATGACTTTTAAGCCCCACGGCCCTGAAATAAAATCCTTCCAAGGGCATTGGAAGC
4561 TCACTCCACCTGAACCATGGCTTTTTCATGCTTCCAAGTGTGAGGGCCTTGCCAGATAGACAGGGCTGACTCTGCTGCCC
4641 CAACCTTTCAAGGAGGAAACCAGACACCTGAGACAGGAGCCTGTATGCAGCCCACTGCAGCCTTGCAAGGACAAGGCTG
4721 GAGGCATTGTCACTACAGATATGCAACTAAATAGACGTGGAGCAAGAGAAATGCATTTCCACCCGAGGCCGCTTTT
4801 TTAGGCCTAGTTGAAAGTCAAGAAGGACAGCAGCAAGCATAGGCTCAGGATTAAAGAAAAAATCTGCTCACAGTCTGTT
4881 CTGGAGGTCACATCACCAACAAAGCTCACGCCCTATGCAGTTCAGAGAAGGTGGAGGCACCAGGCTCAAAAGAGGAAAT
4961 TAGAATTTCTCATTGGGAGAGTAAGGTACCCCCATCCAGAATGATAACTGCACAGTGGCAGAACAACTCCACCCTAAT
5041 GTGGGTGGACCCCATCCAGTCTGTTGAAGGCCTGAATGTAACAAAAGGGCTTATTCTTCTCAAGTAAGGGGGAACCTCCT
5121 GCTTTGGGCTGGGACATAAGTTTCTGCTTTCAGACGCAAACTGAAAAATGGCTCTTCTGGGTCTTGAGCTTGCTGGC
5201 ATATGGACTGAAAGAACTATGCTATTGGATCTCCTGGATCTCCAGCTTGCTGACTGCAGATCTTGAGATATGTCAGCCT
5281 CTACAGTCACAAGAGCTAATTCATTCTAATAAACCAATCTTTC

FIGURE 18C-1

1 AGTGAAGGGGTTTCCCATATGAAAAATACAGAAAGAATTATTTGAATACTA
 52 GCAAATACACAACCTTGATATTTCTAGAGAACCCAGGCACAGTCTTGGAGAC
 103 ATTACTCTGAGAGACTGCAGCTGATGGAAGATGAGCCCCAACTTCTAAAA
 154 ATGTATCACTACCGGATTGAGATACAAACAGCATTAGGAAGGTCTCATC
 205 TGAGTAGCAGCTTCCTGCCCTCCTTCTGGAGATAAGTCGGGCTTTGGTG
 256 AGACAGACTTTCCCAACCTCTGCCCGGCCGTGCCCATGCTTCTGTGGCT
 1 M L L W L
 307 GCTGCTGCTGATCCTGACTCCTGGAAGAGAACAATCAGGGGTGGCCCCAAA
 6 L L L I L T P G R E Q S G V A P K
 358 AGCTGTACTTCTCCTCAATCCTCCATGGTCCACAGCCTTCAAAGGAGAAAA
 23 A V L L L N P P W S T A F K G E K
 409 AGTGGCTCTCATATGCAGCAGCATATCACATTCCTTAGCCCCAGGGAGACAC
 40 V A L I C S S I S H S L A Q G D T
 460 ATATTGGTATCACGATGAGAAGTTGTTGAAAAATAAACATGACAAGATCCA
 57 Y W Y H D E K L L K I K H D K I Q
 511 AATTACAGAGCCTGGAAATTACCAATGTAAGACCCGAGGATCCTCCCTCAG
 74 I T E P G N Y Q C K T R G S S L S
 562 TGATGCCGTGCATGTGGAATTTTCACCTGACTGGCTGATCCTGCAGGCTTT
 91 D A V H V E F S P D W L I L Q A L
 613 ACATCCTGTCTTTGAAGGAGACAATGTCATTCTGAGATGTGAGGGGAAAGA
 108 H P V F E G D N V I L R C Q G K D
 664 CAACAAAAACACTCATCAAAAGGTTTACTACAAGGATGGAACAGCTTCC
 125 N K N T H Q K V Y Y K D G K Q L P
 715 TAATAGTTATAATTTAGAGAAGATCACAGTGAATTCAGTCTCCAGGGATAA
 142 N S Y N L E K I T V N S V S R D N
 766 TAGCAAATATCATTGTACTGCTTATAGGAAGTTTACATACTTGACATTGA
 159 S K Y H C T A Y R K F Y I L D I E
 817 AGTAACTTCAAAACCCCTAAATATCCAAGTTCAAGAGCTGTTTCTACATCC
 176 V T S K P L N I Q V Q E L F L H P
 868 TGTGCTGAGAGCCAGCTCTTCCACGCCCATAGAGGGGAGTCCCATGACCTT
 193 V L R A S S S T P I E G S P M T L
 919 GACCTGTGAGACCCAGCTCTTCCACAGAGGCCAGATGTCCAGCTGCAATT
 210 T C E T Q L S P Q R P D V Q L Q F
 970 CTCCTCTTTCAGAGATAGCCAGACCCTCGGATTGGGCTGGAGCAGGTCCCC
 227 S L F R D S Q T L G L G W S R S P
 1021 CAGACTCCAGATCCCTGCCATGTGGACTGAAGACTCAGGGTCTTACTGGTG
 244 R L Q I P A M W T E D S G S Y W C
 1072 TGAGGTGGAGACAGTGACTCACAGCATCAAAAAAGGAGCCTGAGATCTCA
 261 E V E T V T H S I K K R S L R S Q
 1123 GATACGTGTACAGAGAGTCCCTGTGTCTAATGTGAATCTAGAGATCCGGCC
 278 I R V Q R V P V S N V N L E I R P
 1174 CACCGGAGGGCAGCTGATTGAAGGAGAAAATATGGTCCTTATTTGCTCAGT
 295 T G G Q L I E G E N M V L I C S V
 1225 AGCCCGAGGTTTCAGGGACTGTACATTCTCTGGCACAAGAAGGAAGAGT
 312 A Q G S G T V T F S W H K E G R V
 1276 AAGAAGCCTGGGTAGAAAGACCCAGCGTTCCTGTGTCAGAGCTGCATGT
 329 R S L G R K T Q R S L L A E L H V
 1327 TCTCACCGTGAAGGAGAGTGATGCAGGGAGATACTACTGTGCAGCTGATAA
 346 L T V K E S D A G R Y Y C A A D N
 1378 CGTTCACAGCCCCATCCTCAGCACGTGGATTTCAGATCACCGTGAGAATTCC
 363 V H S P I L S T W I R V T V R I P
 1429 GGTATCTCACCTGTCTCACCTTCAGGGCTCCCAGGGCCACACTGTGGT
 380 V S H P V L T F R A P R A H T V V
 1480 GGGGACCTGTCTGGAGCTTCACTGTGAGTCCCTGAGAGGCTCTCCCCCGAT
 397 G D L L E L H C E S L R G S P I
 1531 CCTGTACCGATTTTATCATGAGGATGTCACCTGGGGAACAGCTCAGCCCC
 414 L Y R F Y H E D V T L G N S S A P
 1582 CTCTGGAGGAGGAGCCTCCTTCAACCTCTCTGACTGCAGAACATTCTGG
 431 S G G G A S F N L S L T A E H S G
 1633 AAATACTCCTGTGATGCAGACAATGGCCTGGGGGCCAGCACAGTCATGG
 448 N Y S C D A D N G L G A Q H S H G
 1684 AGTGAGTCTCAGGGTCACAGTTCCGGTGTCTCGCCCCGTCTCACCTCAG
 465 V S L R V T V P V S R P V L T L R
 1735 GGCTCCCGGGGCCAGGCTGTGGTGGGGGACCTGTGGAGCTTCACTGTGA
 483 A P G A Q A V V G D L L E L H C E
 1786 GTCCCTGAGAGGCTCCTTCCCGATCCTGTACTGGTTTTATCACGAGGATGA
 499 S L R G S F P I L Y W F Y H E D D
 1837 CACCTTGGGGAACATCTCGGCCCACTCTGGAGGAGGGGCATCCTTCAACCT
 516 T L G N I S A H S G G G A S F N L
 1888 CTCTCTGACTACAGAATCTTGGAACTACTCATGTGAGGCTGACAATGG
 533 S L T T E H S G N Y S C E A D N G

1939 CCTGGGGGCCAGCAGCAGTAAAGTGGTGACACTCAATGTTACAGGAACCTC
550 L G A Q H S K V V T L N V T G T S
1990 CAGGAACAGAAGCCCTTACCGCTGCGGGAATCACGGGGCTGGTGCTCAG
567 R N R T G L T A A G I T G L V L S
2041 CATCTCTGTCCTTGTCTGCTGCTGCTGCTGCTGATTAGCCAGGGGCCCG
584 I L V L A A A A A L L H Y A R A R
2092 AAGGAACAGGAGGACCTTCTGCCACTGGAACATCTAGTCACAGTCCTAG
601 R K P G G L S A T G G T S S H S P S
2143 TGAGTGTCCAGGAGCCTTCTCTGCTCCAGGCCTTCCAGGATAGACCCCTCAAGA
618 E C Q E P S S S R P S R I D P Q E
2194 GCCCACTCACTCTAAACCACTAGCCCAATGGAGCTGGAGCCAAATGTACAG
635 P T H S K P L A P M E L E P M Y S
2245 CAATGTAAATCCTGGAGTAGCAACCCGATTATCTCCAGCATCTGGAGCAT
652 N V N P G D S N P I Y S Q I W S I
2296 CCAGCATACAAAAGAAACCTCAGCTAATGTGCTCAATGATGCATCAAGAGCA
669 Q H T K E N S A N C P M H Q E H
2347 TGAGGAACCTACAGTCTCTATTTCAGAACTGAAGAAGACACCCAGACGA
686 E E L T V L Y S E L K K T H P D D
2398 CTCTGCAGGGGAGCTAGCAGCAGAGGCGAGGCCCATGAAGAAGATGATGA
703 S A G E A A S S R G R A H E E D D E
2449 AGAAAACATATAGAATGTACCACGTGTATTACTGCGCTCAGACCACATGCC
720 E N Y E N V P R V L L A S D H
2500 CCTTACCCAGAGTGGCCCCACGGAACAGCGCTGCCACATTTTTTTTCTGT
2551 TCTCTCCAACACACATCATCATCTCTCCAGACTCTGCTCTCTACGAGGC
2602 TGGGCTGCAGGGTATGTGAGGCTGAGCAAAAGGCTGCAAAATCTCCCTGT
2653 GCGTCTCTGTGTGTTCCCGAGGAAGAGAGCAGGCAGCTCTGAGCAAGCA
2704 CTGTGTTATTTTACAGTGTGAGACACGTGGCAAGGCAGGAGGGCCCTCAGC
2755 TCCTTAGGCTGTGCAATAGAGGAGGAGAGAAATGTGCTAGCCAGGGTTA
2805 CAAGGGCACAATCATGACCATTTGATCTCAAGTGTATGTCGAAGAGCTGTTTAA
2857 GTGCTCTCTGTATAAACAAATTTGCTCCAATATTTTGTGTTTCCCTTTTTTGT
2908 GTGCTGTGATGGGCATGTCTGATGTTTTGGTGTATATGCTGTATCCTTGC
2959 TACCATTATGGG

FIGURE 18D-1

```

1  TGGTGACCAAGAGTACATCTCTTTTCAAATAGCTGGATTAGGTCCTCATGC
1  M L
52  TGCTGTGGTCATTGCTGGTCATCTTTGATGCAGTCACTGAACAGGCAGATT
19  L W S L L V I F D A V T E Q A D S
103 CGCTGACCCTTGTTGGCGCCCTCTTCTGTCTTCGAAGGAGACAGCATCGTTC
36  L T L V A P S S V F E G D S I V L
154 TGAATGCCAGGGGAGAACAGAACTGGAAAATTGAGAAGATGGCTTACCATA
53  K C Q G E Q N W K I Q K M A Y H K
205 AGGATAACAAAGAGTTATCTGTTTTCAAAAATTCTCAGATTTCCTTATCC
70  D N K E L S V F K K F S D F L I Q
256 AAAGTGCAGTTTTAAGTGACAGTGGTAACTATTCTGTAGTACCAAAGGAC
87  S A V L S D S G N Y F C S T K G Q
307 AACTCTTTCTCTGGGATAAACTTCAAATATAGTAAAGATAAAAGTCCAAG
104 L F L W D K T S N I V K I K V Q E
358 AGCTCTTTCAACGTCTGTGCTGACTGCCAGCTCCTTCCAGCCCATCGAAG
121 L F Q R P V L T A S S F Q P I E G
409 GGGGTCCAGTGAGCCTGAAATGTGAGACCCGGCTCTCTCCACAGAGGTGG
138 G P V S L K C E T R L S P Q R L D
460 ATGTTCAACTCCAGTTCTGCTTCTTCAGAGAAAACAGGTCCTGGGGTCA
155 V Q L Q F C F F R E N Q V L G S G
511 GCTGGAGCAGCTCTCCGGAGCTCCAGATTCTGCGGTGTGGAGTGAAGACA
172 W S S S P E L Q I S A V W S E D T
562 CAGGGTCTTACTGGTGAAGGCAGAAACGGTGACTCACAGGATCAGAAAAC
189 G S Y W C K A E T V T H R I R K Q
613 AGAGCCTCCAATCCCAGATTACGTGCAGAGAATCCCATCTCTAATGTAA
206 S L Q S Q I H V Q R I P I S N V S
664 GCTTGGAGATCCGGCCCCCGGGGGACAGGTGACTGAAGGACAAAACTGA
223 L E I R A P G G Q V T E G Q K L I
715 TCCTGCTCTGCTCAGTGGCTGGGGGTACAGGAAATGTACATTCTCCTGGT
240 L L C S V A G G T G N V T F S W Y
766 ACAGAGAGGCCACAGGAACCAGTATGGGAAAGAAAACCCAGCGTTCCTGT
257 R E A T G T S M G K K T Q R S L S
817 CAGCAGAGCTGGAGATCCCAGCTGTGAAAGAGAGTGATGCCGGCAAATATT
274 A E L E I P A V K E S D A G K Y Y
868 ACTGTAGAGCTGACAACGGCCATGTGCCTATCCAGAGCAAGGTGGTGAATA
291 C R A D N G H V P I Q S K V V N I
919 TCCCTGTGAGAATTCCAGTGTCTCGCCCTGTCTCACCTCAGGTCTCCTG
308 P V R I P V S R P V L T L R S P G
970 GGGCCCAGGCTGCAGTGGGGGACCTGCTGGAGCTTCACTGTGAGGCCCTGA
325 A Q A A V G D L L E L H C E A L R
1021 GAGGCTCTCCCCAATCTTGTACCAATTTTATCATGAGGATGTCACCCCTTG
342 G S P P I L Y Q F Y H E D V T L G
1072 GGAACAGCTCGGCCCCCTCTGGAGGAGGGGCTCCTTCAACCTCTCTTTGA
359 N S S A P S G G G A S F N L S L T
1123 CTGCAGAACATTTCTGAACTACTCCTGTGAGGCCAACACGGCCTGGGGG
376 A E H S G N Y S C E A N N G L G A
1174 CCCAGTGCAGTGAGGCAGTGCCAGTCTCCATCTCAGGACCTGATGGCTATA
393 Q C S E A V P V S I S G P D G Y R
1225 GAAGAGACCTCATGACAGCTGGAGTTCTCTGGGGACTGTTTGGTGTCTTG
410 R D L M T A G V L W G L F G V L G
1276 GTTTCAGTGGTGTGCTTTGCTGTGTATGCCTTGTTCCACAAGATATCAG
427 F T G V A L L L Y A L F H K I S G
1327 GAGAAAGTTCTGCCACTAATGAACCCAGAGGGGCTTCCAGGCCAAATCCTC
444 E S S A T N E P R G A S R P N P Q
1378 AAGAGTTACCTATTCAAGCCCAACCCAGACATGGAGGAGCTGCAGCCAG
461 E F T Y S S P T P D M E E L Q P V
1429 TGTATGTCAATGTGGGCTCTGTAGATGTGGATGTGGTTTATTCTCAGGTCT
478 Y V N V G S V D V D V V Y S Q V W
1480 GGAGCATGCAGCAGCCAGAAAGCTCAGCAAACATCAGGACACTTCTGGAGA
495 S M Q Q P E S S A N I R T L L E N
1531 ACAAGGACTCCCAAGTCATCTACTCTCTGTGAAGAAATCATAACACTTGG
512 K D S Q V I Y S S V K K S
1582 AGGAATCAGAAGGGGAAGATCAACAGCAAGGATGGGGCATCATTAGACTTG
1633 CTATAAAACCTTATGAAAATGCTTGAGGCTTATCACCTGCCACAGCCAGAA
1684 CGTGCCCTCAGGAGGCACCTCCTGTCAATTTTGTCTCTGATGATGTTTCTCT
1735 CCAATATCTCTTTTACCTATCAATATTCAATGAAGTCTGTACATCCAG
1786 AACTGTGCAAAATAAATATTCTGCTACCTTCTCTTAAGCAATCAGTGTG
1837 TAAAGATTGTAGGGAAGAATGAATAAGAGATCAAGGTCTCACCTTCATCT
1888 ACTGTGAAGTGATGAGAACAGGACTTGATAGTGGTGTATTAACCTTATTAT
1939 GTGCTGCTGGATACAGTTTGCTAATATTTTGTGAGAATTTTGGCAATAT

```

32/34

FIGURE 18D-2

1990 GTTCATTGGGAATATTGGCCTGAAATTTCTTTTCCACTGTGTCTCTGCCA
2041 GAATGTTTGTATCAGGCTGATGCTGGCTTCATAGAATGAGTTAGGCAGGAG
2092 CCCTTCCTCCTTGATTTTGGCATAGTTTCAGCAGGATTGGTACCAGTTA
2143 TTCTTTCTGCATCTTGTAGAATTCAGCTATGAATCCATCTGGTCTAGGGCT
2194 TTTGTGTTGGTTGGTAAGTTTATTACTAATTCAACTTCAGCGCTTGAT
2245 ATTGGTCTAGGAGGGGTTCTGTCTCTCCTGGTTCAATCTTGGGAGATTG
2296 TGTGTTTCCAGGAATTAGCCGTTTCTCCAGATTTCTCTTTATGTGCA
2347 TCGACTTGAGTGTAACATAACTTATATGCACTGGGAAACAAAAATCTG
2398 TGTGACTTGCTTTATTGCAGCATTGTTTATTTTGGTAGTCTGGAAGTGA
2449 ACCTGCAATATCACCAAAGTATGCATATAGTTGCAAAATGTGATTTTGA
2500 CATAGTAAATATGAGTATTTGCAATAAACTATGATATTACTTTGTAAAGTA
2551 TATAGAATAAAATGTAAATAATCTATAAAA

FIGURE 18E-1

1 GAGGCATCTCTAGGTACCATCCCTGACCTGGTCCTC
 37 ATGCTGCCGAGGCTGTTGCTGTGATCTGTGCTCCACTCTGTGAA
 M L P R L L L L I C A P L C E
 82 CCTGCCGAGCTGTTTTGATAGCCAGCCCCCTCCCATCCACAGAG
 P A E L F L I A S P S H P T E
 127 GGGAGCCCAGTGACCCGTGACGTGTAAGATGCCCTTTCTACAGAGT
 G S P V T L T C K M P F L Q S
 172 TCAGATGCCAGTTCCAGTTCTGCTTTTTTCAGAGACACCCGGGCC
 S D A Q F Q F C F F R D T R A
 217 TTGGGGCCAGGCTGGAGCAGCTCCCCAAGCTCCAGATCGCTGCC
 L G P G W S S S S P K L Q I A A
 262 ATGTGGAAGAAGACACAGGGTCATACTGGTGCGAGGACACAGACA
 M W K E D T G S Y W C E A Q T
 307 ATGGCGTCCAAAGTCTTGAGGAGCAGGAGATCCAGATAAATGTG
 M A S K V L R S R R S Q I N V
 352 CACAGGGTCCCTGCTGCTGATGTGAGCTTGGAGACTCAGCCCCCA
 H R V P V A D V S L E T Q P P
 397 GGAGGACAGGTGATGGAGGGAGACAGGCTGGTCCTCATCTGCTCA
 G Q V M E G D R L V L I C S
 442 GTTGCTATGGGCACAGGAGACATCACCTTCTTTGGTACAAAGGG
 V A M G T G D I T F L W Y K G
 487 GCTGTAGGTTTAAACCTTCAGTCAAAGACCCAGCGTTCACTGACA
 A V G L N L Q S K T Q R S L T
 532 GCAGAGTATGAGATTCTTCAGTGAGGGAGAGTGATGCTGAGCAA
 A E Y E I P S V R E S D A E Q
 577 TATTACTGTGTAGCTGAAAATGGCTATGGTCCCAGCCCCAGTGGG
 Y Y C V A E N G Y G P S P S G
 622 CTGGTGAGCATCACTGTCAGAATCCCGGTGTCTCGCCCAATCCTC
 L V S I T V R I P V S R P I L
 667 ATGCTCAGGGCTCCCAGGGCCAGGCTGCAGTGGAGGATGTGCTG
 M L R A P R A Q A A V E D V L
 712 GAGCTTCACTGTGAGGCCCTGAGAGGCTCTCCTCCAATCCTGTAC
 E L H C E A L R G S P P I L Y
 757 TGGTTTTATCAGGAGATATCACCTGGGGAGCAGGTGCGCCCCC
 W F Y H E D I T L G S R S A P
 802 TCTGAGGAGGAGCCTCCTTCAACCTTTCCCTGACTGAAGAACAT
 S G G G A S F N L S L T E E H
 847 TCTGGAATACTACTCTGTGAGGCCAACAATGGCCTGGGGGCCAG
 S G N Y S C E A N N G L G A Q
 892 CGCAGTGAGGCGGTGACACTCAACTTCACAGTGCCTACTGGGGCC
 R S E A V T L N F T V P T G A
 937 AGAAGCAATCATCTTACCTCAGGAGTCATTGAGGGGCTGCTCAGC
 R S N H L T S G V I E G L L S
 982 ACCCTTGGTCCAGCCACCGTGGCCTTATTATTTTGCTACGGCCTC
 T L G P A T V A L L F C Y G L
 1027 AAAAGAAAAATAGGAAGACGTTACGCCAGGGATCCACTCAGGAGC
 K R K I G R R S A R D P L R S
 1072 CTTCCAGCCCTCTACCCCAAGAGTTCACCTACCTCAACTCACCT
 L P S P L P Q E F T Y L N S P
 1117 ACCCCAGGGCAGCTACAGCCTATATATGAAAATGTGAATGTTGTA
 T P G Q L Q P I Y E N V N V V
 1162 AGTGGGGATGAGGTTTATTCAGTGGCGTACTATAACAGCCGGAG
 S G D E V Y S L A Y Y N Q P E
 1207 CAGGAATCAGTAGCAGCAGAAAACCTGGGGACACATATGGAGGAC
 Q E S V A A E T L G T H M E D
 1252 AAGGTTTCTTAGACATCTATTCAGGCTGAGGAAAGCAACATT
 K V S L D I Y S R L R K A N I
 1297 ACAGATGTGGACTATGAAGATGCTATGTAA 1326
 T D V D Y E D A M *
 GGTG ATGGAAGATT CTGCTCTTTG
 1351 AAAACCATCC ATGACCCCAA GCCTCAGGCC TGATATGTTT TCCAGAGATC
 1401 CTGGGGCATT AGCTTTCCAG TATACCTCTT CTGGATGCCA TTCTCCATGG
 1451 CACTATTCTT TCATCTACTG TGAAGTGAAG TTGGCGCAGC CCTGAAGAAA
 1501 CTACCTAGGA GAACTAATAG ACACAGGAGT GACAGGGACT TTGTTATCAG
 1551 AACCAGATTC CTGCCGGCTC CTTTGAAAAC AGGTCAATTT GTGCTCTTCT
 1601 GTTTACAAGA GGAAACAAGA TGAATAAATA GAAATTGGGA TCTTGGGTTG
 1651 GAGGGACAGT GAAGCTTAGA GCACATGAAC TCAAGGTTAG TGACTCTGCA
 1701 GGACTTCACA GAGAGAGCTG TGCCCATCAT TCAGTCCAAG TGCTTTCTCT
 1751 GCCCAGACAG CACAGAATC CAGCCCCGCT ACTTACATGG ATCATCGAGT
 1801 TTCCACCTAA AATATGATTC TATTTATTTT GAGTCACTGT TACCAAATTA

FIGURE 18E-2

```
1851  GAACTAAAAC  AAAGTTACAT  AAAAAGTTAT  TGTGACTCCA  CTTAATTTTA
1901  GTGACGTATT  TTTGTATATA  TAGGCCAACC  TATACCACAT  CCAAAATTAT
1951  GTATCTATTA  CAGCCCCTAG  AAGCTTTATA  AATACAGTGT  GTCTTCTTTT
2001  ATTCACAAA  TTTTGTAAAT  CGTGGTAATA  TGGTTTGAAA  CCTGTATCTT
2051  AATTATTTT  TTTTAAAT  GAGACAGGGT  CTCACTCTGT  CACTCAATCT
2101  GGAATGCAGT  GGCACAATCT  TGCCTCACTG  CAACGCCTGC  CTCTCAGGCT
2151  CAAGCAAACC  TCTCACCTCA  GCCTGCTGAG  TAGCTGGGAC  TACAGGCACA
2201  TGCCACCAA  CTTGGCCATT  TTTGTCTTA  CGTAGAGACA  AGATTCACC
2251  GTTTGTCCA  GGCTGGTCTC  AAACCTCTGG  GCTCAAGCAA  TGTATTGAAT
2301  TTT
```


Page 2

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s), or Section 365(c) of any PCT International Application(s) designating the United States listed below. Insofar as this application discloses and claims subject matter in addition to that disclosed in any such prior Application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56, which became available between the filing date(s) of such prior Application(s) and the national or PCT international filing date of this application:

<u>Provisional Application No.</u>	<u>Filing Date</u>	<u>Status</u>
<u>60/168,151</u>	<u>November 29, 1999</u>	<u>Pending as of 11-28-00</u>
<u> </u>	<u> </u>	<u> </u>
<u> </u>	<u> </u>	<u> </u>
<u> </u>	<u> </u>	<u> </u>
<u> </u>	<u> </u>	<u> </u>

[illegible]

And I hereby appoint

John P. White (Reg. No. 28,678); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); Jay H. Maioli (Reg. No. 27,213); William E. Pelton (Reg. No. 25,702); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29,691); Wendy E. Miller (Reg. No. 35,615); Richard S. Milner (Reg. No. 33,970); Robert T. Maldonado (Reg. 38,232); Paul Teng (40,837); Richard F. Jaworski (Reg. No. 33,515); Elizabeth M. Wieckowski (Reg. No. 42,226); Pedro C. Fernandez (Reg. No. 41,741); Gary J. Gershik (Reg. No. 39,992); Jane M. Love (Reg. No. 42,812); Spencer H. Schneider (Reg. No. 45,923) and Raymond A. Diperna (Reg. No. 44,063).

and each of them, all c/o Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.

Please address all communications, and direct all telephone calls, regarding this application to:

John P. White, Esq. Reg. No. 28,678
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. (212) 278-0400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or
first joint inventor Riccardo Dalla-Favera

Inventor's signature _____

Citizenship Italy Date of signature _____

Residence 445 Riverside Drive, Apt. 122, New York, New York 10025

Post Office Address _____

Full name of joint
inventor (if any) _____

Inventor's signature _____

Citizenship _____ Date of signature _____

Residence _____

Post Office Address _____

Full name of joint
inventor (if any) _____

Inventor's signature _____

Citizenship _____ Date of signature _____

Residence _____

Post Office Address _____